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Abstract  
Cardiovascular disease is a major cause of  death and ill health across the world.  
Psychosocial factors are increasingly being recognised as potential cardiovascular risk 
factors, contributing to the development and progression of  atherosclerotic disease.  
However, the pathways between psychosocial factors and cardiovascular disease are not yet 
fully understood.  
The aims of  this thesis were to explore the associations between psychosocial factors (both 
chronic and acute stress) and measures of  subclinical vascular disease, and to further 
develop and validate, a new method of  assessing vasomotor function.    
Women with both depression and anxiety were found to have increased carotid intima-
media thickness and this relationship was found to be influenced by the presence of  
dyslipidaemia.   When looking at the inflammatory responses to an acute mental stress 
challenge it was shown that those participants who had an elevated fibrinogen response 45 
minutes after the stress challenge had poorer endothelial function 3 years later, as assessed 
by flow-mediated dilatation. These findings suggest that both chronic and acute stress may 
play a role in the development of  cardiovascular disease. 
Good reproducibility was demonstrated with the new method for assessing vasomotor 
function following further development of  the protocol for the method. The technique 
was able to detect differences in vasomotor function between a group of  patients with 
Familial Hypercholesterolaemia compared with age and gender matched controls. In 
addition it was also able to detect improvement in vasomotor function following a single 
lipoprotein apheresis treatment in patients with Familial Hypercholesterolaemia undergoing 
long-term treatment.  These studies demonstrated the potential of  this method for use in 
non-specialist vascular research laboratories and out in the field for the assessment of  
vasomotor function. 
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Definitions and abbreviations 
5-HT    5-hydroxytryptamine serotonin 
ACE   Angiotensin-converting enzyme  
ACH   Acetylcholine  
AIx   Augmentation index 
ANCOVA  Analysis of  covariance 
ANOVA  Analysis of  variance 
Anx   Anxiety 
ApoA   Apolipoprotein A 
ApoB   Apolipoprotein B 
ARH    LDL receptor adaptor protein 1 gene 
AT I   Angiotensin I  
AT II   Angiotensin II  
AUC   Area under curve 
BK   Bradykinin 
BL dia  Baseline diameter 
BLVTI Baseline velocity time integral 
BMI   Body mass index 
BP   Blood pressure 
CES-D  Centre for epidemiological studies depression scale 
CRH   Corticotrophin releasing hormone 
CRP  C-reactive protein 
CV%   Coefficient of  variation 
CVD   Cardiovascular disease 
DALI   Direct adsorption of  lipoprotein 
DBP   Diastolic blood pressure 
DC   Distensibility coefficient 
Dep   Depression 
DSA   Dextran sulphate adsorption  
DSM  Diagnostic and Statistical Manual of  Mental Disorders  
ECG   Electrocardiogram 
EDHF  Endothelium-derived hyperpolarizing factor 
EDTA  Ethylenediaminetetraacetic acid 
eNOS   Endothelial nitric oxide synthase 
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ET-1  Endothelin-1 
FBF  Forearm blood flow 
Fbg   Fibrinogen  
FH   Familial Hypercholesterolaemia 
FMD   Flow-mediated dilatation 
FMDABS  Absolute flow-mediated dilatation 
FMD%  Percentage change flow-mediated dilatation 
FMS   Flow-mediated slowing 
FMSABS  Absolute flow-mediated slowing 
FMS%   Percentage change flow-mediated slowing 
GHQ   General Health Questionnaire 
GMP   Guanosine monophosphate 
GTN  Glyceryl trinitrate 
HDL   High density lipoprotein 
HELP  Heparin extracorporeal LDL precipitation  
HPA  Hypothalamic-pituitary-adrenal axis 
HR   Heart rate 
IDL   Intermediate density lipoprotein 
IL-6   Interleukin 6 
IMT   Intima-media thickness 
LA   Lipoprotein apheresis 
LDL  Low density lipoprotein 
L-NMMA  L-NG-monomethyl Arginine citrate 
LP   Lipoprotein 
MRI  Magnetic resonance imaging  
NHS   National Health Service 
NO   Nitric oxide 
nonHDL  non high density lipoprotein 
NOS   Nitric oxide synthase 
 O2-   Superoxide ion  
PAT  Pulse amplitude tonometry 
PCA   Pulse contour analysis 
PCSK9  Proprotein convertase subtilisin/kexin type 9 
PGF-2α  Prostaglandin F-2α 
PGI2   Prostacyclin 
PFBA   Polyacrylate full blood adsorption   
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PS  Post stress 
PWA   Pulse wave analysis 
PWV  Pulse wave velocity 
R   Receptor  
RH%   Reactive hyperaemia expressed as a percentage 
SBP   Systolic blood pressure 
SES   Socio-economic status  
SMC  Smooth muscle cell 
SNS  Sympathetic nervous system 
SP   Substance P  
TC   Total cholesterol 
TC/HDL Total cholesterol to high density lipoprotein ratio 
Trigs   Triglycerides 
Trigs/HDL  Triglycerides to high density lipoprotein ratio 
TNFα   Tumour necrosis factor 
TxA2   Thromboxane A2, 
UCL  University College London 
 UK   United Kingdom 
VLDL  Very low density lipoprotein 
VTI   Velocity time integral 
WHII   Whitehall II study 
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Chapter 1.  General Introduction 
 
1.1 Biology of  atherosclerosis and cardiovascular risk 
1.1.1 Epidemiology 
Cardiovascular disease (CVD), which encompasses coronary heart disease, heart failure and 
stroke amongst others, is the leading cause of  death by a non-communicable disease 
worldwide.  In 2012, it was responsible for 17.5 million deaths, with an estimated 7.4 
million of  these deaths due to ischaemic heart disease, and 6.7 million due to stroke1. It has 
been projected that by 2030, over 23 million people will die annually from CVD2. 
 
There is still a substantial morbidity and mortality burden due to CVD within the United 
Kingdom (UK), but some good progress is being made in the prevention of  CVD. In 
2012-2013 CVD was overtaken by cancer as the leading cause of  death within the UK. 
Cancer was responsible for 29% of  all deaths, ahead of  CVD with 28%. However, in 
women, CVD remains the major cause of  death ahead of  cancer (28% vs 27%), whilst in 
men CVD has fallen behind cancer (CVD 29% cancer 32%)3. It is not only in the UK 
where a decline in mortality from CVD has been seen; between 1998 and 2008 the annual 
rate of  deaths due to CVD declined by 31% in the United States4. 
 
The reduction in mortality is in part explained by improved treatment of  acute and chronic 
cardiovascular diseases such as myocardial infarction and chronic heart failure. Additionally, 
changes in risk factors such as smoking habits and treatments for high cholesterol and 
hypertension have also helped reduce cardiovascular mortality5. However, many people are 
also living with CVD. Within the UK 2.3 million people are estimated to be living with 
coronary heart disease. The prevalence of  cardiovascular conditions increases with age and 
is greater in men than women, with men 3 times more likely to have had a myocardial 
infarction than women.  CVD was also the third highest main diagnosis in men (at 10%) on 
discharge from NHS hospitals in 2012/2013, behind cancer and digestive system diseases3.  
The economic impact of  these high levels of  CVD is great. In 2012-2013, £6.8 billion was 
spent within the NHS in England on treating CVD, whilst in Wales the cost was £442.3 
million3.  
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Alongside the differences in mortality and prevalence of  CVD between the genders, there 
is also a socio-economic gradient within the UK. Scotland has an age-standardised total 
CVD mortality rate of  347per 100,000 population whereas in South West England it is 
lower at 269/100,000. Within England there is a further North/South divide with those in 
the North having higher mortality rates3. Prevalence of  CVD also varies within the UK. 
Data from the Quality and Outcomes Framework has shown that England has the lowest 
prevalence for all cardiovascular conditions except hypertension.  Scotland has the highest 
prevalence of  CHD, stroke and peripheral arterial disease whilst hypertension, heart failure 
and atrial fibrillation are highest in Wales. As with mortality there is also a North/South 
divide within England, with the prevalence of  CVD being greater in the less advantaged 
North3.  
 
It is not only where someone lives that increases the likelihood of  whether they die or 
suffer from CVD.  Social position, as determined by educational level, occupation, income, 
ethnicity and race and gender, also influences an individual’s risk of  CVD; with manual 
workers at greater risk than those in professional/managerial occupations6. These socio-
economic factors are linked to many other psychosocial factors such as access to health 
care, dietary quality, stress and other lifestyle behaviours (smoking, alcohol) that contribute 
to the increased risk of  CVD. It is therefore important to try and gain a deeper 
understanding of  how psychosocial and biological factors mediate CVD risk in order to 
develop new approaches to CVD prevention.  
 
So although there is evidence that good progress has been made in the overall reduction of  
the impact of  CVD, there is still a need for further investigation into the inequalities in 
mortality and morbidity within the psychosocial environment and how they contribute to 
CVD.  
 
1.1.2 Initiation and development of  atherosclerosis 
A healthy artery wall is made up of  three layers; the intima, media and adventitia (figure 
1.1A). The intima is the innermost layer which consists of  the endothelial cells which lie on 
a basement membrane containing type IV collagen and a few smooth muscle cells7. It is 
separated from the media by an internal elastic lamina. Within the media are elastin, 
collagen, glycoproteins and smooth muscle cells. In elastic arteries such as the aorta there 
are several layers of  elastic lamina between which are the smooth muscle cells and other 
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structural components, whilst in more muscular arteries smooth muscle cells are arranged 
in spiralling layers7, 8. The adventitia is the outermost layer, and consists mainly of  
connective tissue, fibroblasts, smooth muscle cells, microvessels and nerve endings.   
 
 
Figure 1.1: Development of the atherosclerotic plaque. A normal artery; B the initial steps of atherosclerosis; 
C progression of the atherosclerotic lesion; D atherosclerotic plaque with thrombosis. Further explanation is 
within the text of section 1.1.2. LP = lipoprotein; SMC = smooth muscle cell. Adapted from Libby et al9  
 
Exposure of  the artery wall to cardiovascular risk factors such as hypertension, 
hypercholesterolaemia, hyperglycaemia and smoking, and their associated physiological and 
biochemical stressors activates the endothelium. This results in a cascade of  inflammatory 
processes including innate and cellular immune processes.  These in turn encourage greater 
transit and retention of  LDL into the intima which, along with mononuclear cells, which 
take up these lipoproteins, form foam cells. This in turn triggers further inflammatory 
processes, initiating changes within the extracellular matrix and inducing migration of  
vascular smooth muscle cells from the media to the intima and ultimately resulting in the 
development of  a plaque.  The plaque progresses over time and may eventually reach such 
a size that it occludes the lumen or may become unstable and ulcerate/rupture, which can 
cause clinical events such as angina, myocardial infarction or stroke (figure 1.1).  Although 
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the clinical consequences of  atherosclerosis usually occur later in life, the disease process 
has often been silently progressing from much earlier in life and in extreme cases even 
before birth10, 11.  
 
1.1.2.1 The healthy endothelium 
A thin single celled monolayer, the endothelium plays a key role in vascular homeostasis.  It 
is involved in numerous processes such as thrombus prevention, cellular adhesion, 
regulation of  the transport of  macromolecules, inflammation, smooth muscle cell 
proliferation and importantly, vascular tone. 
 
Regulation of  vascular tone plays an important role in the balance of  tissue oxygen supply 
and metabolic demand.  The tone and variation in diameter of  the vessel is controlled 
through the synthesis and release of  vasoconstrictors and vasodilators from the 
endothelium and by its response to, and modification of, circulating vasoactive mediators. 
 
Endothelial cells were first demonstrated to be essential for vascular smooth muscle 
relaxation by Furchgott & Zawadzki by the administration of  acetylcholine to rabbit aortas 
with and without intact endothelium 12. Initially known as endothelium-derived relaxing 
factor, the substance responsible for the relaxation was later identified as Nitric Oxide 
(NO)13.  NO is synthesised from the conversion of  L-Arginine to L-Citrulline by 
endothelial Nitric Oxide Synthase (eNOS) in the presence of  cofactors such as 
tetrahydrobiopterin (BH4).  It then diffuses through to the vascular smooth muscle cells 
where it activates guanylate cyclase leading to relaxation of  the smooth muscle through 
cyclic guanosine monophosphate production14.  Production of  NO is regulated through a 
number of  pathways such as increases in shear stress which enhances eNOS expression15.  
Other signalling molecules which influence NO production are bradykinin, adenosine and 
vascular endothelial growth factor16.  The endothelium also produces other vasodilators 
which are NO independent, for example endothelium derived hyperpolarizing factors 
(EDHF) and prostacyclin17, 18.  Vascular tone is also modulated by the endothelium through 
vasoconstrictors such as angiotensin II and endothelin-1(figure 1.2)19, 20.  
 
Finally, NO is also involved in the inhibition of  inflammation, cell proliferation and 
thrombosis; all actions which help to maintain a healthy endothelium21.  
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Figure 1.2: Endothelium-derived vasodilators and endogenous vasoconstrictors. ACH, Acetylcholine; BK, 
bradykinin; SP, substance P; NOS, nitric oxide synthase;PGI2, prostacyclin; NO, nitric oxide; ACE, 
angiotensin-converting enzyme; TxA2,thromboxane A2; 5-HT, 5-hydroxytryptamine serotonin; AT I, 
angiotensin I; AT II,angiotensin II; EDHF, endothelium-derived hyperpolarizing factor; ET-1, endothelin-
1;O2-, superoxide ion; PGF-2α, prostaglandin F-2α; R, receptor. Adapted from Ellins & Halcox22 
 
1.1.2.2 Endothelial activation and atherogenesis 
Atherogenesis is thought to be triggered by the interaction between the activated 
endothelium and subendothelial lipoprotein transit, retention and cellular uptake23. 
Activation of  the endothelium can occur in response to the effects of  cardiovascular risk 
factors, such as hypercholesterolaemia and hypertension. Furthermore, atherogenesis 
typically develops most favourably within the intima, in regions of  disturbed blood flow23. 
Changes in shear stress along the vessel wall can trigger chemical responses driving the 
endothelium into a proatherogenic dysfunctional state in vulnerable sections of  the arterial 
tree.    
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Activation of  the endothelium increases its permeability which, alongside changes within 
the subendothelial extracelluar matrix, facilitates ApoB lipoproteins to enter into and be 
retained in the subendothelial space where they can be further modified by oxidation24. The 
activated endothelium may be further activated by the retention and oxidation of  
lipoproteins. This may also initiate proinflammatory responses, characterizing the 
production of  both chemokines and inflammatory cytokines which further stimulate the 
endothelium to produce selectins and adhesion molecules which attract and interact with 
mononuclear cells. These molecules facilitate the attraction and adhesion of  mononuclear 
cells, particularly monocytes and T lymphocytes, to the endothelium which migrate into the 
sub-intimal space. Once within the vessel wall, monocytes mature into macrophages which 
ingest both native and modified lipoproteins through a combination of  phagocytosis, 
scavenger receptor-mediated uptake and fluid phase pinocytosis to become cholesterol 
laden foam cells24. In addition, monocytes and T lymphocytes also secrete inflammatory 
cytokines encouraging further endothelial activation and monocyte attraction, adhesion and 
infiltration9. 
 
Smooth muscle cell migration is also an important component of  atheroma formation.  
These cells are already scantily present in the intima, but during atherogenesis, more 
smooth muscle cells migrate in from the media and proliferate in response to mediators. 
They also produce extracellular matrix molecules such as collagen and elastin, and form a 
fibrous cap over the atheroma.  This cap often covers foam cells, which, upon dying, free 
lipids which accumulate extracellularly in the subintima. This can contribute to the 
formation of  the plaque’s necrotic core, which is a lipid-rich pool formed from the build 
up of  debris from cells and the extracellular lipids9. 
 
With this continuous cycle of  inflammatory processes, lipid accumulation, foam cell 
formation and changes within the extracellular matrix, the plaque continues to develop 
increasing in size and complexity. This causes remodelling of  the artery. Initially the plaque 
causes expansion of  the artery wall whilst the lumen remains clear with no intrusion.  
Eventually the plaque may begin to intrude into the lumen of  the artery where it can 
become a blood flow-limiting stenosis leading to ischaemia of  the surrounding tissue.  
Alternatively, the plaque can be breached, either through rupture or erosion of  the 
endothelium.  Plaques that are prone to rupture (vulnerable plaques) have a weakened 
fibrous cap typically due to the actions of  inflammatory cells which produce cytokines and 
metalloproteinase that break down collagen decreasing the tensile strength of  the cap.  
Inflammatory cytokines also enhance cell death and prothrombotic activity within the 
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plaque. The cap eventually is unable to withstand the mechanical forces of  blood pressure 
and fissures appear within the cap exposing the inner core of  the plaque25.  The 
mechanisms of  endothelial erosion are not fully understood but recent work has suggested 
that innate immunity may play a role in this process25.  Either way, both rupture or erosion 
results in exposure of  thrombogenic material within the plaque to platelets and coagulation 
factors in the lumen which activates thrombus formation at the site of  the breach. This 
may lead to obstruction of  local blood flow, or (mirco) embolism which can lodge in distal 
branch arteries both of  which processes can result in ischaemia, stroke or myocardial 
infarction.  
 
1.2 Cardiovascular risk factors and vascular function  
Epidemiological studies have shown that alongside age and gender, there are a number of  
factors that increase a person’s risk of  suffering from CVD or mortality from a 
cardiovascular event. The INTERHEART study, a large study of  12,461 cases and 14,637 
controls from 52 countries demonstrated that 90.4% of  the population attributable 
myocardial infarction (MI) risk was accounted for by 9 modifiable risk factors. In fact just 
five of  these risk factors abnormal lipids, smoking, hypertension, diabetes and obesity, were 
responsible for 80.2% of  the estimated population attributable MI risk26.   
  
1.2.1 Smoking 
Both smoking and passive smoking have been shown to increase the risk of  having a 
cardiac event in men and women27, 28. The exact causative pathways determining the 
relationship between smoking and CVD are not fully understood. However, cigarette 
smoke contains numerous constituents including nicotine, carbon monoxide and free 
radicals and it is thought that these and other toxic components within the smoke promote 
vascular dysfunction, atherogenesis and thrombosis in multiple vascular beds 29.  
 
Smoking has a number of  effects on the cardiovascular system including increasing blood 
pressure, heart rate and cardiac output30. In addition it creates a favourable environment for 
the development and progression of  atherosclerosis through increased numbers of  free 
radicals and oxidative stress, inflammatory cytokines and oxidation of  LDL29.   These can 
all contribute to the endothelial dysfunction seen in response to both active smoking and 
environmental exposure to smoke (passive smoking)31, 32.  Smoking is also associated with 
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the development of  subclinical arterial disease, for example increased arterial stiffness and 
carotid artery intima-media thickness (IMT)33, 34.   
 
Smoking cessation can reduce the relative risk of  mortality in those with coronary heart 
disease by 36%35.  In the UK, there has been a concerted effort by Public Health bodies to 
reduce cigarette consumption within the population and the number of  smokers in 
England has declined from 26% of  adults aged 16 and over in 2003, to 19% in 201336. 
Legislation banning smoking in the work place and indoor public spaces has also made an 
impact on the risk of  cardiac events. A meta-analysis of  31 studies looking at the impact of  
smoking bans on cardiovascular events showed an overall 12% reduction in hospitalizations 
from acute coronary events37. 
 
1.2.2 Hypertension 
High blood pressure (currently defined as ≥140/90 mmHg) is a chronic multifactorial 
systemic disorder38. Blood pressure increases with age and environmental, pathological and 
genetic factors all play an important role in both the control of  and the development of  
increased blood pressure; the relative influence of  which can vary between individuals and 
populations39. High blood pressure is considered a major independent risk factor for CVD 
but is also commonly seen with obesity, insulin resistance and over activity of  the 
sympathetic nervous system40-44. Hypertension is very common, with current estimates 
putting its prevalence at 26.4% of  the adult global population, which is projected to 
increase to 29.2% by 2025, and makes it the leading risk factor for mortality45, 46. In addition 
to their greater risk of  CVD, people with hypertension are also at increased risk for kidney 
disease and stroke.  
 
Hypertension has also been shown to be related to adverse subclinical markers of  vascular 
structure and function. One such marker is endothelial function, which has been shown to 
be diminished in patients with hypertension47, 48. The presence of  endothelial dysfunction 
as assessed by flow-mediated dilatation may identify those patients with hypertension who 
were at greatest risk of  non fatal and fatal CVD events49. Diminished endothelium-
dependent dilatation may be due to a range of  factors notably the reduced bioavailability 
of  NO in response to increased oxidative stress50.  
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Hypertension may also result in the remodelling of  both large and small arteries. 
Alterations in the extracellular matrix and to collagen and elastin fibres within the artery 
wall can lead to changes to the lumen/wall ratio and lumen diameter51. These changes in 
the structure of  the artery walls can result in increased intima-media thickness and arterial 
stiffness; which can further increase blood pressure, creating a vicious cycle52.  
Hypertension-induced changes to the arteries also impact on the heart, for example, 
increased arterial stiffness is associated with left ventricular hypertrophy, a known risk 
factor for cardiovascular events53, 54. 
 
Reduction of  blood pressure through the use of  antihypertensive medication such as ACE 
inhibitors, calcium antagonists, β-blockers, angiotensin receptor antagonists and thiazide 
diuretics, reduces cardiovascular morbidity and mortality with a 30-40% reduction in the 
risk of  fatal and non-fatal stroke and 20% for coronary events38. A meta-analysis looking at 
the use of  blood pressure lowering drugs and CVD prevention showed that a significant 
reduction in risk could be achieved with medication in those with and without CVD 
regardless of  the pre treatment blood pressure, (down to a systolic of  110 mmHg and 
diastolic blood pressure of  70 mmHg)55. In addition, endothelial function and pulse wave 
velocity (PWV) have both been shown to improve in response to antihypertensive therapy, 
whilst there is also evidence of  both IMT regression and the slowing of  its progression in 
patients on blood pressure lowering medications56-63.  However, there is still room for 
improvement as many patients under medical care still have uncontrolled hypertension and 
their risk of  cardiovascular events could be lowered further with better control of  their 
blood pressure64.  
 
1.2.3 Lipids 
Elevated levels of  lipoproteins are a major risk factor for CVD and as discussed previously 
play a key role in the development of  atherosclerosis. Lipoproteins are globular, micelle like 
particles containing a hydrophobic core of  triglycerides and cholesterol esters surrounded 
by an amphipathic coat of  protein, phospholipid and cholesterol.  The apolipoproteins on 
the surface help solubilise the lipids and act as cellular targeting signals. The main function 
of  lipoproteins is to transport triglycerides, cholesterol and phospholipids around the body 
but also have a number of  other biological properties. They are commonly classified into 5 
types of  lipoprotein based on their physical and functional properties; chylomicrons, very 
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low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), low density 
lipoproteins (LDL) and high density lipoproteins (HDL).  
 
Chylomicrons 
 
These triglyceride rich particles are synthesised in the large intestine in response to dietary 
fat intake and are the largest and least dense (0.95g/ml) lipoprotein. They transport dietary 
triglycerides from the intestines to other tissues, predominantly skeletal muscle and adipose 
tissue, and also move triglycerides and cholesterol to the liver.  Chylomicrons contain a 
number of  apolipoproteins which are crucial to lipoprotein metabolism.  Apolipoproteins 
have a number of  functions including a structural role, acting as ligands for lipoprotein 
receptors, guiding the formation of  lipoproteins and activating and inhibiting enzymes 
involved in lipoprotein metabolism.  ApoB-48, a core structural protein is one of  the key 
apolipoproteins in chylomicrons.  Triglycerides from the chylomicrons are hydrolysed by 
lipoprotein lipase, freeing fatty acids and becoming smaller particles called chylomicron 
remnants. These are richer in cholesterol and are potentially pro-atherogenic65.  
 
VLDL, IDL and LDL 
 
 Triglyceride rich VLDLs are synthesised in the liver and transport triglycerides and 
cholesterol from the liver to other tissues, mainly skeletal muscle and adipose tissue. They 
also contain the proatherogenic apolipoprotein ApoB-100 which is a structural protein and 
acts as a ligand for the LDL receptor.  As with chylomicrons, lipoprotein lipase acts on 
triglycerides releasing fatty acids which are taken up for storage. In parallel, exchange of  
triglycerides for cholesterol esters between these ApoB containing lipoproteins and HDL 
further enriches their cholesterol content. As a consequence, the size of  these lipoproteins 
decreases and they become VLDL remnants and eventually IDL particles, some of  which 
will be taken up by the liver. The remaining IDL are converted to LDL which are 
cholesterol rich, contain ApoB-100 and are the main source of  cholesterol to the tissues65. 
LDL receptors play a key role in the delivery of  cholesterol to tissues and consequently 
plasma levels.  Genetic defects which result in reduced numbers or loss of  function of  the 
receptors commonly result in patients with these conditions having very high levels of  
LDL66. Other factors also contribute to levels of  LDL such as dietary habits and in women 
postmenopausal status67. LDL particles vary in size due to differences in the amounts of  
cholesterol esters and triglycerides contained within them.  Those with the lowest number 
of  cholesterol esters and greater triglyceride content are small dense LDL. These are the 
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most proatherogenic as they have less affinity for the LDL receptor on the liver which 
prolongs their time in the circulation.  They also enter the arterial wall relatively easily and 
are retained within the intima and are more susceptible to oxidation, all key features of  the 
atherogenic process. Higher levels of  small dense LDL are commonly seen in association 
with high triglycerides, low HDL levels, obesity, type 2 diabetes and in inflammatory states 
65.   
 
HDL 
 
HDL is a complex lipoprotein with a density of  1.06-1.21 g/ml. It is formed from the 
apolipoprotein ApoA1, which is synthesised in the liver and intestine. The lipid poor 
ApoA1 protein initially acquires lipids through interaction with the cholesterol-
phospholipid transporter ATP Binding Cassette A1 forming a nascent HDL particle. 
Further lipids and additional apolipoproteins are acquired from the degradation of  other 
triglyceride rich lipoproteins. Cholesterol within HDL is converted into cholesterol esters 
forming the core of  the mature HDL particle. These cholesterol esters are then either 
taken up directly by the liver or transferred, often in exchange for triglycerides, to ApoB 
containing lipoproteins68. Reverse cholesterol transport from peripheral tissues to the liver 
is the main function of  HDL, but it also has other important roles, which can be viewed as 
atheroprotective. These include inhibition of  cytokine-induced expression of  adhesion 
molecules, reduction of  the adhesion of  monocytes to the endothelium and inhibition of  
oxidation of  LDL and its transit into the intima69-72. HDL levels are affected by both 
clinical and environmental factors including obesity, type 2 diabetes, inflammation, 
smoking, alcohol, exercise and thyroid hormone68.  
   
1.2.3.1 Dyslipidaemia 
Changes in lipid metabolism can lead to elevated levels of  lipoproteins and alterations in 
their function.  These lipid abnormalities may be a result of  other conditions, lifestyle and 
environmental factors or genetic disposition and both individually or in combination with 
other risk factors contribute to the development of  atherosclerosis.   
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Obesity related dyslipidaemia 
 
A large proportion of  people who are obese have dyslipidaemia. This is mainly due to a 
poor diet combined with a sedentary lifestyle in those with a poor genetic and 
environmental disposition.  Obesity related dyslipidaemia manifests itself  as an atherogenic 
lipid triad of  high levels of  triglyceride rich, ApoB containing lipoproteins such as VLDL 
and small dense LDL, plus low levels of  HDL73, 74.  Additionally postprandial triglycerides 
are often raised in those with obesity, which typically become proatherogenic chylomicron 
remnants.  
 
Familial hypercholesterolaemia 
 
Familial hypercholesterolaemia (FH) is a genetic disorder characterised by elevated levels of  
LDL resulting in premature coronary heart disease. Defects in the hepatic uptake and the 
degradation of  LDL lead to poor clearance of  LDL and its increased levels in the plasma.  
These defects are due to genetic mutations mainly in the LDL receptor gene but also in  
the gene coding ApoB, the gene that encodes proprotein convertase subtilisin/kexin type 9 
(PCSK9) and the LDL receptor adaptor protein 1 gene (ARH)75. FH can either be 
heterozygous with patients often having one of  the first three listed gene mutations or 
homozygous due to homozygous or compound heterozygous mutations in the LDL 
receptor or ARH genes76.  
 
The prevalence of  heterozygous FH has been estimated to be 1 in 500 in white Europeans, 
however, a recent analysis of  the US based National Health and Nutrition  Examination 
Survey has put that figure at 1 in 25077.  Homozygous FH is considerably rarer with a 
prevalence of  1/1 000 00076. Patients with untreated heterozygous FH commonly have 
total cholesterol levels of  8-15 mmol/L and, if  untreated, typically develop coronary heart 
disease before the age of  55 in men and 60 in women. In homozygous FH, total 
cholesterol levels are as high as 12-30 mmol/L. Patients typically develop coronary heart 
disease very early in life and if  untreated commonly die before they are 2076.  
 
In the UK, FH is often diagnosed using the Simon Broome criteria.  Patients have to meet 
a number of  different criteria (as described in table 1.1), and can be given a definite 
diagnosis or a probable diagnosis depending on which criteria they meet78.  Two other 
groups have also developed diagnostic tools; these are the Dutch Lipid Clinic Network 
criteria and US MedPed program criteria79, 80.  However, not all individuals diagnosed as 
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having definite or probable FH using these criteria are found to have an identifiable gene 
mutation 81, 82. Modifications of  these criteria are being tested to improve identification of  
hypercholesterolaemia patients for genetic testing83.   
 
 Criteria 
Definite Diagnosis Adult: total cholesterol >7.5 mmol/l or LDL cholesterol above 4.9 mmol/l  
 
Child <16 years: total cholesterol > 6.7 mmol/l or LDL cholesterol above  
4.0 mmol/l 
 
 (Levels either pre-treatment or highest on treatment) 
 
 Plus 
 Tendon xanthomas in patient, or in 1st degree relative (parent, sibling, child), or in 
2nd degree relative (grandparent, uncle, aunt) 
 
 Or 
 DNA-based evidence of an LDL receptor mutation, familial defective ApoB-100, 
or a PCSK9 mutation.  
  
Probable Diagnosis Adult: total cholesterol >7.5 mmol/l or LDL cholesterol above 4.9 mmol/l  
 
Child <16 years: total cholesterol >6.7 mmol/l or LDL cholesterol above  
4.0 mmol/l 
 
 (Levels either pre-treatment or highest on treatment) 
 Plus at least one of the following 
 A family history of myocardial infarction: at <50 years in a 2nd degree relative or 
<60 years in a 1st degree relative  
 
 Or 
 A family history of raised total cholesterol: >7.5 mmol/l in a adult 1st or 2nd degree 
relative or >6.7 mmol/l in a child or sibling aged younger <16 years.  
 
Table 1.1 : Diagnostic criteria for Familial Hypercholesterolaemia as defined by the Simon Broome Criteria78 
1.2.3.2 Lipids and cardiovascular risk 
Low levels of  HDL have been associated with increased risk of  CVD84. However, this 
finding has not followed through to clinical trials of  drugs to raise HDL levels.  Three 
trials, ILLUMINATE, AIM-HIGH and dal-outcomes, have all successfully raised HDL 
with pharmacological agents but did not see a reduction in cardiovascular events85-87.  It has 
therefore been suggested that it is not HDL “cholesterol” per se that is protective but the 
function of  the HDL particles. Thus future pharmacological agents may need to address 
HDL functions rather than HDL cholesterol concentration68.  
 
 LDL is associated with increased cardiovascular risk both individually and in combination 
with other lipid parameters such as low HDL and high triglycerides67. Where lipid levels are 
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raised by genetic determinants such as FH the risk of  cardiovascular disease is even greater. 
In individuals with treated FH the odds ratio for coronary artery disease was 10.3 (7.8-13.8) 
in comparison to non-FH participants, the risk was even in greater in those with FH but 
not on lipid lowering therapy (13.2 [10.0-17.4])88. 
 
Hypercholesterolaemia and subclinical vascular disease 
 
Prior to the development of  premature CVD, patients with hypercholesterolaemia are more 
likely to demonstrate significant subclinical vascular disease. Individuals with 
hypercholesterolaemia have been shown to have poorer endothelial function than those 
with normal cholesterol levels in a number of  studies and clearly demonstrated in a meta-
analysis in FH patients89-92 .  A meta-analysis by Masoura and colleagues also demonstrated 
that structural atherosclerotic disease as defined by carotid IMT was increased in patients 
with FH92. Increased arterial stiffness has also been associated with hypercholesterolaemia93, 
94.   These findings may reflect the impact of  the high levels of  circulating lipoproteins and 
their uptake and retention into the arterial wall promoting inflammation and oxidative 
stress with consequential impact on the endothelial availability of  NO.  
 
1.2.3.3 Treatment of  dyslipidaemia 
Pharmacological agents 
 
The reduction of  lipid levels with pharmacological agents has played a major role in 
lowering the cardiovascular risk of  patients with hypercholesterolaemia. Statins are one of  
the most commonly used lipid lowering drugs. They decrease LDL cholesterol and other 
ApoB rich lipoproteins through their actions on the hydroxymethylglutaryl coenzyme A 
pathway, decreasing synthesis of  LDL but also increasing LDL receptor expression, further 
enhancing the lipid lowering effect. A meta-analysis of  27 randomized statin trials 
demonstrated a reduction in the risk of  major vascular events of  21% per mmol/L 
decrease in LDL95.  A reduction in risk of  coronary heart disease has been shown in FH 
patients by Versmissen et al, who found an overall risk reduction of  76% in FH patients on 
statin therapy. In addition their risk of  myocardial infarction was found to be not dissimilar 
to that of  an age matched group from the general population96. Statin therapy has also 
been shown to improve endothelial function and reduce IMT92, 97, 98.  
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Other pharmacological agents which are effective at lowering LDL are resins and 
cholesterol adsorption inhibitors which act through different pathways to statins but may 
also contribute to the reduction in cardiovascular risk99.    There are other drugs such as 
fibrates and nicotinic acid, which lower triglycerides and can increase HDL. Fibrates have 
been shown to reduce major CVD events particularly in those with increased triglycerides 
and low HDL100.  As with statins, these drugs have also been shown to improve endothelial 
function, slow progression and promote regression of  IMT101-103. 
 
Lipoprotein apheresis 
 
Lipoprotein apheresis (LA) is often used in combination with lipid lowering agents for 
reducing LDL levels. In the UK, it is normally used for patients with homozygous or 
heterozygous FH, who have evidence of  progressive and symptomatic coronary heart 
disease, despite maximal drug therapy, or are intolerant to drug therapy104. LA is an 
extracorporeal treatment that lowers LDL and other ApoB containing particles and is 
similar in concept to renal dialysis. Observational studies in homozygous FH patients have 
shown a reduction in LDL of  up to 72% with LA treatment105. There are five techniques 
which are used clinically for LA: 
 
Dextran sulphate adsorption (DSA).  Dextran sulphate covalently bound to 
cellulose beads selectively binds VLDL and LDL. Originally this method separated 
out the plasma to remove the lipoproteins but this can now also be achieved using 
whole blood106.   
 
Heparin extracorporeal LDL precipitation (HELP) system. This method adds 
heparin to isolated plasma which then causes precipitation of  the LDL particles 
which are removed by filtration. The filtered blood is then run through an adsorber 
to remove any excess heparin before being ultradialyzed to restore physiological pH 
and remove excess fluid107. 
 
Polyacrylate full blood adsorption (PFBA) or direct adsorption of  lipoprotein 
(DALI). This technique uses a non-haemolytic adsorber.  This was the first method 
which was able to adsorb LDL directly from the patients whole blood without the 
need to isolate the plasma108. 
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Immunoadsorption. In this method plasma is pumped through two columns 
containing polyclonal sheep antibodies to human ApoB-100109. 
 
Filtration plasmapheresis. This method involves two filters. Plasma is separated 
from blood cells by the first filter and the second selectively removes molecules 
with larger molecular weights such as LDL whilst retaining HDL and other useful 
components110. 
 
LA is a challenging treatment for patients with some suffering nausea, vomiting, abdominal 
pain and headaches. Each session takes a few hours and patients have to regularly attend 
fortnightly. It is also an expensive treatment with an estimate of£39,000 per patient per year 
and is therefore limited to those patients most in need105.        
 
In addition to its LDL lowering effects, decreases in major adverse cardiovascular events 
and the need for myocardial revascularisation have also been attributed to this treatment, 
although definitive large scale randomized control trials have not been performed 111, 112. In 
addition a number of  studies have demonstrated improved endothelial and vasomotor 
function in both the micro and macro coronary vasculature following apheresis 
treatment113-115. Improvement in endothelial function has also been shown in the peripheral 
microvasculature immediately after apheresis treatment116. The one study looking at 
endothelial function within a conduit artery assessed by flow-mediated dilatation (FMD) in 
the brachial artery in patients with FH, found that patients undergoing long term apheresis 
treatment had similar FMD to controls but did not see an additional improvement in FMD 
immediately following apheresis treatment117. An improvement in FMD was seen by 
Morimoto and colleagues, 4 weeks after the tenth and final apheresis treatment in a group 
of  patients with peripheral arterial occlusive disease118. Improvements have also been 
shown in other subclinical vascular measures. In a group of  patients undergoing lipid 
apheresis treatment IMT progression was slowed in those with homozygous FH whilst a 
reduction in IMT was seen in those patients with heterozygous FH119. However, there are 
currently no studies that have seen an improvement in arterial stiffness either immediately 
after a session of  apheresis or after a year of  regular treatment120, 121.  
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1.2.4 Obesity 
Obesity, defined as a BMI greater than 30 kg/m2 or a waist circumference of  more than 
102 cm for males and 88 cm females, is an increasing problem.  Between 1993 and 2012 the 
proportion of  men in England with a BMI ≥ 30 kg/m2 rose from 13.2% to 24.4%, whilst 
in women it increased from 16.4% to 25.1%.  The proportion of  those with a raised waist 
circumference has also risen from 23% to 39%122. Being overweight and obesity have both 
been associated with increased risk of  CVD123-125. Where the fat is stored (either 
subcutaneously or intra-abdominally)  is also important, as visceral fat has been shown to 
be associated with metabolic abnormities such as insulin resistance and dyslipidaemia 
which are related to increased cardiovascular risk126. Hypertension is also commonly 
associated with obesity and the clustering of  this risk factor plus insulin resistance and 
dyslipidaemia, with obesity as determined by waist circumference (an indicator of  
abdominal obesity), have been termed the metabolic syndrome and is also associated with 
increased cardiovascular risk127. 
 
Endothelial dysfunction has been associated with obesity and metabolic syndrome128-131.  
This is likely due to the impact of  increased free fatty acids, oxidative stress, inflammatory 
cytokines on the availability of  NO and the increased presence of  vasoconstrictors132. 
Arterial stiffness and IMT have also been shown to be increased in those with obesity or 
metabolic syndrome133-135.  
 
Weight loss and lifestyle interventions reduce blood pressure and prevent or delay the onset 
of  type 2 diabetes lowering the risk of  cardiovascular disease136, 137. A dietary and exercise 
intervention in obese children demonstrated an improvement in FMD after 6 weeks and a 
regression in carotid IMT after 1 year in those who continued with the exercise program138.  
 
1.3 Non-invasive assessment of  subclinical vascular function 
and disease 
With the greater understanding of  the processes responsible for atherogenesis, such as the 
role of  the endothelium, and the changes that occur to the structure and function of  the 
arteries throughout the development of  atherosclerosis, a variety of  methods have been 
developed for assessing endothelial function, carotid intima-media thickness and arterial 
stiffness.  Assessing subclinical vascular disease has provided insights into the 
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pathophysiology of  atherosclerotic disease at an early stage, enabled the study of  the 
impact of  interventions and helped identify individuals who are potentially at greater risk 
of  future cardiovascular events. 
 
1.3.1 Endothelial function testing 
Based on the findings of  Furchgott and Zawadzki who demonstrated the importance of  
the endothelium for vascular smooth muscle relaxation, a number of  methods have been 
developed that assess endothelial function12.  These encompass a range of  both invasive 
and non-invasive techniques, which use changes in blood flow or the administration of  
pharmacological agents to assess endothelial function in the coronary circulation, resistance 
vessels or conduit arteries.  These methods have been shown to be related to cardiovascular 
risk factors such as smoking, hypertension, diabetes and dyslipidaemia and to be predictive 
of  cardiovascular events31, 47, 91, 139-144. 
1.3.1.1 Invasive methods 
Endothelial vasomotor function was first clinically assessed in the coronary circulation. 
Using quantitative coronary angiography and Doppler flow-wire techniques changes in the 
epicardial and microvascular responses to endothelium-dependent pharmacological agents 
are measured during cardiac catheterization. Vasodilatation in response to acetylcholine 
indicates preserved epicardial coronary endothelial function. Whereas, constriction of  the 
vessel is suggestive of  the smooth muscle response to direct muscarinic receptor 
stimulation overwhelming the absent or depressed dilation that follows from reduced 
bioavailability of  endothelial NO145. Due to the invasive nature of  this technique, its use is 
restricted to individuals in the more advanced stages of  arterial disease who have clinical 
indications for cardiac catheterization. Despite this limitation, coronary vascular function 
testing has provided important insights into the effects of  atherosclerosis and its risk 
factors on coronary regulatory physiology and risk stratification as well as demonstrating 
the potential reversibility of  endothelial dysfunction in response to treatments such as 
statins and ACE-inhibitors142, 146, 147. 
 
A second invasive method, which is commonly used to assess vasomotor function of  the 
resistance vessels in the forearm, is venous occlusion plethysmography.  This technique 
assesses changes in forearm blood flow (FBF) in response to pharmacological agents. It 
provides its own control by using the contralateral arm, permitting adjustments to be made 
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for systemic influences that affect basal flow and blood pressure in the non-infused arm. 
Most studies measure percentage differences in FBF and vascular resistance between the 
experimental and control arms following administration of  endothelium-dependent and -
independent agonists. Evaluation of  the contribution of  NO to vasomotor regulation can 
be made using eNOS antagonists such as L-NG-monomethyl Arginine citrate (L-NMMA). 
One advantage of  this technique over assessment of  changes in the coronary circulation is 
that it can be used in healthy controls as well as patients, thus enabling study of  the 
endothelium from early in the disease process. Additionally, vasomotor pathways other 
than NO can also be evaluated. However, it is still an invasive technique which limits its 
repeatability and also restricts its use to small studies.   The clinical relevance to 
atherosclerosis has also been questioned, as microvascular pathophysiology may not 
necessarily reflect changes in the conduit arteries in which atherosclerosis develops. 
1.3.1.2 Non-invasive methods 
Flow-mediated dilatation 
 
The ultrasound based technique FMD, is the current gold standard technique for non-
invasive assessment of  the endothelium. This method, first developed by Celemajer et al, 
uses a period of  forearm ischemia (induced by a cuff  around the forearm inflated to 
suprasystolic pressure) followed by reactive hyperaemia to increase brachial arterial blood 
flow and, consequently, local shear stress90. This stimulates the endothelium to generate and 
release NO, activating guanylyl cyclase to produce cyclic GMP in vascular smooth muscle 
which causes relaxation and dilatation of  the artery148, 149. The changes in blood flow and 
vessel diameter can be assessed by imaging the brachial artery and measuring blood flow 
with high resolution 2D ultrasound and Doppler  
 
FMD is normally used in the research laboratory as it is a technically demanding technique 
and is initially expensive to set up,  but has been shown to have good reproducibility in this 
setting150.  It can also be used with care in large epidemiological studies and is increasingly 
being used in clinical trials151, 152.  
 
Differences do exist in the methodology for carrying out assessment of  FMD. The reactive 
hyperaemic stimulus can be affected by both cuff  position and duration of  the occlusion 
period. When the occlusion cuff  is positioned above the ultrasound probe, the whole arm 
is made ischemic including the arterial segment being measured and a larger reactive 
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hyperaemic response and vasodilatation of  the vessel is seen than when the cuff  is placed 
on the forearm distal to the study segment149, 153. A cuff  occlusion of  15 minutes also 
causes a larger hyperaemic response than a 5 minute period89. Therefore, both proximal 
cuff  positioning and longer occlusion periods may not specifically represent NO-mediated 
endothelium-dependent function 149, 154. In contrast, more distal positioning of  the cuff  and 
using a 5 minute occlusion period has been demonstrated to induce NO-mediated 
vasodilatation149, 155.  There has also been much debate on whether the FMD response 
(normally expressed as either a percentage or an absolute change) should be normalized for 
the reactive hyperaemic stimulus. However, a consensus has not yet been reached regarding 
whether or not this should be done nor the best method for doing this.   
 
Pulse wave analysis (PWA) and pulse contour analysis (PCA) 
 
Endothelial function can be assessed by the administration of  agents such as the β2 
adrenergic receptor agonist salbutamol. These can be administered via an inhaler or IV 
infusion and at standard clinical doses, do not affect blood pressure156-158. Salbutamol causes 
the release of  NO from the endothelium via vascular endothelial β2 receptor activation. 
This leads to a reduction in arterial tone and stiffness, and can be measured in the 
peripheral waveform with either PWA by applanation tonometry at the radial artery or 
PCA with digital photoplethysmography. Although the relative simplicity of  this technique 
compared with other methods and a relatively low cost appear advantageous, there are 
some practical concerns regarding its reproducibility compared with FMD150, 159. Also, little 
correlation has been observed between FMD and results with these techniques, which 
could implicate distinct pathophysiological influences at different levels of  the vasculature 
requiring further evaluation150. 
 
Endo-PAT 
 
Another method which is technically straight forward and uses reactive hyperaemia as the 
stimulus to activate the endothelium is pulse amplitude tonometry (PAT).  The Endo-PAT 
system uses a fingertip probe to measures changes in arterial pulsatile volume. It provides 
its own internal control as recordings are made simultaneously in the right and left index 
fingers both prior to and following a 5 minute period of  forearm ischemia.  The reactive 
hyperaemic PAT index is calculated as the ratio of  the average amplitude of  the PAT signal 
over a 1min time interval starting 60 seconds after cuff  deflation, divided by the average 
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amplitude of  the PAT baseline. Reactive hyperaemic-PAT index values from the study arm 
are normalized to the control arm. 
 
Endo-PAT has been shown to have similar reproducibility to that of  FMD and that 
mechanistically the vasodilatation is mediated at least in part by NO160, 161. However, it is 
not entirely NO-dependent, and there is likely to be an important interaction with the 
autonomic nervous system that may confound interpretation of  the results from a 
specifically endothelial perspective. This may account for heterogeneity between the results 
in some studies which have included both Endo-PAT and FMD162, 163.  A second limitation 
of  the technique is the inability to take into account the impact of  autonomic influences on 
endothelium-independent response to systemic glyceryl trinitrate (GTN) due to lack of  a 
simultaneous unexposed control arm. Finally, the fingertip probes used for measuring 
changes in arterial pulsatile volume can only be used once which increases the cost of  using 
this system.  
 
Pulse wave velocity 
 
Endothelial function can also be assessed by measurement of  PWV. PWV is the time taken 
for a pulse waveform to travel along the artery wall; it is calculated as distance over time 
and provides a measurement of  arterial stiffness. In the brachial artery, it reflects both 
arterial wall composition and smooth muscle tone. In response to a reactive hyperaemic 
stimulus, which increases shear stress and stimulates endothelial NO release, PWV slows 
due to the resultant drop in smooth muscle tone164. This simple technique was first 
developed by Naka et al and uses two cuffs, one placed at the wrist and one on the upper 
arm, to assess PWV over the brachio-radial tract; the reactive hyperaemic stimulus is 
induced by wrist cuff  occlusion. In their study, Naka et al demonstrated that PWV reduced 
by 14.2% in the upper limb of  healthy volunteers following reactive hyperaemia164.  When 
they looked at the response in a group of  patients with chronic heart failure the reduction 
in PWV was lower at 8%.  However, in both groups PWV decreased similarly in response 
to administration of  GTN indicating that the differences between the healthy and disease 
groups were due to endothelial dysfunction. Additionally Naka et al looked at the effects of  
stimulating and inhibiting NO production on PWV by the administration of  acetylcholine 
and the nitric oxide synthase inhibitor L-NMMA.  Stimulation of  NO caused a decrease in 
PWV whilst inhibition increased PWV indicating a role of  NO in mediating changes in 
PWV. In unpublished observations the group had also noted that L-NMMA had been 
shown to inhibit hyperaemic changes in PWV164.  
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Other groups have since carried out further studies using this technique but have used the 
carotid to radial pathway, and different methods of  assessing PWV.  Reproducibility of  the 
method in the carotid to radial tract has been demonstrated by two groups, one, using the 
Sphygmocor for measuring PWV had a coefficient of  variation (CV%) of  12% whilst the 
second group, Graf  et al, who assessed PWV with mechanotransducers, had a CV% of  
9.7%165, 166.   A further methodological discrepancy between these studies and the technique 
as originally published by Naka et al is with the positioning of  the occlusion cuff.  Naka et 
al placed the occlusion cuff  at the wrist, Kamran et al, positioned it around the upper arm, 
whilst Graf  et al occluded the forearm164-166.  As discussed in the section regarding FMD 
the positioning of  the occlusion cuff  may have implications on how much the slowing in 
PWV following reactive hyperaemia is mediated by NO.  It is also worth noting that the use 
of  the carotid to radial arterial tract involves the more elastic carotid artery. Muscle tone 
has less influence on the stiffness of  the carotid artery than the brachial and radial arteries 
which may influence the changes in pulse wave velocity following hyperaemia.  
 
Additional studies have been carried out in groups with risk factors where the decrease in 
PWV following the reactive hyperaemic stimulus has been shown to be diminished in those 
with increasing Framingham risk scores, congestive heart failure and in pregnant and non-
pregnant hypertensives165, 167-171.  
 
1.3.1.3 Utility of  endothelial function testing  
Endothelial function testing has been used in a wide range of  studies from small cross 
sectional studies to large cohort studies.  This has enabled demonstration of  its role in the 
causal pathway of  atherosclerosis by showing endothelial dysfunction in children with 
FH139.  In addition, the relationships between endothelial function and cardiovascular risk 
factors have been seen in smaller studies and confirmed in the larger cohort studies172, 173.  
Furthermore, prospective studies have enabled the demonstration of  the linkage between 
endothelial function and arterial disease with an inverse association between FMD and 
carotid IMT in the Young Finns study, whilst a second study has shown that FMD is 
predictive of  IMT progression174, 175.  Prospective studies have also shown the association 
between endothelial function and prediction of  cardiovascular events142, 176.   
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Endothelial function testing is also increasingly used in intervention studies as it is possible 
to detect changes in endothelial function relatively quickly in comparison to other longer 
term time points such as changes in the carotid and coronary wall or the occurrence of  
clinical cardiovascular events. It also enables the study of  additional beneficial drugs 
outside of  their primary aim.  For example statins have been demonstrated to have a 
beneficial effect on endothelial function in addition to their lipid lowering properties92. 
 
Despite the increasing usage of  endothelial function testing in a wide range of  trials, there 
are still limitations with the current techniques in terms of  equipment and expertise 
required to carry out these methods.  There is still room for alternative methods that are 
cheaper, simpler to use and more easily scalable to further progress the use of  endothelial 
function testing.     
 
1.3.2 Measurement of  arterial stiffness 
Arteries stiffen with age due to changes in their shape and the composition of  their major 
structural proteins collagen and elastin8. This increased stiffening may contribute to the 
development of  cardiovascular disease by raising systolic blood pressure, increasing cardiac 
after load and reducing cardiac perfusion177.   
 
There are a number of  different indices and methods for measuring arterial stiffness.  Two 
commonly used indices are PWV (the speed at which a pulse wave travels) and distensibility 
(the relative diameter change for a pressure increment). 
 
Carotid to femoral PWV is currently viewed as the “gold standard” method for assessing 
regional arterial stiffness.  Other arterial tracts can be assessed such as the brachial to 
femoral arteries and the carotid to radial arteries. Common techniques for assessing PWV 
are applanation tonometry (Sphygmocor), mechanotransducers (Complior) and 
oscillometry (Vicorder).  Magnetic resonance imaging (MRI) is also being increasingly used 
for assessing PWV and although not such an accessible or easy to use method, it has the 
advantage of  being able to provide accurate path length measurements,  this being a much 
debated methodological area177.   
 
Distensibility is a measure of  local stiffness and is often measured in the carotid artery due 
to its accessibility. It is commonly assessed by ultrasound often with echotracking software 
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to assess the change in diameter over the cardiac cycle. Ideally the blood pressure local to 
the site being measured should be used, but brachial blood pressure is commonly used for 
calculating carotid artery distensibility. MRI can also be used for assessment of  
distensibility particularly of  the aorta177, 178.   
 
Both increased PWV and decreased carotid distensibility have been shown to be associated 
with cardiovascular risk factors and predictive of  cardiovascular events and stroke93, 178-182.  
 
1.3.3 Measurement of  atherosclerosis  
One of  the simplest measures for assessing atherosclerosis is IMT.  This is the distance 
between the intimal and medial layers of  the artery wall.  Atherosclerosis mainly occurs in 
the intimal layer of  the vessel wall183. However, it is not possible to determine with 
ultrasound in which layer the thickening occurs, therefore some thickening of  the wall may 
be of  non-atherogenic origin184.  Numerous studies have shown an association between 
IMT and its progression with cardiovascular risk factors, it is also a predictor of  
cardiovascular events such as stroke and myocardial infarction52, 92, 133, 185, 186. A thickened 
IMT of  ≥0.9mm is considered to be a surrogate marker of  generalized atherosclerosis38. 
 
IMT is normally assessed using B-mode high resolution ultrasound often in the common 
carotid artery but also in the internal carotid artery and carotid bulb.  Originally the 
distance between the intima and media was measured from end-diastolic images using 
ultrasonic callipers. However, this method has now been replaced with the development of  
echotracking and edge detection software which allow for a more detailed and accurate 
measurement. Due to its relative ease of  use, reliability and applicability, assessment of  
IMT has been used in a wide range studies including epidemiological studies and clinical 
trials187, 188.  
 
In addition to assessing IMT using ultrasound, it is also possible to identify plaques within 
the artery.  These are defined as areas of  the artery wall where the IMT is considerably 
greater than adjacent sites or where encroachment on the lumen can be identified189.  The 
presence of  plaque is related to increased risk of  cardiovascular events190.  Although 
ultrasound is very useful for identifying plaques and can detect some features of  the plaque 
such as whether it is calcified or lipid rich, it does have its limitations in its ability to 
distinguish the constituents and morphology of  plaque .  Other methods have been 
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developed such as magnetic resonance imaging, computerised tomography and positron 
emission tomography that can provide more detailed information on the features and 
components of  plaques in the carotid and coronary arteries. These methods have been 
reviewed by Joshi et al191. 
  
1.4 Mental stress and cardiovascular disease 
“Stress is a state of  threatened homeostasis provoked by a psychological, environmental, or 
physical stressor” 192.  
 
An increasing body of  work has demonstrated the effects of  stress on the cardiovascular 
system. Stress can generally be divided into two categories, psychosocial/chronic stressors, 
which can lead to accelerated atherosclerosis and higher rates of  coronary heart disease 
incidence, and acute stressors which can trigger acute cardiac events such as myocardial 
infarction or angina.   
 
1.4.1 Pyschosocial/ chronic stress 
There are a wide range of  psychosocial factors that can impact on the development and 
risk of  cardiovascular disease.  These broadly consist of  groupings such as socio-economic 
status and social class, occupation related stress, such as job strain or job control, social 
factors, such as low social support or isolation, and negative emotional states, such as 
depression, anxiety or hostility. 
  
1.4.1.1 Depression 
Major depression can be characterised by the presence of  a depressed mood and a lack of  
interest in all activities which lasts for at least two weeks and is accompanied by changes in 
a number of  areas such as appetite, sleep disturbance, feelings of  guilt or worthlessness, 
problems concentrating and suicidal thoughts193. It is often diagnosed through the use of  
structured questionnaires administered by trained clinicians based on the description of  
psychiatric disorders in the Diagnostic and Statistical Manual of  Mental Disorders (DSM). 
In a European study looking at the prevalence of  common mental disorders in general 
practice attendees 13.9 % women and 8.5% men were identified as having a major 
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depressive disorder194.  The greater prevalence of  depression in women has also been seen 
in a study based purely on UK general practice data195. Additionally, in patients with known 
heart disease the prevalence of  depression in cross-sectional studies is about 20%196.  
 
1.4.1.2 Anxiety 
 Anxiety is characterized by transient fear, uncertainty, and apprehension about the future, 
but individuals vary on the frequency and intensity with which they experience anxiety197. 
Anxiety disorders can include generalised anxiety disorder, panic disorder and phobias. The 
prevalence of  anxiety disorders has been shown to be 10% in women and 5% in men 
within Europe194. In the United States, the lifetime prevalence of  any anxiety disorder has 
been shown to be over 28%198.  Additionally, there is a high level of  co morbidity between 
anxiety and depression197.  
 
1.4.2 Acute mental stress 
Acute mental stressors are stimuli or activities that can cause negative emotional states. 
These can include earthquakes, war, terrorist attacks, sporting events, anger and acute work 
stresses such as high pressure deadlines. Negative emotional states can lead to acute 
physiological or pathophysiological changes that in this context can trigger a cardiovascular 
event199.   
 
1.4.3 Associations with cardiovascular disease  
A large number of  studies have demonstrated an association between psychosocial 
/chronic stress and CVD. One of  the largest studies to have looked at the influence of  
psychosocial factors on cardiovascular events is the INTERHEART study200. It included 
11,119 patients with a first myocardial infarction and 13, 468 controls and asked four 
simple questions about stress at work and at home, financial stress and major life events in 
the past year.  There was a greater prevalence of  all four stress factors in those who 
presented with a myocardial infarction compared to controls, and the presence of  
psychosocial stressors increased the risk of  acute myocardial infarction200. Increased risk of  
CVD has been shown to be associated with numerous individual chronic stressors 
including for example social isolation, care of  a sick partner and job strain201-203.  
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The relationship between depression and CVD is a much studied area in part due to the 
consistent association between the two.  Patients with CVD and depressive symptoms are 
at greater risk of  future cardiovascular events and mortality204-206. Whilst those who have 
had major depressive disorders are also at increased risk of  cardiovascular disease207.   
Population based studies in participants free from CVD have shown that depression 
predicts subsequent CVD and cardiovascular events in both men and women208, 209.  A 
meta-analysis of  11 prospective studies found that the relative risk of  depressed patients 
developing coronary heart disease was 1.6 with the risk being greater in those with clinical 
depression than those with depressive mood210.   
 
Anxiety has also been shown to be a predictor of  CVD and death.  A meta-analysis of  20 
studies reporting on incident of  coronary heart disease in initially healthy participants, 
showed hazard ratios of  1.26 for risk of  coronary heart disease and 1.48 for cardiac 
death211.  However, in patients who already have cardiovascular disease the findings have 
been mixed. Some studies have demonstrated an association between higher levels of  
anxiety and poorer prognosis and increased recurrence of  cardiovascular events, whereas 
other studies have suggested that anxiety may be protective in coronary patients212-215.   
 
Acute stressors are more difficult to assess than chronic stressors. However, through the 
use of  retrospective data, associations between acute mental stressors and cardiac events 
have been seen. Increases in sudden cardiac death and acute myocardial infarction (MI) 
have been seen following earthquakes in Northridge, Los Angeles and Hanshin- Awaji, 
Japan216, 217.  However, there was no difference in the numbers admissions for acute MI on 
the day of  an earthquake in the San Francisco Bay area compared with the days before or 
after the earthquake218. The discrepancy in these findings has been suggested to be due to 
the time of  day of  the earthquake, with both the Northridge and Hanshin-Awaji occurring 
in the early morning, thereby adding a second stressor to the stress of  waking,  whereas the 
San Francisco earthquake took place in the afternoon219.   
 
Other events such as national side football matches in international tournaments have also 
been associated with an increase with cardiac events.  On the day of  a European 
Championship football match between France and Holland there was a relative risk of  
death from acute MI or stroke of  1.51 for Dutch men in comparison to the 5 days either 
side of  the match.  There was no change in women220.  Other studies have also seen 
increases in events with other crucial matches, although, some studies have not 
demonstrated an effect221-223.  Finally, individual emotional triggers such as anger and acute 
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stressors such as high pressure deadlines have been associated with increased risk of  
cardiovascular events224, 225. 
 
1.4.4 Mechanisms of  mental stress   
As discussed above, both chronic and acute emotional stressors are associated with 
increased risk of  cardiovascular disease and events. However chronic stressors seem to 
increase cardiovascular risk largely through acceleration of  the atherosclerotic process, 
whereas acute emotional stressors appear to trigger acute arrhythmic, thrombotic or 
mechanical events226.   
 
The responses to acute mental stressors are largely mediated through activation of  the 
hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system (SNS).  
Stimulation of  the hypothalamus causes the release of  corticotrophin releasing factor 
which acts on the anterior pituitary causing the production of  adrenocorticotrophic 
hormone which leads to the release of  cortisol from the adrenal cortex.  Cortisol has a 
number of  effects which include, increasing blood pressure, insulin resistance, anti-
inflammatory effects, central obesity and increased coagulation, many of  which are 
considered to be cardiovascular risk factors227-230.  Activation of  the SNS leads to the release 
of  catecholamines, mainly adrenaline. The effects of  these include increases in heart rate, 
decreased heart rate variability, the release of  inflammatory cytokines such as IL-6, 
increases in coagulation factors and raised blood pressure44, 231-234. Figure 1.3 gives a 
summary of  this process and some of  the changes brought about by activation of  the HPA 
and SNS. 
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.  
Figure 1.3: Pathways of the stress response featuring the hypothalamic-pituitary-adrenal axis and the 
sympathetic nervous system. CRH = corticotrophin releasing hormone. The cardiovascular responses are at 
the bottom of the figure, with those responses controlled by both axes in the centre. Adapted from Brotman 
et al226. 
 
A key part of  the response to acute stress which may play a role in the development of  
atherosclerosis is the inflammatory response.  Acute stressors trigger the inflammatory 
acute phase response which involves the generation of  the pro-inflammatory cytokine IL-
6.  One of  the numerous roles of  this cytokine is the inducement of  the acute phase 
hepatic response which results in the production of  acute phase proteins such as CRP and 
fibrinogen. Both of  these are present in patients with coronary disease and are predictors 
of  future coronary risk in healthy subjects235, 236. Fibrinogen causes endothelial and smooth 
muscle cell activation, increases blood viscosity, platelet activation and aggregation and 
immune cell recruitment which are all key in the development of  atherosclerosis237-240.  In 
addition, it plays a key role in the coagulation cascade where it is broken down into fibrin 
monomers which form a clot; fibrin is also found in atherosclerotic plaques240, 241. 
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Many of  the responses referred to above, such as HPA dysregulation, also relate to those 
found in chronic stress.  Cortisol levels in both urine and plasma have been found to be 
increased in patients with major depression242, 243.  In addition patients with depression have 
been shown to have adrenal hypertrophy, impaired suppression of  cortisol after a 
dexamethasone challenge and blunted cortisol reactivity and recovery to psychological 
stress challenges244-246.  Elevated levels of  cortisol are also seen in patients with anxiety 
disorders247. The dysregulation of  the HPA axis seen in psychological disorders does not 
only result in its hyperactivity with elevated cortisol levels, sufferers of  post-traumatic stress 
disorder have been shown to have low levels of  cortisol and diminished cortisol responses 
to stressors248. Sympathetic hyperactivity has also been recorded in those with depressive 
disorders evidenced by increased levels of  catecholamines and decreased heart rate 
variability249, 250.  In addition subjects with a high Beck depression score have shown delayed 
adrenaline recovery in response to a stressful task251.  Depression and anxiety have also 
been associated with hypertension, dyslipidaemia, obesity and weight gain, metabolic 
syndrome, diabetes, increased CRP and other cytokines252-259.  
 
In addition to these physiological consequences of  psychosocial factors such as depression 
and anxiety and their relationship with cardiovascular disease, behavioural changes should 
also be taken into account.  Those with depression and anxiety are more likely to smoke, be 
non-compliant with medication and lead sedentary lifestyles than those without these 
psychosocial factors260, 261. 
 
1.4.5 Depression, anxiety and IMT and arterial stiffness 
A number of  studies have investigated the relationship between psychosocial factors and 
subclinical measures of  atherosclerosis such as IMT and arterial stiffness to try and provide 
an early insight into the development of  arteriosclerotic and atherosclerotic disease.  
However, there has been notable variation within the results.  
 
Depression and symptoms of  depression have been associated with increased IMT in a 
number of  studies. In a study of  1505 Asian Indians, Poongothai et al found that high 
levels of  depressive symptoms were associated with both increased IMT and augmentation 
index (AIx), although the relationship with AIx was lost after adjustment for cardiovascular 
risk factors (age, gender, BMI, glucose, cholesterol and hypertension)262. Similarly, 
Faramawi et al showed that those with depressive symptoms had increased IMT in an 
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elderly population, as did two other studies looking at late onset depression263-265.  However, 
Kabir et al only saw an association between depression score and IMT in the carotid bulb 
and not in the internal or common carotid arteries in a population of  young adults266.  
Further analysis also found that there was a significant negative effect of  the interaction 
between depression and total cholesterol / HDL ratio on IMT.  Sub analyses showed that 
those in the highest quartile of  TC/HDL had a negative association between IMT and 
depression score, whereas in the lowest quartile it was a positive relationship.  It is worth 
noting that only approximately 5% of  the total population (n=996) were in the highest 
depression category which may have an impact the applicability of  the findings 266.  In an 
analysis by Hamer et al, it was found that increased IMT was positively associated with 
depression score and that those with depression were more likely to have metabolic 
syndrome.  The presence of  metabolic syndrome accounted for 21% of  the association 
between depressive symptoms and IMT267. However, in a study of  police officers, Violanti 
et al initially found no relationship between IMT and depression symptoms but on 
stratification of  the data by hypertension status showed that a higher CES-D score was 
associated with greater IMT but only in officers without hypertension268.   
 
Differences in the relationship between depressive symptoms and IMT have been seen 
according to gender. In the Young Finns study, depressive symptoms were associated with 
increased common carotid IMT in males but not females269.  Chirinos et al did not find an 
association between IMT and depressive symptoms in a multivariate analysis, but found a 
moderating effect of  gender on the relationship, with a significant association between 
depressive symptoms and increased IMT only in males270. It was suggested that the lack of  
association between IMT and depression in the middle-aged women may partly be due to 
the protective effects of  oestrogen. Lee et al showed IMT was greater in Korean women 
with depressive symptoms; a relationship which remained after adjustment for 
cardiovascular risk factors, menopause and postmenopausal hormonal state. However, in 
this study they did not find a relationship between IMT and depression in men271. In 
another study of  336 healthy middle-aged women, those women with recurrent major 
depression had a 2 fold greater risk of  carotid plaque in comparison to those without a 
lifetime history of  depression.  However, IMT was not increased in those with recurrent or 
isolated major depressive episodes272.  A second study in a large community population also 
found that history of  depression was related to presence of  plaque but not IMT273. A lack 
of  association between IMT and symptoms of  depression has also been seen in other 
studies with both genders 274-277. It is worth noting that in these studies a variety of  
questionnaires such as the CES-D scale, Beck Depression Inventory or Patient Health 
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Questionnaire were used to identify symptoms of  depression which may partly contribute 
to the differences in findings.   
 
Relationships have also been seen between symptoms of  depression and the progression 
of  IMT278, 279. Stewart et al found increased IMT progression with greater depressive 
symptoms. They also found that somatic symptoms of  depression were associated with 
IMT progression but there was no relationship with cognitive symptoms.  Additionally, 
they looked at the relationship with symptoms of  anxiety, but saw no association with IMT 
progression279. This was in contrast to Paterniti et al who found that men with sustained 
anxiety (high anxiety scores at both baseline and 2 year follow up) had the greatest 
progression in IMT and a high risk of  plaque occurrence 4 years after baseline 
assessment280.  There was a similar trend in IMT progression for women but this did not 
reach significance (p=0.07)280. However, Paterniti et al looked at sustained anxiety, whilst 
Stewart et al only measured anxiety at baseline, which may account for the differences in 
findings279, 280. The majority of  studies have not found an association between future or 
concurrent IMT and anxiety symptoms270, 272, 275, 281-284. One recent study in South Asians 
living in America, has shown that men have increased IMT with higher levels of  anxiety 
symptoms and a second Brazilian study also found a positive association having included 
adjustment for gender, but in general there is less evidence of  a relationship between IMT 
and anxiety than with symptoms of  depression277, 285.  
 
Fewer studies have looked at the influence of  depression and anxiety on arterial stiffness as 
a measure of  subclinical atherosclerosis. Tiemeier et al found in an elderly population that 
those participants with greater arterial stiffness, as measured by central PWV and carotid 
distensibility coefficient, were more likely to have a depressive disorder286. Whereas, 
Seldenrijk et al did not find a relationship between carotid distensibility coefficient with 
either depression or anxiety disorders, but did show that AIx was increased in both 
disorders in comparison to controls287. Anxiety has also been found to be predictive of  
increased central PWV in Korean Americans independent of  other confounding risk 
factors288.  Other studies have also shown increased PWV in those with anxiety disorders 
when compared with control participants but again conflicting results have also been 
seen289-292.   
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1.4.6 Depression, anxiety and endothelial function 
The first study to show an association between depression and FMD was by Rajagopalan 
and colleagues in 2001293.  FMD was reduced in a group of  young depressed patients 
without cardiovascular risk factors when compared with matched controls. This 
relationship remained after multivariate analysis including adjustment for cardiovascular 
risk factors.  This finding was closely followed by Broadley et al, who also demonstrated 
diminished FMD in patients with treated depression but free from CVD risk factors in 
comparison with healthy controls294. However, Taylor et al, found no difference in FMD 
between depressed and matched non-depressed subjects, who were all at high risk for 
coronary artery disease due to either elevated blood pressure or lipid levels295. Another 
study, looking at postmenopausal women who had a life time history of  major depressive 
disorder but were free of  cardiovascular disease had significantly lower FMD than never 
depressed controls296. The number of  depressive episodes was also related to poorer 
endothelial function. The same group also found that recurrent depressive disorder was 
associated with lower FMD in women with type 2 diabetes297.   
 
Further work has looked at the relationships between symptoms of  depression and anxiety 
as assessed by scales such as the CES-D or Beck Anxiety Inventory, and endothelial 
function. Hemingway et al, in data from the Whitehall II study, showed that decreased 
FMD was associated with mild depression but not with other psychosocial factors such as 
anxiety, in a healthy non-smoking middle-aged population284.  However, lower FMD was 
associated with measures of  both anxiety and depression symptoms in postmenopausal 
women and healthy adults 298, 299. In a group of  patients free of  coronary heart disease but 
with at least two risk factors for it, those with depressive symptoms had lower FMD and 
increased total cholesterol and inflammatory markers compared to those without 
symptoms253. Patients with coronary heart disease or stable angina and high scores of  
depressive symptoms have both been shown to have impaired FMD compared with 
patients with these conditions but low depressive symptoms300, 301.  
 
Not all studies have found an association between psychosocial traits and endothelial 
function.  In a longitudinal study of  care givers who were assessed annually for 3 years, 
there was no relationship between depressive symptoms and FMD overtime302.  
Furthermore, in a study of  332 older adults, despite associations between suppressed anger 
and FMD for females and hostility and FMD for males, there was no association with 
symptoms of  either depression or anxiety for either gender.  However, the scores for both 
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depression and anxiety were skewed towards the lower end of  the scale which may account 
for the lack of  association in this study303.  Another study which did not see an association 
between FMD and anxiety in patients with clinically diagnosed atherosclerotic vascular 
disease did find that both endothelium dependent and independent resistance vessel 
function was reduced which may suggest a different mechanism for anxiety304. 
  
Overall the body of  evidence suggests that FMD is impaired in the presence of  high 
depressive scores or major depressive disorders.  This is further substantiated by a 
systematic review by Cooper et al who concluded that there was an inverse correlation 
between FMD and depressed mood305.  There is less evidence for a relationship between 
FMD and anxiety and this remains an area for further exploration. 
 
1.4.6.1 Acute mental stress and vascular structure and function 
The assessment of  cardiovascular responses to acute laboratory mental stressors allows the 
investigation into the potential mechanisms which underlie the development of  CVD and 
can trigger cardiac events. These tests can include either a single stress challenge or a 
combination of  tests such as an arithmetic test, mirror tracing task, colour word association 
(stroop) or a public speaking task. A number of  studies have looked at how these tests or 
physiological responses to the challenges relate with measures of  vascular structure and 
function which are early makers of  cardiovascular disease.  
 
As a measure of  vascular structure, studies looking at the relationships between IMT and 
acute stress have focused on whether differences in the physiological responses to acute 
stressors are associated with increased IMT.  Studies in adults have shown that changes in 
systolic, diastolic and pulse pressure have all been associated with both contemporaneously 
assessed and future IMT306-309. A recent study has also found that carotid systolic blood 
pressure reactivity (stress response minus baseline) to stress is positively associated with 
IMT in healthy adults310. It is not only the response to stress that has been shown to be 
important, but also the recovery from the stress response. A study by Steptoe et al found 
that delayed systolic blood pressure recovery was associated with increased IMT in those 
with lower socio-economic status311.  In children, systolic blood pressure reactivity to stress 
has been shown to be predictive of  IMT312-314. Another study in adolescents, where 
responses to mental stress challenges were assessed at two times points, demonstrated a 
positive association between increased diastolic blood pressure reactivity and IMT315. In 
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addition to blood pressure changes, alterations in heart rate in response to acute mental 
stress challenges have also been associated with IMT.  Both greater heart rate reactivity and 
better recovery have been associated with lower IMT316, 317.  It has also been suggested that 
the association between heart rate reactivity to stress and IMT is mediated through the 
association of  heart rate reactivity with obesity and smoking318.  
 
A few studies have looked at the impact of  acute mental stress challenges on measures of  
arterial stiffness. Vlachopoulos et al demonstrated that both aortic PWV and AIx (as a 
measure of  wave reflection) were increased following a mental arithmetic test319.  Other 
studies have also seen increases in these parameters and a decrease in arterial compliance 
either during or following mental stressors320-322. Other studies have looked at the 
association of  physiological responses to stress with carotid stiffness. Lipman et al, found 
that greater arterial pressure responses to stress were associated with increased carotid 
stiffness323.  Another study has shown that participants with the greatest inflammatory 
responses to acute stressors had increased carotid distensibility at a subsequent assessment 
3 years later324. However, there is limited work in this area in both the immediate responses 
to acute stress and future relationships. 
 
Studies looking at the relationship between endothelial function and acute mental stress 
have investigated this in two ways, by either assessing endothelial function during the stress 
test or at time points following the stress tasks.  The first study to show a relationship 
between acute mental stress and endothelial function in healthy adults was by Ghiadoni et 
al325.  FMD was assessed before a stress test, which involved preparing a speech to defend 
themselves against a false allegation of  shoplifting, and at 30, 90 and 240 minutes after the 
stress test.  It was found that FMD in healthy subjects was significantly lower at 30 and 90 
minutes post stress.  Importantly endothelium-independent vasodilatation as assessed by 
GTN was not affected.  In this study they also looked at the effect of  mental stress on 
FMD in non-insulin-dependent diabetes patients but did not see any significant changes325. 
Other studies have also seen diminished FMD post acute mental stress challenges in 
healthy subjects326-331.   
 
When endothelial function has been assessed during the acute mental stress tests the results 
have been more varied. Two studies saw no change in FMD; however when Lind et al 
normalized their data for blood flow, a significant decrease in FMD during mental stress 
became apparent332, 333 .  A study by Gottdiener et al also saw a reduction in brachial artery 
vasodilatation when expressed as the time-diameter integral (area under the curve -AUC) 
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when mental stress was administrated during cuff  occlusion and compared with cuff  
occlusion alone334. In this study Gottdiener et al also compared the responses in subjects 
with and without elevated cholesterol. They found that those with elevated cholesterol had 
less dilatation of  the brachial artery (as expressed by AUC) during a mental stress challenge 
alone, but there was no difference between the two groups for dilatation induced by cuff  
occlusion when assessed alone and concomitantly with mental stress334.   One study has 
shown an improvement in FMD during a standard mental arithmetic challenge. However it 
is worth noting that the baseline brachial artery diameter recorded during the stress test was 
lower than for the pre-test FMD and may partly account for this finding.  Vasoconstriction 
of  the brachial artery during stress testing has also been shown by Ghiadoni et al325.   A 
meta-analysis of  the studies included here concluded that FMD did not change 
significantly when assessed during the mental stressor but there was a significant reduction 
in FMD post stress challenge335. 
 
There is only one study which has looked at physiological responses to acute mental stress 
and FMD.  In the Young Finns study, participants who had better respiratory sinus 
arrhythmia recovery in response to a stress challenge and above median FMD assessed 2 
years later, had lower IMT.  Whilst those participants with low FMD and a slower pre-
ejection period recovery and was related to increased IMT336.  Therefore, there is a gap in 
the knowledge about whether physiological responses to acute stressors and the future 
development of  cardiovascular disease are mediated by changes in endothelial function. 
Also there is limited information about whether there are differences in the responses to 
mental stress and how these relate to measures of  subclinical vascular disease in those who 
already have cardiovascular risk factors.   
 
1.5 Aims of  thesis 
Aim 1: To investigate the associations between stress, both chronic and acute, and 
measures of  subclinical vascular structure and function in the Whitehall II cohort. 
 
The evidence for an association between measures of  subclinical vascular disease such as 
IMT and arterial stiffness and depression and anxiety is mixed. Although there is stronger 
evidence for an association with FMD and depression there is a paucity of  evidence in 
those with anxiety in all measures.  Furthermore it is unclear whether the presence of  other 
cardiovascular risk factors which are commonly present in those with depression and 
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anxiety further exacerbates any associations between subclinical vascular disease and these 
chronic stressors.  For acute stress, there is limited evidence on the impact of  an 
individual’s responses to acute stressors on future subclinical vascular disease and the 
influence of  the presence of  other cardiovascular risk factors.  The Whitehall II cohort is a 
well characterised, large epidemiological study which includes measures of  depression and 
anxiety symptoms and measures of  artery structure and function.  In addition, it also 
includes a substudy of  participants who have undergone an acute mental stress challenge 
assessment. Thus, it is an appropriate cohort to permit exploration of  the associations 
between chronic and mental stressors and cardiovascular disease. 
 
Aim 2: To demonstrate the reproducibility of, and further validate a new technique for the 
assessment of  vasomotor function. 
 
There are a number of  methods currently available for assessing endothelial function using 
invasive and non-invasive occlusion such as forearm plethysmography and flow-mediated 
dilatation respectively.  However, these methods have their limitations, including the risk of  
invasive methods and the cost and complexity for non-invasive methods.  Therefore, there 
is a need for a new simple and relatively inexpensive method with the potential to be used 
effectively by a wider range of  researchers both in the research laboratory and out in the 
field.  However, any new method will need to have been shown to be reproducible, 
repeatable and sensitive enough to detect differences in vasomotor function before it can 
be put to wider use. 
 
Dyslipidaemia is a well known cardiovascular risk factor and is associated with increased 
IMT and arterial stiffness and poor endothelial function which have all been demonstrated 
to improve with treatment. This makes it a useful model for further investigating its impact 
on relationships between both chronic and acute stressors and subclinical vascular 
dysfunction and disease. Furthermore, it could be considered a useful paradigm for 
validation of  a new model of  endothelial function assessment. For example, by testing 
whether the new method is sensitive enough to detect differences in those with and 
without dyslipidaemia and also the impact of  treatment known to improve other validated 
markers of  subclinical disease.  
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Chapter 2. Whitehall II methods  
 
2.1 Whitehall II population 
The Whitehall II study consisted of  10,308 (3,413 women) nonindustrial civil servants, 
aged 35 to 55, who were recruited between 1985 and 1988, to investigate social and 
occupational influences on health and disease337.  The study entailed repeated follow-ups 
every 2 to 5 years including clinic visits and self-administered questionnaires.  Phase 7 
(2003-2004 )of  the study involved a clinic visit and participants were also invited to attend 
the Vascular Physiology Unit at the Institute of  Child Health, UCL, for an additional 
assessment of  their carotid artery intima-media thickness.  In addition, a subgroup of  
participants was invited to also undergo endothelial function assessment.  This subgroup 
consisted of  three groups of  participants.   During the previous clinical assessment at 
phase 5 (1997 to 1998), a random sample of  non-smokers had been invited to take part in a 
vascular function substudy of  whom 140 participants took part.  A further 143 of  the 
Whitehall II participants were identified based on glucose tolerance tests as having 
metabolic syndrome, glucose intolerance or glucose tolerance and also underwent vascular 
studies at phase 5. Both of  these groups of  participants were invited for a repeat 
endothelial function assessment at phase 7. Finally, participants from a psychobiology study 
were also included in the subgroup for endothelial function evaluation. Figure 2.1 gives 
more detail of  the Whitehall II population and study phases.  
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Figure 2.1: Summary of the Whitehall II study from phase 1, including the substudies that formed the 
population who underwent flow-mediated dilatation (FMD) assessment at phase 7. IMT = intima-media 
thickness. 
 
2.2 Whitehall II phase 7 assessment 
Participants attended a clinic where they underwent a wide range of  clinical assessments 
and completed an extensive questionnaire, the link for which is included in appendix 1. 
 
2.2.1 Identification of  symptoms of  depression and anxiety 
Participants completed two self-administered questionnaires to identify symptoms of  
depression and anxiety.  The first questionnaire was the 30-item General Health 
Questionnaire (GHQ).  It is a screening instrument designed for population-based surveys 
and trials and is widely used in such studies338. Each questionnaire item enquires about a 
specific symptom. From the questionnaire a depression symptom score was calculated 
from the responses to the following four items, ‘been thinking of  yourself  as a worthless 
person’, ‘felt that life is entirely hopeless’, ‘felt that life isn’t worth living’, and ‘found at 
times you couldn’t do anything because your nerves were too bad’.  These items are a 
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subset of  the seven items in the depression subscale of  the GHQ-28338. They were 
assessed using a four point Likert scale (range 0-3). The scores for each item were added 
together and those with a total score of  4 or more were identified has having the presence 
of  depressive symptoms as has been used in other studies of  this cohort339-341. 
 
In addition, the GHQ was used to identify those with anxiety symptoms using a ﬁve-item 
anxiety symptom score (‘lost much sleep over worry’, ‘felt constantly under strain’, ‘been 
getting scared or panicky for no good reason’, ‘found everything getting on top of  you’, 
‘been feeling nervous and strung up all the time’).  These are a subset of  the seven items of  
the GHQ-28 anxiety scale and were assessed using a Likert scale (range 0-3).  As in a 
previous study those whose score was in the top quartile were classified as having 
anxiety284. 
 
The second questionnaire used for assessing symptoms of  depression was the Centre for 
Epidemiologic Studies Depression Scale (CES-D)342. The 20 items of  the CES-D measures 
symptoms associated with depression.  Participants were asked to score the frequency of  
occurrence of  specific symptoms during the previous week on a four point scale (0=less 
than one day, 1= 1-2 days, 2= 3-4 days & 3= 5-7 days).  The scores for each item were 
summed to yield a total score between 0 & 60. Those participants scoring ≥16 were 
defined as having CES-D depressive symptoms343.  A validation study of  274 Whitehall II 
participants demonstrated a sensitivity of  89% and specificity of  86% for CES-D 
symptoms when compared with a structured psychiatric interview344.  
 
Participants were also asked whether they had taken any medication in the last 14 days and 
to provide the name of  the medication if  they had done so. Antidepressants and 
anxiolytics were identified using British National Formulary codes.  Finally, participants had 
been asked on a previous questionnaire (phase 4), whether they had ever been told that 
they had depression. 
2.2.2 Blood pressure 
Seated systolic and diastolic blood pressure was measured twice after a 5 minute rest with 
an automated Omron 907 device. A mean of  the two readings was taken.  
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2.2.3 Anthropometric measures 
Weight was measured using a bio impedance scale (Tanita) and was read to the nearest 
0.1 kg. Height was measured to the nearest mm using a stadiometer with the participant 
standing straight with the head in the Frankfort plane. BMI was calculated as weight in 
kilograms divided by height in metres squared.  
Waist and hip circumference were measured with the participants standing and unclothed, 
using a fibreglass tape measure at 600g tension.  Waist circumference was taken as the 
smallest circumference at or below the costal margin and hip circumference was measured 
at the level of  the greater trochanter. The waist to hip ratio was then calculated. 
 
2.2.4 Blood tests 
Venous blood was taken either in the fasting state or at least 5 hours after a light, fat-free 
breakfast. Samples were collected into plain and fluoride Sarstedt monovettes.  Serum for 
lipid analyses was stored at -4°C and assayed within 72 hours. Cholesterol and triglycerides 
were measured using enzymic colorimetric methods. High-density lipoprotein cholesterol 
was assessed by precipitating non-HDL cholesterol with dextran sulfate-magnesium 
chloride using a centrifuge and measuring cholesterol in the supernatant. LDL cholesterol 
was calculated using the Friedewald formula345.  
Glucose was measured in fluoride plasma by an electro-chemical glucose oxidase method 
on a YSI model 2300 Stat Plus Analyzer (YSI Corporation, Yellow Springs, OH). 
  
IL-6 and CRP were measured in serum that had been stored at -70OC until analysis. CRP 
was assessed using a high sensitivity immunonephelometric assay in a BN ProSpec 
nephelometer (Dade Behring, Milton Keynes, UK). Values lower than the detection limit 
(0.154 mg/l) were assigned a value equal to half  the detection limit. For assessment of  
short term biological variation and laboratory error a repeated sample was taken from 533 
participants. Intra- and inter-assay coefficients of  variation were 4.7% and 8.3%. Reliability 
between samples was assessed with Pearson’s r correlation coefficients: r = 0.72.  
 
Il-6 was assessed using a high - sensitivity enzyme-linked immunosorbent assay (ELISA) 
(R&D systems, Oxford, UK). Values lower than the detection limit (0.08pg/ml) were 
assigned a value equal to half  the detection limit. For assessment of  biological variation 
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and laboratory error, a repeated sample was taken from 329 participants at phase 7. Intra 
and inter-assay coefficients of  variation were 7.5% and 8.9%. Reliability between samples 
was assessed with Pearson’s r correlation coefficients: r = 0.63.   
 
2.2.5 Other measures 
Questions on current smoking status, socio-economic status and medications were 
included in the questionnaire completed by the participants at phase 7.  
 
Socio-economic status was defined by current or last known grade of  employment. The 
civil service consists of  12 employment grades and these were reduced to 3 categories.  
Group 1 consisted of  the senior administrator grades, group 2 was the middle-ranking 
executives and group 3 was the clerical and office support grades.   
 
The information provided by the participants on medications was coded using the British 
National Formulary.   
 
2.2.6 Vascular methods 
2.2.6.1 Carotid artery intima-media thickness and distensibility coefficient 
Participants lay supine in a temperature-controlled vascular laboratory (22–26OC). A 3-lead 
electrocardiogram (ECG) was attached to the participants chest and a blood pressure cuff  
positioned initially on the right arm (OmronM5-I sphygmomanometer). After a 10 minute 
period of  acclimatization, the left and right carotid arteries were imaged using a Prosound 
5500 ALOKA (Keymed, Southend-on-Sea, UK) with a high resolution (7.5MHz) linear 
array probe. A transverse image of  the carotid arteries was captured to define the carotid 
bifurcation.  The common carotid artery was then imaged longitudinally approximately 
1cm proximal to the carotid bifurcation, the optimal image was then zoomed and triggered 
to the R-wave of  the ECG and a 10 second recording made to the hard drive of  the 
ultrasound machine and on Super VHS videotape for assessment of  intima-media 
thickness (IMT).  To measure distension the echo-tracking subsystem integral to the 
ultrasound machine was used346. Care was taken to ensure that the cursors for the echo 
tracking were accurately positioned and a recording made to the hard drive of  the 
ultrasound machine.  Ipsilateral blood pressure was taken immediately after each carotid 
measurement.  
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Using the images stored on the ultrasound machine, electronic callipers were used to 
measure the distance between the lumen-intima interface and the media-adventitia 
interface.  Measurements were taken from three separate frames for each carotid artery and 
the results for the two arteries were then averaged.  
 
Using the integral software within the ultrasound machine, distension was calculated from a 
minimum of  3 waveforms.  The distension data and blood pressure values were then used 
to calculate the distensibility coefficient separately for the right and left carotid arteries 
using the formula (2x distension / diastolic diameter) / pulse pressure347.  The results for 
the two arteries were then averaged.  
 
Three observers were responsible for the image collection and analysis. The coefficient of  
variation for repeated measures of  IMT was <5%.  
 
2.2.6.2 Flow-mediated dilatation 
Participants were supine and rested for 5 minutes in a temperature controlled laboratory.  
Blood pressure measurements were taken from the left arm both prior to and immediately 
following the study.  A 3-lead ECG was attached to the participant’s chest. 
 
The right arm was positioned at 80O to the body resting on foam supports to keep the 
forearm off  the study table and for participant comfort. A long bladdered narrow cuff  
attached to a rapid cuff  inflator, was positioned securely around the forearm just below the 
medial epicondyle.  Using high resolution B-mode ultrasound (Prosound 5500 ALOKA 
with a 7.5MHz linear probe), the right brachial artery was imaged longitudinally.  Once a 
straight and clear section of  artery had been identified the image was magnified using the 
zoom function set at 2 by 2 cm. The single focus point of  the ultrasound was positioned to 
the centre of  the artery or just below the posterior wall and the B-mode gain optimised to 
give clear lumen/wall definition.  Once a good quality and stable image was achieved the 
sterotactic clamp holding the ultrasound probe was tightened to fix the probe in position.  
Fine tuning of  the image could then be made using the micrometer screw.  The B-mode 
image was then triggered to the R-wave of  the ECG so that measurements were only made 
on end-diastolic images. To assess changes in blood flow during the study the Doppler 
cursor was positioned in the centre of  the artery.  
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Once the image was set, baseline recordings of  brachial diameter and blood flow were 
made for 1 minute.  The forearm cuff  was then inflated to 300mmHg for 5 minutes, upon 
deflation of  the cuff  the recording of  both the artery and blood flow continued for a 
further 5 minutes.  Images were captured to both Super VHS videotape and via a frame 
grabber set to capture an image every 3 seconds, to a computer. 
 
Brachial artery diameter was measured using the edge detection software Brachial Tools 
Analyzer (MIA). The recordings of  the study were played through and a section of  artery 
was selected that remained stable throughout the study.  A region of  interest box was 
positioned over the selected section ensuring that the artery walls were within the 
boundaries of  the box.  The placing of  the edge detection line was then checked and 
adjusted if  necessary to ensure that it was correctly positioned.  The analysis was then run 
and each frame checked to make sure the edge detection line was accurately positioned at 
the edge of  the artery wall. Baseline diameter was then calculated from the average of  the 
first 20 frames which equated to the first minute of  recording.  Peak diameter was taken as 
the maximum diameter measurement post cuff  release.  Absolute change was calculated as 
Peak diameter – baseline diameter. Percentage change was calculated as (absolute 
change/baseline diameter)x100.  
 
Doppler waveforms were traced using integral software on the ultrasound machine.  
Velocity time integral was used and the average of  3 waveforms from the baseline minute 
were taken to give baseline VTI.  The largest waveform from waveforms assessed at 5, 10 
and 15 seconds post cuff  release was taken as peak VTI. Reactive hyperaemia was 
calculated as (peak VTI/baseline VTI) x 100.  
 
2.3 Whitehall II psychobiology population 
Participants were drawn from the Whitehall II epidemiological cohort for a psychobiology 
testing substudy led by Prof  Andrew Steptoe, in which the laboratory stress testing was 
performed in 1999 to 2000 at UCL.  Criteria for entry to the study included no history or 
objective signs of  coronary heart disease and no previous diagnosis or treatment for 
hypertension, inflammatory diseases, or allergies.  Selection was stratified by grade of  
employment to include those of  higher, intermediate and lower status; all participants were 
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in full time employment and lived in the London area.  As part of  phase 7 of  the wider 
Whitehall II study participants from the substudy were invited to undergo endothelial 
function assessment at the Vascular Physiology, Institute of  Child Health UCL (local 
principle investigator, Prof  John Deanfield).  This took place approximately 3 years later 
than the stress testing.  
2.3.1 Protocol  
Participants were prohibited from using any antihistamine or anti-inflammatory medication 
24 hours prior to testing and were rescheduled if  they reported colds or other infections on 
the day of  testing.  Participants were tested individually in a light and temperature 
controlled laboratory. Measures of  height and weight were taken using standardised 
techniques. A 21-gauge venous cannula was inserted. Blood pressure and heart rate were 
recorded using a Portapres-2. After a 30 minute rest period mental stress was induced by 
two 5-min tasks, administered in random order under time pressure.  Blood samples were 
taken at the end of  the 30 minute baseline, immediately after the tasks and at 45 minutes 
post stress.  
 
2.3.2 Blood pressure and heart rate 
Blood pressure and heart rate were continuously recorded from the fingers of  the non-
dominant hand using a Portapres-2.  Values of  SBP, DBP and heart rate were averaged 
across the final 5 minutes of  the 30 minute rest period.  Readings taken over the course of  
each of  the two stress tasks and during the recovery period at 15-20 and 40-45 minutes 
post stress tasks were averaged.  The results for the two stress tasks were then combined. 
 
2.3.3 Mental stress tasks 
Two tasks were used for the mental stress challenge, stroop and mirror tracing. The two 
tasks were administered in a random order with each task lasting for 5 minutes with a 5 
minute inter-task interval. Both tests were introduced with a short and standardized 
explanation which was designed to also induce feelings of  time pressure and of  
competition. 
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2.3.3.1 Stroop colour-word interference task 
The test was a computerized version of  the Stroop colour-word interference task and 
involved the successive presentation of  target colour words (e.g., green, yellow) printed in 
another colour (e.g., blue, red)348. The names of  four colours were printed in incongruous 
colours at the bottom of  the computer screen and were selected by identified computer 
keys. Participants were asked to press the computer key to select the name of  the colour 
that matched the name of  the colour in which the target word was printed. The rate of  
presentation of  stimuli was adjusted to the performance of  the participant, to ensure 
sustained demand. 
 
2.3.3.2 Mirror tracing 
The task, which was designed to challenge and frustrate participants, involved the tracing 
of  a star with a metal stylus, which could only be seen in a mirror image (Lafayette 
Instruments, Lafayette, IN, USA).   A loud beep was emitted by the apparatus each time 
the stylus came off  the star to signal a mistake and the number of  mistakes was recorded in 
front of  the participants.  
 
2.3.4 Blood tests 
A 21-gauge venous cannula was inserted into the non-dominant arm for the collection of  
repeated samples. 
 
2.3.4.1 Lipids 
Non fasted blood was collected in serum gel tubes and centrifuged immediately at 2,500 
rpm for 10 min at room temperature. The serum was removed and snap frozen at -70 °C 
within 1 hour until analysis. Total cholesterol and triglycerides were measured in a 
centrifugal analyzer by enzymatic colorimetric methods, and HDL cholesterol was 
determined after dextran sulfate-magnesium chloride precipitation of  non-HDL 
cholesterol. LDL cholesterol was computed using the Friedewald formula  
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2.3.4.2 Inflammatory markers 
Blood was collected in tubes containing EDTA and was immediately centrifuged at room 
temperature at 2500 rpm for 10 minutes. The plasma was removed and frozen at -80 OC 
until analysis.  It has previously been shown that fibrinogen responds immediately to a 
mental stress task whereas there is a delay in the cytokine responses349, 350.  Therefore 
fibrinogen was analysed in all blood samples, whilst IL-6 and TNFα were analysed at 
baseline and 45 minutes post stress challenge. CRP was measured at baseline only.   
 
IL-6 and TNFα were measured using high-sensitivity two-site ELISA assay (R&D systems, 
Oxford, UK). The limit of  detection for IL-6 was 0.09pg/ml, and the intra- and inter-assay 
variability was 5.3 and 9.2%, respectively. For the TNFα assay, the limit of  detection was 
0.10pg/ml with intra- and inter-assay coefficients of  variation of  6.9% and 8.4%. 
Fibrinogen was measured from plasma by an automated Clauss assay in an MDA-180 
coagulometer (Oragon Teknika, Cambridge, UK). The coefficient of  variation was <8%. 
CRP was measured using a sensitive, two-site ELISA with antibodies from Dako 
diagnostics (Ely, Cambs, UK). Coefficients of  variation for intra and inter- assay were 
<10%. 
 
2.3.5 Anthropometric measurements 
Height was measured with the head in the Frankfort plane to standardize the measurement. 
Body weight was measured to the nearest 0.1kg. Body Mass Index (BMI) was calculated as 
previously described. The waist circumference was measured midway between the lowest 
rib and iliac crest, and the hip circumference was measured at the level of  the great 
trochanters. 
 
2.4 Summary 
Access to the unique WHII data provides a very well characterised population with a 
wealth of  well validated measures. This rich dataset allows an unprecedented opportunity 
to explore thoroughly the principal questions of  this thesis, whilst adequately accounting 
for potentially important confounding variables.  
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Chapter 3. Chronic stress, lipids and 
subclinical vascular disease in an 
epidemiological cohort (Whitehall II 
data) 
 
3.1 Introduction 
Psychosocial factors have been associated with increased risk of  cardiovascular disease 
(CVD) in addition to the traditional risk factors200. Depression in particular, has been 
related to increased risk of  CVD within the general population and recurrent events in 
patients with established coronary heart disease204, 351. However, it is not fully understood 
whether these chronic stressors trigger cardiovascular events in those with underlying 
disease or are involved earlier in the development of  atherosclerotic disease.  Although a 
less studied area, anxiety has also been shown to be associated with increased 
cardiovascular risk211.  There is high co-morbidity between anxiety and depression which 
has not always been taken into account in studies looking at the relationship between 
anxiety and CVD and may influence the findings197.  
 
Abnormal measures of  vascular structure and function such as intima-media thickness 
(IMT), arterial stiffness and endothelial function, which are early indicators and predictors 
of  cardiovascular disease and events, have been associated with the chronic stressors, 
depression and anxiety 263, 279, 284, 287, 293, 294.  However, there are conflicting results, for 
example with IMT, significant associations with depression have been found in some 
studies but others have found no association or a relationship has only been seen in males 
and not females and vice versa263, 269-271, 274, 276, 279. Due to the heterogeneity of  these results it 
is important to explore further the relationships between depression, anxiety and 
subclinical measures of  vascular structure and function. 
 
Dyslipidaemia plays an important role in the pathogenesis of  atherosclerosis. Arterial 
stiffness, increased IMT and endothelial dysfunction are all associated with dyslipidaemia89, 
90, 352.  Raised levels of  total cholesterol (TC), low density lipoprotein (LDL) and 
triglycerides alongside low high density lipoprotein (HDL) have been found in those with 
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depression and anxiety disorders252, 253, 353. Previous studies looking at associations between 
depression and anxiety with subclinical vascular measures often adjust for the effects of  
lipids as a cardiovascular risk factor within their analyses but have not explored the specific 
impact of  dyslipidaemia on these associations263, 275.  It is therefore important to investigate 
the relationships between depression and anxiety and dyslipidaemia with vascular structure 
and function.  
 
The Whitehall II study consists of  a well characterised cohort, established to explore 
relationships between socio-economic status, stress and CVD.  Previous findings from this 
study have demonstrated relationships between psychosocial factors (such as depression 
and social position) and cardiovascular disease354-358 .  Analyses have also shown that 
impaired endothelial function (low flow-mediated dilatation [FMD] of  the brachial artery) 
is predictive of  progression of  atherosclerosis (change in carotid IMT between phase 5 and 
7)174.  At phase 7 of  this study, a large number of  participants underwent vascular 
assessment and completed questionnaires assessing symptoms of  anxiety and depression 
alongside other clinical measures.  This ideally places this ageing cohort for a cross-
sectional analysis of  the relationships between depression, anxiety, dyslipidaemia and 
subclinical vascular disease.  
 
Using an array of  methods for assessing sub clinical vascular disease allows a thorough 
investigation of  the psychophysiological effects of  chronic stress on different aspects of  
arterial pathophysiology. FMD provides insights on the potential effects on endothelial 
function.  Assessment of  IMT gives an indication of  changes to the structure of  the artery 
wall and the early development of  atherosclerotic changes within the wall, whilst the 
distensibility coefficient provides information on local arterial stiffness and arteriosclerosis. 
3.2 Aim and hypotheses  
Aim: to investigate the influence of chronic stress, with and without dyslipidaemia, on 
endothelial function, carotid artery wall thickness and stiffness. 
 
Hypotheses:   1. Chronic stress (depression/anxiety) is associated with greater IMT and 
lower distensibility coefficient (DC)  
2. Chronic stress (depression or anxiety) is associated with endothelial 
dysfunction 
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3. The presence of dyslipidaemia influences the relationship between 
chronic stress and subclinical vascular dysfunction/disease. 
 
3.3 Methods 
3.3.1 Whitehall II cohort 
Participants were from the Whitehall II cohort which originally recruited 10,308 civil 
servants between 1985 and 1988 (see Chapter 2). As part of the phase 7 (2003 to 2004) 
reassessment, participants were invited for an additional examination of their carotid 
arteries to assess intima-media thickness and carotid artery stiffness.  
3.3.1.1 Endothelial function substudy 
Participants from the phase 5 vascular substudy and the psychobiology substudy were 
invited to undergo endothelial function assessment at phase 7 in addition to the carotid 
artery assessment as detailed in Chapter 2.   
3.3.2 Phase 7 assessment 
Anthropometric measures such as height, weight, hip and waist measurements were taken 
as described in Chapter 2. In addition, a fasting blood sample was taken and TC, HDL, 
Trigs, LDL, glucose, CRP and IL-6 were measured and nonHDL was calculated from TC 
and HDL.   Samples were assessed as described in Chapter 2. Seated brachial blood 
pressure was assessed using an automated Omron 907 device. 
3.3.2.1 Measures of  Chronic stress 
As part of  the phase 7 assessment, participants completed the 30-item General Health 
Questionnaire (GHQ) and the Centre for Epidemiologic Studies Depression Scale (CES-
D). From the GHQ subscales were identified for depression and anxiety using factor 
analysis.  Depression was defined as having a score of  4 or more on the subscale and 
anxiety was identified as having a score in the top quartile. Using the CES-D scale 
depression was defined as having a score of  16 or more.  Participants had also been 
questioned on previous diagnoses of  depression and medications.  
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3.3.3 Vascular measures 
3.3.3.1 Intima-media thickness and distensibility coefficient  
Participants rested in a supine position and then their right and left common carotid 
arteries were imaged using an ALOKA Prosound 5500 ultrasound machine.  Transverse 
and longitudinal sections of  the carotid arteries were imaged to identify the bifurcation.  
Longitudinal images of  the common carotid artery approximately 1 cm proximal to the 
bifurcation, with a clearly defined far wall intima-media complex, were zoomed and 
triggered to the R-wave of  the ECG and recorded for later analysis.  A separate 
untriggered recording was made using an echo-tracking subsystem integral to the 
ultrasound machine for measurement of  arterial distension346.   Ipsilateral blood pressure 
measurements were taken immediately after each carotid measurement using an Omron 
M5-I sphygmomanometer. 
 
IMT was measured as the distance between the leading edge of  the intima and the media-
adventitia border using callipers integral to the ultrasound machine.  Three measurements, 
each from a separate frame, were taken from the left and right arteries; mean IMT was 
calculated from the combined results.  The distensibility coefficient was calculated from 
arterial distension and blood pressure data using the equation (2x distension / diastolic 
diameter) / pulse pressure347. 
 
3.3.3.2 Flow-mediated dilatation 
The right brachial artery was imaged longitudinally using ultrasound.  Once a good quality 
image with clear walls was found the image was zoomed and triggered to the R-wave of  the 
ECG.  A Doppler cursor was positioned in the centre of  the artery to assess blood flow.  
Baseline diameter and blood flow was recorded for 1 minute, after which a cuff  positioned 
around the forearm just below the medial epicondyle was inflated to 300mmHg for 5 
minutes. On release of  the occlusion cuff, diameter and blood flow were recorded for a 
further 5 minutes.  Images were acquired direct to a computer for later off-line analysis. 
FMD was calculated as the difference between baseline and peak diameter post cuff  release 
as an absolute and percentage change. 
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3.3.4 Statistical analysis 
3.3.4.1 IMT and distensibility coefficient analysis. 
Participants were categorised as having depression if  they met one of  the following 
categories: had a score of  4 or more on the GHQ subscale; a score of  16 or more on the 
CESD scale; previously been informed they were depressed; on antidepressants.  Anxiety 
was categorised by participants meeting one of  the following criteria: in the top quartile of  
the GHQ questionnaire for anxiety (mean score 6.62±2.04 range 5-15) and or on anxiolytic 
medication. 
 
Variables that were positively skewed were transformed using natural log transformation 
(Fasting glucose, Trigs, HDL, CRP & IL-6).  All analyses were carried out separately for 
each gender. Chronic stress variables, depression and anxiety, were looked at individually 
and in combination.  For the combination analyses participants were defined as having 
depression and anxiety, just depression, just anxiety and neither. 
 
Cardiovascular risk factors were compared between the groups using independent t-tests or 
Chi square where appropriate. Associations between IMT or DC and cardiovascular risk 
factors were evaluated with Pearson correlation. The relationships between IMT or DC 
with chronic stress measures were investigated using analysis of  covariance (ANCOVA) 
with IMT /DC as the dependent variable, chronic stress as the independent variable and 
adjustment for age included in all models.  Each risk factor was studied individually within 
this model.    Larger models were then compiled based on the Framingham risk factors 
(age, systolic blood pressure (SBP), TC, HDL and Glucose).  Metabolic factors were then 
added to the model (waist, BMI & Trigs), then inflammatory factors (CRP, IL-6), social 
factors smoking and SES, finally heart rate (HR) was also added to the model. 
Relationships were looked at separately for gender and separately and combined for 
depression and anxiety. 
 
This is a relatively healthy population with a low prevalence of  major lipid disorders. 
Therefore, a pooled classification was utilised whereby those with one or more of  the 
following were considered to have dyslipidaemia, TC >6, Trigs>1.7, HDL<1 and LDL>4 
(mmol/L). Those with and without dyslipidaemia were then further divided by whether 
participants had depression or anxiety (chronic stress) to give a total of  four groups within 
each gender: dyslipidaemia and chronic stress; dyslipidaemia without chronic stress; normal 
cholesterol and chronic stress and normal cholesterol and no chronic stress.  Analyses to 
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investigate the influence of  dyslipidaemia on relationships between measures of  chronic 
stress and subclinical vascular disease were carried out as described above.  
3.3.4.2 Endothelial function 
Depression and anxiety were categorised as described above (anxiety top quartile mean 
score 6.81±2.07 range 5-15).  Variables were checked for normality, those variables which 
were positively skewed were transformed using natural log transformation (fasting glucose, 
Trigs, HDL, CRP and IL-6).  Male and female participants were not analysed separately due 
to the size of  the cohort.  Differences in risk factors between the groups and associations 
with FMD were carried out in the same way as in the IMT and DC analysis.  For the initial 
ANCOVA models with adjustment for individual risk factors, all analyses were adjusted for 
age, gender, baseline brachial artery diameter and reactive hyperaemia.  Larger models with 
adjustments for Framingham risk factors, metabolic, inflammatory and social factors were 
then run including age, gender, baseline brachial artery diameter and reactive hyperaemia.   
Due to the size of  the cohort the larger ANCOVA models with multiple modifiable 
covariates were only used when investigating anxiety and depression separately.  
 
3.4 Results 
3.4.1 Chronic stress and carotid artery structure and function  
4111 participants (61±6 years) attended for the vascular studies. Participants were excluded 
from the analysis if  they were on antihypertensive (944) and/or lipid lowering therapy 
(451). In total 2991 participants were included in the analysis. Of  this population 6.4% 
were smokers and 3.7% had diabetes. 
3.4.1.1 Depression score 
As hypothesised, depression was associated with greater IMT. However, this was 
relationship was only apparent in women. DC was found to be greater in women with 
depression but there was no difference between the groups in men. 
 
757 (25%) of  the cohort were categorised as having depression. Table 3.1 shows 
conventional cardiovascular risk factors in those with and without depression. Those with 
depression were significantly younger with lower SBP.  The proportion of  women in the 
depression group was higher than in the non-depression group (38 % vs 24 %).   
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There was no difference in IMT between the two groups, but DC was significantly greater 
in the depression group. 
 
  Depression (757) No depression (2234) p 
Age (yrs) 60 ± 6 61 ± 6 0.002 
Women (%) 289 (38) 544 (24) <0.001 
Waist (cm) 
   Men 94.56 ± 10.54 94.18 ± 10.02 0.47 
Women 85.02 ± 13.10 85.28 ± 13.45 0.79 
Waist/hip ratio 
   Men 0.95 ± 0.06 0.95 ± 0.06 0.05 
Women 0.85 ± 0.08 0.85 ± 0.08 0.46 
BMI (kg/m2) 26.00 ± 4.30 25.99 ± 3.91 0.95 
SBP (mmHg) 124 ± 16 126 ± 16 0.003 
DBP (mmHg) 72 ± 10 73 ± 10 0.07 
HR (bpm) 68 ± 11 68 ± 11 0.92 
Glucose (mmol/L) 5.28 ± 0.88 5.34 ± 0.92 0.06 
TC (mmol/L) 5.80 ± 0.96 5.83 ± 0.97 0.50 
HDL (mmol/L) 1.61 ± 0.45 1.61 ± 0.46 0.90 
Trigs (mmol/L) 1.29 ± 0.79 1.27 ± 0.78 0.56 
LDL (mmol/L) 3.60 ± 0.88 3.64 ± 0.89 0.29 
NonHDL (mmol/L) 4.19 ± 1.01 4.22 ± 1.01 0.47 
CRP (mg/L) 2.30 ± 4.46 2.15 ± 3.85 0.32 
IL-6 (pg/ml) 2.13 ± 1.96 2.11 ± 1.81 0.99 
IMT (mm) 0.78 ± 0.14 0.78 ± 0.15 0.50 
DC (10-3 kPa-1) 15.87 ± 5.14 15.17 ± 4.75 0.001 
Table 3.1: Participant characteristics for those with and without depression. 
 
Depression by gender 
To look at the relationships between those with and without depression and subclinical 
vascular measures separately in men and women, the cohort was divided by gender.  Males 
with depression were significantly younger with lower TC, HDL and LDL than non- 
depression males. There was no difference in IMT or DC between the depression and non-
depression males (table 3.2). 
 
Females with depression had significantly lower heart rates and higher Trigs than those 
without depression, HDL was also lower in women with depression symptoms but this was 
at borderline significance. IMT and DC were both greater in women with depression than 
those in the non- depression group (table 3.2).  
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  Males  Females 
 
Depression 
n= 468 
No 
depression 
n=1690 p 
 
Depression 
n=289 
No 
depression 
n=544 p 
Age (yrs) 60 ± 6 61 ± 6 <0.001  60 ± 6 60 ± 6 0.91 
Waist (cm) 94.56 ± 10.54 94.18 ± 10.02 0.47  85.02 ± 13.1 85.28 ± 13.45 0.79 
Waist/hip ratio 0.95 ± 0.06 0.95 ± 0.06 0.05  0.85 ± 0.08 0.85 ± 0.08 0.46 
BMI (kg/m2) 26.08 ± 3.79 25.99 ± 3.58 0.61  25.87 ± 5.02 26.00 ± 4.79 0.71 
SBP (mmHg) 125 ± 15 127 ± 15 0.013  123 ± 17 124 ± 18 0.43 
DBP (mmHg) 73 ± 10 74 ± 10 0.77  71 ± 10 72 ± 11 0.10 
HR (bpm) 67 ± 11 67 ± 11 0.51  68 ± 10 70 ± 10 0.041 
Glucose (mmol/L) 5.37 ± 0.83 5.39 ± 0.92 0.60  5.14 ± 0.92 5.16 ± 0.91 0.50 
TC (mmol/L) 5.67 ± 0.94 5.79 ± 0.95 0.016  6.01 ± 0.96 5.95 ± 1.02 0.42 
HDL (mmol/L) 1.47 ± 0.36 1.51 ± 0.39 0.034  1.84 ± 0.48 1.91 ± 0.50 0.06 
Trigs (mmol/L) 1.36 ± 0.87 1.33 ± 0.81 0.71  1.18 ± 0.61 1.08 ± 0.65 0.010 
LDL (mmol/L) 3.58 ± 0.83 3.67 ± 0.88 0.042  3.63 ± 0.95 3.54 ± 0.94 0.18 
NonHDL (mmol/L) 4.20 ± 0.98 4.28 ± 0.99 0.14  4.17 ± 1.06 4.04 ± 1.05 0.10 
CRP (mg/L) 2.26 ± 4.86 2.01 ± 3.55 0.39  2.36 ± 3.74 2.58 ± 4.62 0.80 
IL-6 (pg/ml) 2.27 ± 2.22 2.13 ± 1.84 0.37  1.93 ± 1.44 2.02 ± 1.72 0.63 
IMT (mm) 0.77 ± 0.15 0.79 ± 0.16 0.09  0.78 ± 0.14 0.75 ± 0.13 0.015 
DC (10-3 kPa-1) 14.94 ± 4.47 14.82 ± 4.47 0.59  17.36 ± 5.77 16.28 ± 5.40 0.008 
Table 3.2:  Risk factors for participants with and without depression by gender. 
 
 Males IMT  DC 
 Depression  No depression  Depression  No depression 
  r p  r p  r p  r p 
Age (yrs) 0.33 <0.001  0.31 <0.001  -0.27 <0.001  -0.27 <0.001 
Waist (cm) 0.10 0.033  0.15 <0.001  -0.24 <0.001  -0.22 <0.001 
Waist/hip ratio 0.11 0.017  0.15 <0.001  -0.22 <0.001  -0.22 <0.001 
BMI (kg/m2) 0.09 0.045  0.12 <0.001  -0.27 <0.001  -0.21 <0.001 
SBP (mmHg) 0.23 <0.001  0.22 <0.001  -0.32 <0.001  -0.33 <0.001 
DBP (mmHg) 0.13 0.004  0.08 0.001  -0.35 <0.001  -0.35 <0.001 
HR (bpm) -0.04 0.41  -0.06 0.010  -0.35 <0.001  -0.32 <0.001 
Glucose (mmol/L) 0.07 0.14  0.13 <0.001  -0.13 0.007  -0.09 <0.001 
TC (mmol/L) 0.11 0.022  0.13 <0.001  -0.04 0.39  -0.06 0.014 
HDL (mmol/L) -0.12 0.012  -0.03 0.20  0.18 <0.001  0.06 0.011 
Trigs (mmol/L) 0.08 0.09  0.06 0.009  -0.15 0.001  -0.10 <0.001 
LDL (mmol/L) 0.16 0.001  0.13 <0.001  -0.08 0.09  -0.07 0.007 
NonHDL (mmol/L) 0.15 0.002  0.14 <0.001  -0.11 0.022  -0.08 0.001 
CRP (mg/L) 0.11 0.016  0.07 0.004  -0.18 <0.001  -0.10 <0.001 
IL-6 (pg/ml) 0.12 0.011  0.09 <0.001  -0.14 0.002  -0.13 <0.001 
IMT (mm) 
 
 
  
 -0.16 0.001  -0.08 0.001 
DC (10-3 kPa-1) -0.16 0.001  -0.08 0.001           
Table 3.3: Correlations between IMT and cardiovascular risk factors and DC and cardiovascular risk factors 
for males with and without depression. 
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In males IMT was correlated with all cardiovascular risk factors except for heart rate, 
glucose and triglycerides in the depression group and HDL in the non-depression group 
(table 3.3). Only TC and LDL were not correlated with DC in males in the depressed 
group.  
 
 In females IMT was positively correlated with age, waist, waist-hip, BMI, SBP, LDL, 
nonHDL and negatively correlated with DC in the depression group. In the non-
depression group IMT was only correlated with age, SBP and DC.  Correlations with DC 
were more consistent between the two groups (table 3.4).  
 
Females IMT  DC 
 Depression  No depression  Depression  No depression 
  r p  r p  r p  r p 
Age (yrs) 0.25 <0.001  0.29 <0.001  -0.37 <0.001  -0.35 <0.001 
Waist (cm) 0.12 0.041  0.07 0.09  -0.16 0.007  -0.09 0.044 
Waist/hip ratio 0.13 0.025  0.07 0.10  -0.19 0.001  -0.06 0.14 
BMI (kg/m2) 0.13 0.030  0.06 0.17  -0.13 0.025  -0.12 0.008 
SBP (mmHg) 0.23 <0.001  0.28 <0.001  -0.44 <0.001  -0.39 <0.001 
DBP (mmHg) 0.11 0.05  0.08 0.06  -0.33 <0.001  -0.31 <0.001 
HR (bpm) -0.08 0.17  -0.06 0.15  -0.23 <0.001  -0.25 <0.001 
Glucose (mmol/L) -0.06 0.34  0.02 0.71  -0.15 0.009  -0.02 0.57 
TC (mmol/L) 0.15 0.013  0.04 0.36  0.00 0.93  -0.02 0.64 
HDL (mmol/L) -0.08 0.16  -0.05 0.25  0.12 0.035  0.05 0.24 
Trigs (mmol/L) 0.07 0.26  0.03 0.48  -0.11 0.06  -0.16 <0.001 
LDL (mmol/L) 0.17 0.004  0.06 0.14  -0.04 0.51  -0.01 0.91 
NonHDL (mmol/L) 0.17 0.004  0.06 0.15  -0.06 0.31  -0.04 0.31 
CRP (mg/L) 0.11 0.07  0.08 0.06  -0.04 0.51  -0.06 0.14 
IL-6 (pg/ml) 0.07 0.27  0.08 0.07  -0.11 0.08  -0.16 <0.001 
IMT (mm) 
 
 
  
 -0.20 0.001  -0.17 <0.001 
DC (10-3 kPa-1) -0.20 0.001  -0.17 <0.001  
  
 
  Table 3.4: Correlations between IMT and cardiovascular risk factors and DC and cardiovascular risk factors 
for females with and without depression. 
To take into account the effect of  individual cardiovascular risk factors on relationships 
between depression and both IMT and DC, ANCOVA models were run with adjustments 
for risk factors.  In males, there was no relationship between depression and IMT or DC.  
However, the significantly increased IMT and greater DC in the depression women 
remained after adjustment for age and individual cardiovascular risk factors (table 3.5).  
These relationships persisted following additional adjustment within a larger model based 
on Framingham risk factors (age, gender, SBP, TC, HDL & Glucose).  The addition of  
further risk factors such as measures of  obesity, inflammatory markers, smoking or SES 
did not alter these relationships (table 3.6 & figure 3.1).  
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Adjustment variable 
 
Males  Females 
IMT  DC  IMT  DC 
F p  F p  F p  F p 
Age (yrs)$ 0.38 0.54  0.19 0.67  6.62 0.010  8.01 0.005 
Waist (cm) 0.51 0.47  0.09 0.77  6.76 0.009  7.96 0.005 
Waist/hip ratio 0.77 0.38  0.00 0.99  6.56 0.011  8.44 0.004 
BMI 0.42 0.52  0.18 0.67  6.81 0.009  7.91 0.005 
SBP (mmHg) 0.05 0.82  1.12 0.29  7.94 0.005  7.49 0.006 
DBP (mmHg) 0.29 0.59  0.39 0.53  7.58 0.006  5.93 0.015 
HR (bpm) 0.27 0.60  0.07 0.79  5.80 0.016  6.02 0.014 
Glucose (mmol/L) 0.34 0.56  0.25 0.62  6.62 0.010  7.93 0.005 
TC (mmol/L) 0.12 0.73  0.31 0.58  6.50 0.011  7.95 0.005 
HDL (mmol/L) 0.61 0.43  0.08 0.78  6.12 0.014  8.91 0.003 
Trigs (mmol/L) 0.40 0.53  0.23 0.63  6.63 0.010  9.45 0.002 
LDL (mmol/L) 0.15 0.70  0.40 0.53  6.00 0.015  8.20 0.004 
NonHDL (mmol/L) 0.15 0.70  0.40 0.53  6.09 0.014  8.15 0.004 
CRP (mg/L) 0.28 0.60  0.05 0.83  7.12 0.008  8.41 0.004 
IL-6 (pg/ml) 0.21 0.65  0.05 0.82  6.97 0.008  7.91 0.005 
Table 3.5: Associations between depression and IMT and depression and DC in males and females adjusted 
for age and each individual risk factor. $ = non-adjusted. 
 
  Males 
 
Females 
 
IMT 
 
DC 
 
IMT 
 
DC 
  F p 
 
F p 
 
F p 
 
F p 
Model 1 0.04 0.83  0.81 0.37  6.94 0.009  7.74 0.006 
Model 2 0.05 0.83  0.80 0.37  7.98 0.005  8.14 0.004 
Model 3 0.02 0.90  0.38 0.54  8.64 0.003  8.10 0.005 
Model 4 0.12 0.73  0.33 0.57  8.10 0.005  6.79 0.009 
Model 5 0.05 0.83  0.15 0.70  7.25 0.007  5.91 0.015 
Table 3.6:  Relationship between depression and IMT and depression and DC with adjustments for 
cardiovascular risk factors for males and females.  
Model 1 = Age, SBP, TC, HDL & Glucose; 
Model 2 =Age, SBP, TC, HDL, Trigs, Glucose, BMI & waist;  
Model 3 = Age, SBP, TC, HDL, Trigs, Glucose, BMI, waist, CRP & IL-6;  
Model 4 = Age, SBP, TC, HDL, Glucose, BMI, waist, CRP, IL-6, Smoking & SES;  
Model 5 = Age, SBP, TC, HDL, Glucose, BMI, waist, CRP, IL-6, HR, Smoking & SES.  
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Figure 3.1: IMT in males (A) and females (B) DC in males (C) and females (D) in those with and without 
depression.  Both IMT and DC are adjusted for age, SBP, TC, HDL, Trigs, glucose, BMI, waist, CRP IL-6, 
HR, smoking and SES. Data presented as mean±SEM.  
3.4.1.2 Anxiety 
In this section it was found that women with anxiety had greater DC, whereas DC was 
similar in men with and without anxiety.  There was also no difference in IMT between the 
groups for both men and women. 
  
827 (28%) participants met the definition for anxiety.  Table 3.7 shows the participant 
characteristics for those with and without anxiety.  Those participants with anxiety were 
younger, with a higher proportion of  women than men in the group in comparison to 
those without anxiety and had lower SBP.  Although anxious participants had lower IMT 
and greater DC, further analyses were undertaken to adjust for potential influences of  age, 
gender, SBP and other possible determinants on the vascular outcome measures. 
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  Anxiety (827) No Anxiety(2164) p 
Age (yrs) 59 ± 6 61 ± 6 <0.001 
Women (%) 293 (35) 540 (25) <0.001 
Waist (cm) 
   
Men 94.50 ± 10.34 94.18 ± 10.07 0.53 
Women 85.84 ± 13.73 84.83 ± 13.1 0.30 
Waist/hip ratio 
   
Men 0.95 ± 0.06 0.95 ± 0.06 0.37 
Women 0.85 ± 0.08 0.84 ± 0.08 0.11 
BMI (kg/m2) 26.06 ± 4.3 25.96 ± 3.9 0.56 
SBP (mmHg) 124 ± 16 126 ± 16 0.002 
DBP (mmHg) 73 ± 11 73 ± 10 0.15 
HR (bpm) 68 ± 11 67 ± 11 0.05 
Glucose (mmol/L) 5.31 ± 0.96 5.33 ± 0.89 0.32 
TC (mmol/L) 5.79 ± 0.95 5.83 ± 0.98 0.32 
HDL (mmol/L) 1.62 ± 0.46 1.60 ± 0.45 0.34 
Trigs (mmol/L) 1.27 ± 0.82 1.28 ± 0.77 0.63 
LDL (mmol/L) 3.60 ± 0.87 3.64 ± 0.90 0.26 
NonHDL (mmol/L) 4.17 ± 0.99 4.23 ± 1.02 0.17 
CRP (mg/L) 2.14 ± 4.11 2.21 ± 3.97 0.52 
IL-6 (pg/ml) 2.05 ± 1.79 2.14 ± 1.87 0.18 
IMT (mm) 0.77 ± 0.15 0.78 ± 0.15 0.005 
DC (10-3 kPa-1) 15.84 ± 4.88 15.16 ± 4.84 0.001 
Table 3.7:  Participant characteristics for those with and without anxiety. 
 
Anxiety by gender 
 
To investigate differences in the relationships between those with and without anxiety and 
subclinical vascular measures by gender, the cohort was divided into males and females 
with and without anxiety.  Both men and women with anxiety were significantly younger 
than those without anxiety. Anxious males had greater heart rates and lower systolic blood 
pressure as well as decreased IMT. Females with anxiety had higher DC than non-anxious 
women (table 3.8). 
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  Males  Females 
 
Anxiety    
n= 534 
No anxiety 
n=1624 p  
Anxiety 
n=293 
No anxiety 
n=540 p 
Age (yrs) 59 ± 5 61 ± 6 <0.001  59 ± 6 61 ± 6 0.012 
Waist (cm) 94.5 ± 10.34 94.18 ± 10.07 0.53  85.84 ± 13.73 84.83 ± 13.10 0.30 
Waist/hip ratio 0.95 ± 0.06 0.95 ± 0.06 0.37  0.85 ± 0.08 0.84 ± 0.08 0.11 
BMI (kg/m2) 26.14 ± 3.78 25.96 ± 3.58 0.32  25.92 ± 5.11 25.97 ± 4.73 0.89 
SBP (mmHg) 124 ± 15 127 ± 15 0.001  123 ± 18 123 ± 17 0.81 
DBP (mmHg) 73 ± 11 74 ± 10 0.55  71 ± 11 72 ± 10 0.42 
HR (bpm) 68 ± 11 67 ± 11 0.012  69 ± 10 70 ± 10 0.19 
Glucose (mmol/L) 5.40 ± 1.01 5.38 ± 0.86 0.83  5.14 ± 0.84 5.17 ± 0.96 0.57 
TC (mmol/L) 5.70 ± 0.92 5.78 ± 0.96 0.07  5.96 ± 0.99 5.98 ± 1.01 0.85 
HDL (mmol/L) 1.48 ± 0.36 1.51 ± 0.4 0.11  1.88 ± 0.49 1.89 ± 0.5 0.83 
Trigs (mmol/L) 1.35 ± 0.9 1.33 ± 0.79 0.87  1.12 ± 0.64 1.11 ± 0.64 0.70 
LDL (mmol/L) 3.61 ± 0.83 3.67 ± 0.88 0.21  3.58 ± 0.94 3.57 ± 0.95 0.89 
NonHDL (mmol/L) 4.22 ± 0.97 4.27 ± 1.00 0.26  4.08 ± 1.04 4.09 ± 1.07 0.94 
CRP (mg/L) 2.12 ± 4.60 2.05 ± 3.59 0.76  2.17 ± 3.04 2.68 ± 4.89 0.21 
IL-6 (pg/ml) 2.15 ± 1.97 2.17 ± 1.91 0.68  1.88 ± 1.42 2.05 ± 1.73 0.23 
IMT (mm) 0.76 ± 0.15 0.79 ± 0.16 0.001  0.77 ± 0.14 0.76 ± 0.13 0.31 
DC (10-3 kPa-1) 14.94 ± 4.18 14.81 ± 4.56 0.56  17.47 ± 5.6 16.21 ± 5.49 0.002 
Table 3.8: Risk factors for those participants with and without anxiety by gender. 
 
In males all risk factors were correlated with IMT except for heart rate and Trigs in those 
with anxiety and HDL in those without anxiety. Only TC was not correlated with DC in 
the male anxious group, there were no non-significant correlations in the non-anxious 
groups (table 3.9).  For females, IMT was positively correlated with age, SBP, LDL and 
nonHDL and negatively correlated with DC in both groups.  In addition, IMT in the 
anxious group was also negatively correlated with heart rate and HDL, whilst in the non-
anxious group there were additional correlations with waist, waist hip, BMI, DBP, TC, CRP 
and IL-6.  DC was associated with all risk factors except glucose, TC, LDL, nonHDL and 
CRP in both groups (table 3.10)  
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  IMT  DC 
 Anxiety  No anxiety  Anxiety  No anxiety 
  r p  r p  r p  r p 
Age (yrs) 0.30 <0.001  0.31 <0.001  -0.25 <0.001  -0.27 <0.001 
Waist (cm) 0.12 0.005  0.14 <0.001  -0.22 <0.001  -0.23 <0.001 
Waist/hip ratio 0.13 0.002  0.14 <0.001  -0.23 <0.001  -0.21 <0.001 
BMI (kg/m2) 0.10 0.018  0.12 <0.001  -0.23 <0.001  -0.22 <0.001 
SBP (mmHg) 0.21 <0.001  0.23 <0.001  -0.31 <0.001  -0.33 <0.001 
DBP (mmHg) 0.11 0.012  0.08 0.001  -0.38 <0.001  -0.35 <0.001 
HR (bpm) -0.04 0.41  -0.06 0.016  -0.37 <0.001  -0.32 <0.001 
Glucose (mmol/L) 0.14 0.001  0.11 <0.001  -0.09 0.031  -0.10 <0.001 
TC (mmol/L) 0.13 0.003  0.12 <0.001  -0.07 0.11  -0.05 0.038 
HDL (mmol/L) -0.09 0.043  -0.04 0.13  0.15 0.001  0.07 0.005 
Trigs (mmol/L) 0.08 0.07  0.06 0.011  -0.12 0.004  -0.10 <0.001 
LDL (mmol/L) 0.15 <0.001  0.13 <0.001  -0.10 0.024  -0.06 0.017 
NonHDL (mmol/L) 0.16 <0.001  0.13 <0.001  -0.12 0.005  -0.08 0.002 
CRP (mg/L) 0.12 0.008  0.07 0.008  -0.14 0.002  -0.11 <0.001 
IL-6 (pg/ml) 0.10 0.019  0.09 <0.001  -0.14 0.001  -0.13 <0.001 
IMT (mm) 
 
 
  
 -0.10 0.020  -0.10 <0.001 
DC (10-3 kPa-1) -0.10 0.020  -0.10 <0.001  
  
 
  Table 3.9: Correlations between IMT and cardiovascular risk factors and DC and cardiovascular risk factors 
for males with and without anxiety.  
 
 IMT  DC 
 Anxiety  No anxiety  Anxiety  No anxiety 
  r p  r p  r p  r p 
Age (yrs) 0.28 <0.001  0.29 <0.001  -0.39 <0.001  -0.33 <0.001 
Waist (cm) 0.01 0.85  0.14 0.002  -0.12 0.044  -0.12 0.007 
Waist/hip ratio 0.01 0.89  0.14 0.001  -0.13 0.026  -0.10 0.019 
BMI (kg/m2) 0.05 0.36  0.10 0.019  -0.14 0.016  -0.11 0.011 
SBP (mmHg) 0.26 <0.001  0.26 <0.001  -0.48 <0.001  -0.36 <0.001 
DBP (mmHg) 0.08 0.19  0.09 0.028  -0.36 <0.001  -0.29 <0.001 
HR (bpm) -0.14 0.018  -0.03 0.46  -0.22 <0.001  -0.26 <0.001 
Glucose (mmol/L) -0.10 0.08  0.04 0.37  -0.11 0.06  -0.05 0.22 
TC (mmol/L) 0.07 0.26  0.09 0.047  0.00 0.96  -0.02 0.73 
HDL (mmol/L) -0.13 0.023  -0.03 0.53  0.14 0.019  0.03 0.43 
Trigs (mmol/L) 0.08 0.17  0.03 0.44  -0.19 0.001  -0.10 0.026 
LDL (mmol/L) 0.12 0.041  0.10 0.023  -0.02 0.78  -0.01 0.81 
NonHDL (mmol/L) 0.13 0.031  0.09 0.030  -0.07 0.24  -0.03 0.48 
CRP (mg/L) 0.01 0.83  0.13 0.002  -0.07 0.21  -0.04 0.36 
IL-6 (pg/ml) 0.02 0.76  0.10 0.016  -0.16 0.006  -0.13 0.003 
IMT (mm) 
 
 
  
 -0.21 <0.001  -0.15 <0.001 
DC (10-3 kPa-1) -0.21 <0.001  -0.15 <0.001  
  
 
  Table 3.10: Correlations between IMT and cardiovascular risk factors and DC and cardiovascular risk factors 
for females with and without anxiety.   
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ANCOVA models were run with adjustment for cardiovascular risk factors to take into 
account the effect these factors may have on relationships between anxiety and IMT or 
DC. In males there was a significant association between DC and anxiety having adjusted 
for age and SBP and age and DBP.   The previously significant finding of  increased IMT in 
those males without anxiety was lost with adjustment for age (table 3.11). Women with 
anxiety had greater DC than those women without anxiety following adjustment for age 
and individual cardiovascular risk factors.  There was a borderline association between 
presence or absence of  anxiety and IMT (anxious women had greater IMT) notably after 
adjusting for age and CRP (p=0.050) (table 3.11).   
 
 
 
Males 
  
Females 
 
IMT 
 
DC 
 
IMT 
 
DC 
  F p 
 
F p 
 
F p 
 
F p 
Age (yrs)$ 1.19 0.27 
 
2.40 0.12 
 
3.19 0.07 
 
5.56 0.019 
Waist (cm) 1.43 0.23 
 
2.19 0.14 
 
2.87 0.09 
 
6.20 0.013 
Waist Hip 1.64 0.20 
 
1.67 0.20 
 
2.58 0.11 
 
6.14 0.013 
BMI 1.36 0.24 
 
2.37 0.12 
 
3.17 0.08 
 
5.64 0.018 
SBP (mmHg) 0.48 0.49 
 
5.19 0.023 
 
3.14 0.08 
 
7.01 0.008 
DBP (mmHg) 0.97 0.33 
 
4.06 0.044 
 
3.54 0.06 
 
4.89 0.027 
HR (bpm) 0.75 0.39 
 
0.60 0.44 
 
2.87 0.09 
 
4.57 0.033 
Glucose (mmol/L) 1.42 0.23 
 
2.50 0.11 
 
3.21 0.07 
 
5.58 0.018 
TC (mmol/L) 0.88 0.35 
 
2.78 0.10 
 
3.23 0.07 
 
5.64 0.018 
HDL (mmol/L) 1.35 0.25 
 
2.53 0.11 
 
3.19 0.07 
 
5.71 0.017 
Trigs (mmol/L) 1.17 0.28 
 
2.97 0.08 
 
3.22 0.07 
 
5.98 0.015 
LDL (mmol/L) 0.91 0.34 
 
3.04 0.08 
 
3.26 0.07 
 
5.33 0.021 
NonHDL (mmol/L) 0.88 0.35 
 
3.10 0.08 
 
3.20 0.07 
 
5.63 0.018 
CRP (mg/L) 1.26 0.26 
 
2.22 0.14 
 
3.84 0.05 
 
5.64 0.018 
IL-6 (pg/ml) 1.15 0.28 
 
2.25 0.13 
 
3.43 0.06 
 
5.41 0.020 
Table 3.11:  Association between anxiety and IMT and also anxiety and DC adjusted for age and each 
individual risk factor in males and females. $ = non-adjusted. 
In males, the relationship between DC and anxiety became significant following 
adjustments in models 1-4; however, when HR was added to the model the relationship 
was lost.  
 
The association between anxiety and increased DC in women remained after adjustment 
using larger models based initially on Framingham risk score variables and with subsequent 
addition of  measures of  obesity, inflammation and SES (table 3.12 & figure 3.2D). The 
relationship between IMT and anxiety in women remained at borderline significance in all 
models.   
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  Males 
 
Females 
 
IMT 
 
DC 
 
IMT 
 
DC 
  F p 
 
F p 
 
F p 
 
F p 
Model 1 0.50 0.48 
 
5.51 0.019 
 
3.03 0.08 
 
6.97 0.008 
Model 2 0.58 0.45 
 
5.05 0.025 
 
3.09 0.08 
 
6.85 0.009 
Model 3 0.55 0.46 
 
4.53 0.033 
 
3.65 0.06 
 
6.81 0.009 
Model 4 0.67 0.41 
 
4.55 0.033 
 
3.33 0.07 
 
6.29 0.012 
Model 5 0.13 0.72 
 
1.91 0.17 
 
2.98 0.08 
 
5.68 0.017 
 Table 3.12: Relationships between anxiety and IMT and also anxiety and DC with adjustments for 
cardiovascular risk factors in males and females.  
Model 1 = Age, SBP, TC, HDL & Glucose;  
Model 2 =Age, SBP, TC, HDL, Trigs, Glucose, BMI & waist; 
 Model 3 = Age, SBP, TC, HDL, Trigs, Glucose, BMI, waist, CRP & IL-6;  
Model 4 = Age, SBP, TC, HDL, Trigs, Glucose, BMI, waist, CRP, IL-6, Smoking & SES;  
Model 5 = Age, SBP, TC, HDL, Trigs, Glucose, BMI, waist, CRP, IL-6, HR, Smoking & SES.  
 
Figure 3.2: IMT for males (A) and females (B) DC males (C) and females (D) in those with and without 
anxiety.  IMT and DC are adjusted for age, SBP, TC, HDL, Trigs, glucose, BMI, waist, CRP, IL-6, HR, 
smoking and SES. Data presented as mean±SEM.  
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3.4.1.3 Depression and anxiety 
The major finding in this section was that those women with both depression and anxiety 
had the greatest IMT.  There were no relationships between depression +/- anxiety and 
IMT or DC in men.  
 
To investigate whether there were differences in vascular structure and function due to the 
different measures of  chronic stress participants were divided into four groups. Those with 
depression and anxiety symptoms (D+A+), those with depression and without anxiety 
symptoms (D+A-), no depression but anxiety symptoms (D-A+) and neither depression 
nor anxiety symptoms (D-A-).  Table 3.13 shows the numbers and mean IMT and DC for 
each group by gender. There were significant differences in IMT for males, with post hoc 
testing indicating this to be between men with anxiety having lower IMT than those 
without either depression or anxiety (p=0.024).  Whilst women with either just depression 
or just anxiety had greater DC than those with neither (p=0.033 & p=0.045 respectively).   
 
  Males  Females 
  n IMT (mm) DC (10-3 kPa-1)  n IMT (mm) DC (10-3 kPa-1) 
D+A+ 297 0.77 ± 0.15 14.84 ± 4.28  180 0.78 ± 0.14 17.33 ± 5.56 
D+A- 171 0.78 ± 0.15 15.13 ± 4.78  109 0.77 ± 0.13 17.40 ± 6.13 
D-A+ 237 0.76 ± 0.15 15.07 ± 4.06  113 0.75 ± 0.14 17.69 ± 5.69 
D-A- 1453 0.79 ± 0.16 14.78 ± 4.53  431 0.76 ± 0.13 15.91 ± 5.27 
p   0.006 0.65    0.08 0.001 
Table 3.13: Combined depression and analysis categorisation with mean ± SD for IMT and DC by gender. 
D+A+ = depression and anxiety, D+A- = depression only; D-A+ = anxiety only; D-A- neither depression 
nor anxiety. P= testing for differences between the chronic stress groups. 
The relationships between measures of  chronic stress and subclinical vascular measures 
were further tested with adjustment for cardiovascular risk factors. Following adjustment 
for age, the relationship between IMT and chronic stress in males did not remain (table 
3.14). However, the relationship between DC and chronic stress in females remained 
following adjustment for age and individual cardiovascular risk factors. Additionally, the 
relationship between IMT and chronic stress became significant in women after adjustment 
for age. This association only lost significance following individual adjustments for heart 
rate, HDL, LDL and nonHDL. Further adjustments in models based on the Framingham 
risk factors, obesity, inflammatory markers and heart rate, and SES measures maintained 
the relationships seen between chronic stress and IMT and DC in females (table 3.15 and 
figure 3.3). 
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  Males  Females 
 
IMT 
 
DC 
 
IMT 
 
DC 
  F p 
 
F p 
 
F p 
 
F p 
Age (yrs)$ 0.45 0.71  1.00 0.39  2.66 0.047  4.65 0.003 
Waist (cm) 0.55 0.65  1.01 0.39  2.70 0.045  4.91 0.002 
Waist Hip 0.62 0.60  0.87 0.46  2.61 0.050  4.92 0.002 
BMI 0.50 0.68  0.97 0.41  2.73 0.043  4.72 0.003 
SBP (mmHg) 0.22 0.88  1.91 0.13  3.09 0.027  5.24 0.001 
DBP (mmHg) 0.38 0.76  1.67 0.17  2.97 0.031  3.91 0.009 
HR (bpm) 0.31 0.82  0.34 0.80  2.41 0.07  3.71 0.011 
Glucose (mmol/L) 0.49 0.69  0.94 0.42  2.65 0.048  4.74 0.003 
TC (mmol/L) 0.33 0.80  1.08 0.36  2.62 0.050  4.67 0.003 
HDL (mmol/L) 0.53 0.66  1.10 0.35  2.52 0.06  5.00 0.002 
Trigs (mmol/L) 0.44 0.73  1.17 0.32  2.66 0.047  5.28 0.001 
LDL (mmol/L) 0.35 0.79  1.22 0.30  2.48 0.06  4.54 0.004 
NonHDL (mmol/L) 0.33 0.80  1.17 0.32  2.51 0.06  4.72 0.003 
CRP (mg/L) 0.43 0.73  0.93 0.42  2.92 0.033  4.72 0.003 
IL-6 (pg/ml) 0.39 0.76  0.92 0.43  2.81 0.039  4.53 0.004 
Table 3.14: Association by gender between IMT and chronic stress and DC and chronic stress adjusted for 
age, and each individual risk factor. $ = non-adjusted. 
 
  Males 
 
Females 
 
IMT 
 
DC 
 
IMT 
 
DC 
  F p 
 
F p 
 
F p 
 
F p 
Model 1 0.20 0.89 
 
2.03 0.11 
 
2.76 0.041 
 
5.35 0.001 
Model 2 0.23 0.88 
 
1.85 0.14 
 
3.05 0.028 
 
5.45 0.001 
Model 3 0.21 0.89 
 
1.72 0.16 
 
3.41 0.017 
 
5.38 0.001 
Model 4 0.24 0.87 
 
1.76 0.15 
 
3.20 0.023 
 
4.81 0.003 
Model 5 0.06 0.98 
 
0.88 0.45 
 
3.00 0.030 
 
4.21 0.006 
Table 3.15: Relationship between chronic stress and IMT and chronic stress and DC with adjustments for 
cardiovascular risk factors.  
Model 1 = Age, SBP, TC, HDL & Glucose;  
Model 2 =Age, SBP, TC, HDL, Trigs, Glucose, BMI & waist;  
Model 3 = Age, SBP, TC, HDL, Trigs, Glucose, BMI, waist, CRP & IL-6;  
Model 4 = Age, SBP, TC, HDL, Trigs, Glucose, BMI, waist, CRP, IL-6, Smoking & SES; 
Model 5 = Age, SBP, TC, HDL, Trigs, Glucose, BMI, waist, CRP, IL-6, HR, Smoking & SES.  
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Figure 3.3: IMT in males (A) and females (B) DC males (C) and females (D) in those with and without  
chronic stress.  Both IMT and DC are adjusted for age, SBP, TC, HDL, Trigs, glucose, BMI, waist, CRP, IL-
6, HR, smoking and SES. Post hoc Bonferroni analysis showed that the difference in IMT in females was 
between those with both depression & anxiety and neither (p=0.029). For DC, Bonferroni post hoc tests did 
not reach significance. D+A+ = depression and anxiety; D+A-= depression only; D-A+ anxiety only D-A- 
no depression or anxiety; F = female; M= male. Data presented as mean±SEM.  
3.4.1.4 Dyslipidaemia 
The novel finding in this section was that dyslipidaemia adversely influenced the 
relationship between chronic stress and IMT, but only in women. Differences observed in 
IMT in men were due to dyslipidaemia and not chronic stress. Dyslipidaemia did not 
appear to influence the relationship between chronic stress and DC for either gender. 
  
To investigate whether dyslipidaemia influences the relationship between chronic stress and 
IMT and DC, participants were categorised by presence or absence of  dyslipidaemia by 
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meeting one or more of  the criteria as set out in table 3.16. Fifty three percent of  men and 
women were classified as having dyslipidaemia.  High total cholesterol was the most 
commonly met criteria for both genders.   
  
Dyslipidaemia categories  No of categories met 
    TC ≥6 Trigs ≥1.7 HDL <1 LDL ≥4  1 2 3 4 Dyslipidaemia 
Yes M 863 497 83 749  353 544 229 16 1142 
 
F 401 118 5 272  148 238 56 1 443 
No M 1281 1646 2060 1377  
     
  F 430 713 826 554  
     Table 3.16:  Number of males and females who met each lipid category and the number of criteria for 
dyslipidaemia that they met (units=mmol/L). 
Similar numbers of  participants were classified as having depression and/or anxiety in both 
those with or without dyslipidaemia.  Tables 3.17 and 3.18 show the cardiovascular risk 
factor profiles for all four groups for males and females. For males with dyslipidaemia, 
there were significant differences between those with and without chronic stress for age, 
waist/hip ratio, heart rate, HDL & triglycerides. Males without dyslipidaemia but with 
chronic stress were significantly younger, with lower SBP and triglycerides than those 
without chronic stress. In both males with and without dyslipidaemia, those who suffered 
with chronic stress had significantly lower IMT but there was no difference in DC.  
 
  Dyslipidaemia 
 
Normal 
 
Dep/Anx 
n=356 
No 
dep/anx 
n=786 p 
 
Dep/Anx 
n=345 
No dep/anx 
n=656 p 
Age (yrs) 59 ± 6 61 ± 6 <0.001 
 
59 ± 5 61 ± 6 <0.001 
Waist (cm) 96.86 ± 9.8 95.65 ± 9.97 0.06 
 
92.13 ± 10.53 92.38 ± 9.68 0.70 
Waist/hip ratio 0.97 ± 0.06 0.96 ± 0.06 0.007 
 
0.94 ± 0.06 0.94 ± 0.06 0.82 
BMI (kg/m2) 26.82 ± 3.57 26.5 ± 3.6 0.17 
 
25.35 ± 3.91 25.34 ± 3.36 0.96 
SBP (mmHg) 127 ± 15 128 ± 15 0.09 
 
123 ± 14 125 ± 15 0.013 
DBP (mmHg) 75 ± 10 75 ± 10 0.69 
 
72 ± 10 72 ± 10 0.76 
HR (bpm) 70 ± 12 67 ± 11 0.002 
 
66 ± 10 66 ± 11 0.64 
Glucose (mmol/L) 5.43 ± 0.96 5.40 ± 0.78 0.87 
 
5.33 ± 0.98 5.38 ± 0.96 0.31 
TC (mmol/L) 6.29 ± 0.8 6.38 ± 0.82 0.07 
 
5.08 ± 0.57 5.10 ± 0.57 0.65 
HDL (mmol/L) 1.39 ± 0.36 1.46 ± 0.42 0.003 
 
1.56 ± 0.34 1.58 ± 0.37 0.57 
Trigs (mmol/L) 1.79 ± 1.13 1.63 ± 0.88 0.009 
 
0.92 ± 0.30 0.96 ± 0.31 0.026 
LDL (mmol/L) 4.12 ± 0.74 4.18 ± 0.79 0.20 
 
3.09 ± 0.54 3.07 ± 0.55 0.67 
NonHDL (mmol/L) 4.9 ± 0.75 4.92 ± 0.81 0.66 
 
3.51 ± 0.59 3.52 ± 0.61 0.93 
CRP (mg/L) 2.4 ± 5.05 1.92 ± 2.56 0.12 
 
1.79 ± 3.25 2.21 ± 4.64 0.10 
IL-6 (pg/ml) 2.18 ± 1.74 2.17 ± 1.87 0.76 
 
2.11 ± 2.14 2.17 ± 1.97 0.26 
IMT (mm) 0.78 ± 0.16 0.81 ± 0.17 0.024 
 
0.75 ± 0.14 0.77 ± 0.15 0.042 
DC (10-3 kPa-1) 14.58 ± 3.98 14.50 ± 4.44 0.78 
 
15.39 ± 4.64 15.13 ± 4.63 0.39 
Table 3.17: Risk factors for male participants by depression /anxiety category, and by dyslipidaemia category. 
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For females with dyslipidaemia, those with depression and /or anxiety had significantly 
lower fasting glucose than those without chronic stress. Non-dyslipidaemia females with 
depression and or anxiety had lower heart rate but increased triglycerides.  Both IMT and 
DC were greater in females with dyslipidaemia and chronic stress, whilst in those without 
dyslipidaemia only DC was significantly greater in those with chronic stress (table 3.18). 
 
  Dyslipidaemia 
 
Normal 
 
Dep/Anx 
n=209 
No dep/anx 
n=234 p 
 Dep/Anx 
n=193 
No dep/anx 
n=195 p 
Age (yrs) 61 ± 6 61 ± 6 0.41 
 
59 ± 6 60 ± 6 0.17 
Waist (cm) 88.14 ± 12.82 86.52 ± 12.83 0.18 
 
82.8 ± 14.06 82.92 ± 12.93 0.93 
Waist/hip ratio 0.87 ± 0.08 0.85 ± 0.08 0.06 
 
0.83 ± 0.08 0.83 ± 0.08 0.75 
BMI (kg/m2) 26.58 ± 4.74 26.33 ± 4.29 0.56 
 
25.25 ± 5.32 25.57 ± 5.08 0.54 
SBP (mmHg) 124 ± 17 124 ± 17 0.59 
 
122 ± 18 123 ± 18 0.96 
DBP (mmHg) 71 ± 10 73 ± 11 0.20 
 
71 ± 11 72 ± 11 0.43 
HR (bpm) 69 ± 10 69 ± 10 0.97 
 
68 ± 10 71 ± 10 0.002 
Glucose (mmol/L) 5.10 ± 0.59 5.21 ± 0.52 0.024 
 
5.20 ± 1.04 5.12 ± 1.35 0.19 
TC (mmol/L) 6.68 ± 0.78 6.64 ± 0.81 0.66 
 
5.23 ± 0.48 5.15 ± 0.55 0.10 
HDL (mmol/L) 1.84 ± 0.51 1.92 ± 0.56 0.13 
 
1.89 ± 0.43 1.9 ± 0.44 0.87 
Trigs (mmol/L) 1.38 ± 0.73 1.30 ± 0.80 0.12 
 
0.89 ± 0.29 0.82 ± 0.29 0.016 
LDL (mmol/L) 4.23 ± 0.8 4.12 ± 0.83 0.15 
 
2.93 ± 0.52 2.87 ± 0.56 0.29 
NonHDL (mmol/L) 4.84 ± 0.86 4.73 ± 0.9 0.18 
 
3.35 ± 0.54 3.25 ± 0.6 0.11 
CRP (mg/L) 2.42 ± 3.69 2.55 ± 3.75 0.62 
 
2.18 ± 3.39 2.85 ± 6.1 0.44 
IL-6 (pg/ml) 1.9 ± 1.28 2.05 ± 1.72 0.63 
 
1.90 ± 1.70 2.11 ± 1.78 0.12 
IMT (mm) 0.79 ± 0.14 0.76 ± 0.13 0.036 
 
0.75 ± 0.13 0.75 ± 0.12 0.96 
DC (10-3 kPa-1) 17.13 ± 5.32 15.77 ± 5.09 0.007 
 
17.80 ± 6.16 16.02 ± 5.5 0.003 
Table 3.18: Risk factors for female participants by depression/anxiety category, and by dyslipidaemia 
category. 
  Males  Females 
 
IMT (mm) 
 
DC (10-3 kPa-1) 
 
IMT (mm) 
 
DC (10-3 kPa-1) 
  F p 
 
F p 
 
F p 
 
F p 
Age (yrs)$ 8.85 <0.001  4.52 0.004  3.71 0.011  4.63 0.003 
Waist (cm) 5.89 0.001  1.20 0.31  3.20 0.023  5.00 0.002 
Waist/hip ratio 5.88 0.001  0.95 0.42  3.03 0.029  5.01 0.002 
BMI (kg/m2) 5.86 0.001  1.19 0.31  3.41 0.017  4.74 0.003 
SBP (mmHg) 5.79 0.001  2.27 0.08  3.89 0.009  5.19 0.001 
DBP (mmHg) 6.84 <0.001  0.80 0.49  3.86 0.009  3.92 0.009 
HR (bpm) 9.78 <0.001  1.76 0.15  3.72 0.011  3.61 0.013 
Glucose (mmol/L) 8.37 <0.001  4.22 0.006  3.68 0.012  4.72 0.003 
CRP (mg/L) 8.63 <0.001  4.83 0.002  3.71 0.011  4.66 0.003 
IL-6 (pg/ml) 8.80 <0.001  5.01 0.002  3.70 0.012  4.45 0.004 
Table 3.19:  Association between chronic stress and IMT and chronic stress and DC and the presence of 
dyslipidaemia adjusted for age, and each individual risk factor. $ = non-adjusted. 
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The relationships with IMT and DC were further investigated by adjusting for age and 
cardiovascular risk factors individually. For males, it can be seen from table 3.19 significant 
differences remained between the groups for IMT; whereas for DC the relationships only 
remained with adjustment for age, glucose and CRP individually. For females the 
relationships between the groups remained with both IMT and DC following adjustment.   
 
Following adjustment for the larger risk factor models the relationships between chronic 
stress and dyslipidaemia with IMT remained in both males and females and with DC in 
females only (table 3.20).   
 
 
 
Males 
 
Females 
 
IMT (mm) 
 
DC (10-3 kPa-1) 
 
IMT (mm) 
 
DC (10-3 kPa-1) 
  F p 
 
F p 
 
F p 
 
F p 
Model 1 5.71 0.001  2.23 0.08  3.81 0.010  5.23 0.001 
Model 2 4.41 0.004  0.98 0.40  3.56 0.014  5.15 0.002 
Model 3 4.76 0.003  1.12 0.34  3.59 0.014  4.95 0.002 
Model 4 4.73 0.003  1.16 0.33  3.37 0.018  4.41 0.004 
Model 5 5.73 0.001  0.36 0.78  3.54 0.014  3.82 0.010 
Table 3.20: Relationship between chronic stress, presence of dyslipidaemia and IMT and DC by gender with 
adjustments for cardiovascular risk factors.  
Model 1 = Age, SBP & Glucose;  
Model 2 =Age, SBP, Glucose, BMI & waist;  
Model 3 = Age, SBP, Glucose, BMI, waist, CRP & IL-6;  
Model 4 = Age, SBP, Glucose, BMI, waist, CRP, IL-6, Smoking & SES  
Model 5 = Age, SBP, Glucose, BMI, waist, CRP, IL-6, HR, Smoking & SES.  
 
In figure 3.4A it can be seen that males with dyslipidaemia had greater IMT than those men 
without, irrespective of  chronic stress status. Whereas in females, it was those with both 
dyslipidaemia and chronic stress who had the greatest IMT (figure 3.4B).  Presence of  
depression and or anxiety appeared to have more influence on DC than dyslipidaemia in 
women, as DC was greatest in both of  the chronic stress groups irrespective of  lipid status 
(figure 3.4D). However, post hoc testing did not reach significance. 
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Figure 3.4: IMT for males (A) and females (B) DC males (C) and females (D) in those with and without 
dyslipidaemia and chronic stress.  Both IMT and DC are adjusted for age, SBP, TC, HDL, Trigs, glucose, 
BMI, waist, CRP IL-6, HR, smoking and SES. Post hoc Bonferroni analyses showed that the differences in 
IMT in males were between those with dyslipidaemia without chronic stress vs Dys+ DA+ p=1.00; Dys-
DA+ p=0.030; Dys-DA-p=0.001 females were between those with dyslipidaemia and chronic stress vs Dys+ 
DA- p=0.067; Dys-DA+ p=0.042; Dys-DA-p=0.040. For DC, Bonferroni post hoc tests did not reach 
significance.  Dys+ = dyslipidaemia; Dys- = not dyslipidaemic; D+A+ = depression and anxiety; D+A-= 
depression only; D-A+ anxiety only D-A- no depression or anxiety. Data presented as mean±SEM.  
 
 
3.4.2 Chronic stress and endothelial function 
358 participants underwent endothelial function testing at phase 7 of  the Whitehall II 
study.  Following exclusion of  those participants who were diabetic, smokers or on 
antihypertensive, lipid lowering, or diabetes medication, 288 participants remained in the 
study.   Table 3.21 shows the characteristics of  these participants compared with the 
population in the carotid artery structure and function measures analysis. The FMD cohort 
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was significantly younger than the IMT cohort with lower blood pressure and triglycerides 
and inflammatory markers.  There was also a significantly greater proportion of  women in 
the FMD cohort in comparison to the IMT group.  
 
  
FMD cohort 
(n=288) 
IMT cohort  
 (n=2991) p 
Age (yrs) 58.32 ± 4.94 60 ± 6 <0.001 
Women (%) 120 (42) 833 (28) <0.001 
Waist (cm) 
   
Men 92.85 ± 10.95 94.26 ± 10.14 0.09 
Women 84.82 ± 13.07 85.19 ± 13.33 0.78 
Waist/hip ratio 
   
Men 0.94 ± 0.06 0.95 ± 0.06 0.026 
Women 0.85 ± 0.08 0.85 ± 0.08 0.81 
BMI (kg/m2) 25.72 ± 4.17 25.99 ± 4.01 0.28 
SBP (mmHg) 121 ± 15 125 ± 16 <0.001 
DBP (mmHg) 71 ± 10 73 ± 10 <0.001 
HR (bpm) 66 ± 9 68 ± 11 0.005 
Glucose (mmol/L) 5.2 ± 0.46 5.32 ± 0.91 0.001 
TC (mmol/L) 5.78 ± 1.00 5.82 ± 0.97 0.45 
HDL (mmol/L) 1.69 ± 0.47 1.61 ± 0.45 0.004 
Trigs (mmol/L) 1.13 ± 0.80 1.27 ± 0.78 <0.001 
LDL (mmol/L) 3.56 ± 0.91 3.63 ± 0.89 0.22 
NonHDL (mmol/L) 4.09 ± 1.06 4.21 ± 1.01 0.046 
CRP (mg/L) 1.66 ± 2.32 2.19 ± 4.01 0.003 
IL-6 (pg/ml) 1.82 ± 1.55 2.11 ± 1.85 <0.001 
Table 3.21: Comparison of characteristics of participants in the FMD and IMT cohorts. 
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3.4.2.1 Depression and endothelial function 
In this section it was found that there was no association between depression and 
endothelial function. 
 
66 participants within this cohort were classified has having depression. As can be seen 
from table 3.22 the only difference between the two groups was in IL-6 which was 
significantly higher in those with depression. There was no difference in FMD between the 
two groups. 
 
  Depression (66) No depression (222) p 
Age (yrs) 59± 5 58 ± 5 0.17 
Women (%) 34 (52) 86 (39) 0.06 
Waist (cm) 
   
Men 94.92 ± 13.24 92.37 ± 10.33 0.24 
Women 84.23 ± 12.89 85.05 ± 13.21 0.76 
Waist/hip ratio 
   
Men 0.96 ± 0.07 0.94 ± 0.06 0.09 
Women 0.84 ± 0.07 0.85 ± 0.08 0.55 
BMI (kg/m2) 26.09 ± 5.26 25.61 ± 3.79 0.42 
SBP (mmHg) 123 ± 18 120 ± 14 0.17 
DBP (mmHg) 71 ± 11 71 ± 10 0.92 
HR (bpm) 67 ± 10 66 ± 9 0.53 
Glucose (mmol/L) 5.17 ± 0.5 5.20 ± 0.45 0.59 
TC (mmol/L) 5.84 ± 1.07 5.76 ± 0.99 0.57 
HDL (mmol/L) 1.72 ± 0.52 1.68 ± 0.45 0.68 
Trigs (mmol/L) 1.23 ± 1.07 1.10 ± 0.7 0.52 
LDL (mmol/L) 3.54 ± 0.88 3.57 ± 0.91 0.82 
NonHDL (mmol/L) 4.12 ± 1.10 4.08 ± 1.06 0.76 
CRP (mg/L) 1.82 ± 2.14 1.61 ± 2.38 0.25 
IL-6 (pg/ml) 2.16 ± 1.64 1.72 ± 1.52 0.024 
BL dia (mm) 3.70 ± 0.69 3.62 ± 0.64 0.36 
FMD% (%) 5.07 ± 2.79 5.60 ± 3.26 0.23 
FMDABS (mm) 0.18 ± 0.09 0.19 ± 0.10 0.29 
RH % (%) 656 ± 277 646 ± 256 0.79 
Table 3.22: Participant characteristics for those with and without depression. BL dia = baseline diameter; 
RH% = reactive hyperaemia. 
 
When looking at correlations between measures of  endothelial function and cardiovascular 
risk factors it was shown that FMD% was positively associated with heart rate whilst, 
FMDABS had borderline associations with both diastolic blood pressure and heart rate in 
the depressed group (table 3.23). For those without depression FMD% was negatively 
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associated with age, triglycerides and nonHDL and positively associated with heart rate.  
FMDABS was only negatively associated with age in this group.  
 
 
FMD% 
 
FMDABS 
 
Depression 
 
No depression 
 
Depression 
 
No depression 
  r p 
 
r p 
 
r p 
 
r p 
Age (yrs) -0.11 0.39 
 
-0.19 0.004 
 
-0.06 0.63 
 
-0.15 0.024 
Waist (cm) 
  
 
  
 
  
 
  
Men 0.08 0.68 
 
0.00 0.96 
 
0.13 0.49 
 
0.06 0.51 
Women -0.33 0.05 
 
-0.03 0.79 
 
-0.24 0.17 
 
0.01 0.93 
Waist/hip ratio 
  
 
  
 
  
 
  
Men 0.04 0.85 
 
-0.04 0.69 
 
0.03 0.88 
 
0.00 0.98 
Women -0.13 0.46 
 
0.02 0.88 
 
-0.08 0.64 
 
0.04 0.74 
BMI (kg/m2) -0.09 0.47 
 
-0.08 0.26 
 
0.00 0.99 
 
0.01 0.85 
SBP (mmHg) 0.16 0.21 
 
-0.09 0.18 
 
0.20 0.10 
 
-0.06 0.34 
DBP (mmHg) 0.22 0.08 
 
0.04 0.54 
 
0.24 0.05 
 
0.04 0.56 
HR (bpm) 0.24 0.049 
 
0.16 0.015 
 
0.24 0.05 
 
0.10 0.14 
Glucose (mmol/L) 0.05 0.69 
 
-0.01 0.87 
 
0.10 0.42 
 
0.01 0.87 
TC (mmol/L) -0.06 0.64 
 
-0.12 0.08 
 
-0.12 0.35 
 
-0.09 0.20 
HDL (mmol/L) 0.13 0.28 
 
0.09 0.18 
 
0.02 0.89 
 
-0.01 0.92 
Trigs (mmol/L) -0.17 0.18 
 
-0.16 0.018 
 
-0.11 0.39 
 
-0.09 0.16 
LDL (mmol/L) -0.03 0.81 
 
-0.12 0.07 
 
-0.07 0.60 
 
-0.06 0.39 
NonHDL (mmol/L) -0.12 0.34 
 
-0.14 0.031 
 
-0.12 0.33 
 
-0.07 0.27 
CRP (mg/L) -0.13 0.30 
 
0.05 0.46 
 
-0.08 0.50 
 
0.07 0.28 
IL-6 (pg/ml) -0.05 0.70 
 
0.02 0.82 
 
-0.02 0.88 
 
0.06 0.39 
BL dia (mm) -0.46 <0.001 
 
-0.43 <0.001 
 
-0.12 0.32 
 
-0.18 0.006 
FMDABS (mm) 0.92 <0.001 
 
0.95 <0.001 
 
0.94 <0.001 
 
0.96 <0.001 
RH % (%) 0.08 0.55 
 
0.05 0.44 
 
0.12 0.36 
 
0.01 0.88 
Table 3.23: Correlations between FMD% and FMDABS with cardiovascular risk factors for depressed and 
non-depressed. 
There were no relationships between endothelial function and depression having adjusted 
for baseline brachial artery diameter and reactive hyperaemia.  Adding age and gender to 
this model did not change the results nor did adding each cardiovascular risk factor 
individually to the model (table 3.24).  
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FMD% 
 
FMDABS 
  F p 
 
F p 
BL dia & RH%* 0.52 0.47 
 
0.55 0.46 
BL dia, RH%, age & gender 0.01 0.91 
 
0.04 0.84 
Waist  (cm) 0.02 0.90 
 
0.02 0.88 
Waist/hip ratio 0.01 0.91 
 
0.02 0.90 
BMI (kg/m2) 0.01 0.92 
 
0.02 0.90 
SBP (mmHg) 0.00 0.97 
 
0.01 0.90 
DBP (mmHg) 0.01 0.94 
 
0.03 0.87 
HR (bpm) 0.00 0.98 
 
0.01 0.91 
Glucose (mmol/L) 0.04 0.83 
 
0.08 0.78 
TC (mmol/L) 0.01 0.90 
 
0.04 0.83 
HDL (mmol/L) 0.01 0.92 
 
0.04 0.84 
Trigs (mmol/L) 0.02 0.90 
 
0.05 0.83 
LDL (mmol/L) 0.04 0.84 
 
0.11 0.74 
NonHDL (mmol/L) 0.01 0.91 
 
0.04 0.84 
CRP (mg/L) 0.00 0.96 
 
0.01 0.91 
IL-6 (pg/ml) 0.01 0.94 
 
0.02 0.90 
Table 3.24: Association between depression and FMD% and depression and FMDABS adjusted for baseline 
brachial artery diameter, reactive hyperaemia, age, gender and each individual risk factor. *= adjusted for 
baseline diameter and reactive hyperaemia.  
When FMD% and FMDABS were adjusted for Framingham risk factor variables there were 
no relationships with depression.  Adding markers for obesity, inflammation and SES to 
the model did not improve the lack of  association (table 3.25). 
 
 
FMD% 
 
FMDABS 
  F p 
 
F p 
Model 1 0.03 0.87 
 
0.05 0.82 
Model 2 0.06 0.81 
 
0.09 0.76 
Model 3 0.07 0.80 
 
0.09 0.76 
Model 4 0.07 0.79 
 
0.08 0.78 
Table 3.25:  Relationship between depression and FMD% and depression and FMDABS with adjustments for 
cardiovascular risk factors.  
Model 1 = Age, gender, SBP, TC, HDL & Glucose;  
Model 2 =Age, gender , baseline diameter, reactive hyperaemia, SBP, TC, HDL, Trigs, Glucose, waist/hip 
ratio & waist; Model 3 = Age, gender, baseline diameter, reactive hyperaemia, SBP, TC, HDL, Trigs, Glucose,  
waist/hip ratio, waist, CRP & IL-6;  
Model 4 = Age, gender, baseline diameter, reactive hyperaemia, SBP, TC, HDL, Trigs, Glucose, waist/hip 
ratio, waist, CRP, IL-6 & SES. 
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3.4.2.2 Anxiety 
In this section it was found that there was no association between anxiety and endothelial 
function.  
88 participants were classified as having anxiety.  Table 3.26 shows that there were no 
differences in the risk factor profile for those with and without anxiety. 
 
  Anxiety (88) No anxiety (200) p 
Age (yrs) 58 ± 5 59 ± 5 0.18 
Women (%) 43 (49) 77 (39) 0.10 
Waist (cm) 
   
Men 94.38 ± 11.61 92.29 ± 10.69 0.28 
Women 85.24 ± 12.88 84.58 ± 13.26 0.79 
Waist/hip ratio 
   
Men 0.95 ± 0.06 0.94 ± 0.06 0.36 
Women 0.85 ± 0.09 0.85 ± 0.08 0.99 
BMI (kg/m2) 25.92 ± 4.71 25.64 ± 3.92 0.60 
SBP (mmHg) 121 ± 17 120 ± 14 0.58 
DBP (mmHg) 71 ± 11 71 ± 10 0.76 
HR (bpm) 67 ± 9 66 ± 10 0.50 
Glucose (mmol/L) 5.18 ± 0.46 5.21 ± 0.46 0.58 
TC (mmol/L) 5.76 ± 1.02 5.78 ± 1.00 0.88 
HDL (mmol/L) 1.76 ± 0.49 1.66 ± 0.46 0.08 
Trigs (mmol/L) 1.06 ± 0.61 1.16 ± 0.87 0.31 
LDL (mmol/L) 3.51 ± 0.92 3.59 ± 0.9 0.50 
NonHDL (mmol/L) 4.00 ± 1.02 4.13 ± 1.08 0.36 
CRP (mg/L) 1.76 ± 2.45 1.62 ± 2.27 0.77 
IL-6 (pg/ml) 1.95 ± 1.5 1.76 ± 1.57 0.21 
BL dia (mm) 3.61 ± 0.69 3.65 ± 0.63 0.67 
FMD% (%) 5.44 ± 2.71 5.50 ± 3.34 0.88 
FMDABS (mm) 0.19 ± 0.09 0.19 ± 0.10 0.77 
RH% (%) 647 ± 264 650 ± 259 0.94 
Table 3.26: Participant characteristics for those with and without anxiety. 
 
Correlations between the two measures of  endothelial function and cardiovascular risk 
factors within the anxious and non-anxious groups showed that FMD% was negatively 
correlated with CRP in the group with anxiety whilst FMDABS was positively correlated 
with diastolic blood pressure. In the group without anxiety FMD% was negatively 
correlated with age and all lipid variables except HDL and positively associated with heart 
rate.  FMDABS was not correlated with any risk factors in this group (table 3.27). 
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FMD% (%) 
 
FMDABS (mm) 
 
Anxiety 
 
No anxiety 
 
Anxiety 
 
No anxiety 
Anxiety r p 
 
r p 
 
r p 
 
r p 
Age (yrs) -0.18 0.09 
 
-0.18 0.010 
 
-0.13 0.23 
 
-0.14 0.05 
Waist (cm) 
  
 
  
 
  
 
  
Men -0.09 0.55 
 
0.03 0.75 
 
-0.02 0.90 
 
0.09 0.33 
Women -0.04 0.82 
 
-0.12 0.30 
 
-0.01 0.93 
 
-0.06 0.60 
Waist/hip ratio 
  
 
  
 
  
 
  
Men -0.14 0.35 
 
0.00 0.97 
 
-0.13 0.40 
 
0.04 0.70 
Women 0.08 0.60 
 
-0.05 0.65 
 
0.07 0.67 
 
-0.01 0.92 
BMI (kg/m2) -0.11 0.29 
 
-0.07 0.33 
 
-0.04 0.74 
 
0.00 0.99 
SBP (mmHg) 0.04 0.69 
 
-0.07 0.32 
 
0.10 0.36 
 
-0.04 0.55 
DBP (mmHg) 0.16 0.13 
 
0.05 0.48 
 
0.22 0.044 
 
0.04 0.62 
HR (bpm) 0.20 0.06 
 
0.17 0.017 
 
0.18 0.09 
 
0.11 0.12 
Glucose (mmol/L) 0.11 0.29 
 
-0.04 0.61 
 
0.20 0.06 
 
-0.03 0.68 
TC (mmol/L) 0.04 0.74 
 
-0.16 0.026 
 
0.01 0.94 
 
-0.13 0.06 
HDL (mmol/L) 0.14 0.20 
 
0.09 0.23 
 
0.01 0.92 
 
-0.01 0.93 
Trigs (mmol/L) -0.14 0.18 
 
-0.17 0.018 
 
-0.10 0.37 
 
-0.10 0.15 
LDL (mmol/L) 0.02 0.88 
 
-0.15 0.038 
 
0.03 0.75 
 
-0.10 0.18 
NonHDL (mmol/L) -0.02 0.85 
 
-0.18 0.010 
 
0.01 0.92 
 
-0.12 0.09 
CRP (mg/L) -0.21 0.045 
 
0.10 0.18 
 
-0.15 0.15 
 
0.11 0.12 
IL-6 (pg/ml) -0.05 0.66 
 
0.01 0.92 
 
-0.02 0.89 
 
0.05 0.48 
BL dia (mm) -0.47 <0.001 
 
-0.43 <0.001 
 
-0.15 0.16 
 
-0.18 0.010 
FMDABS (mm) 0.93 <0.001 
 
0.95 <0.001 
 
0.93 <0.001 
 
0.95 <0.001 
RH% (%) -0.04 0.71 
 
0.09 0.22 
 
-0.02 0.82 
 
0.05 0.46 
Table 3.27:  Correlations between FMD% and cardiovascular risk factors and FMDABS and cardiovascular 
risk factors for anxiety and non-anxiety. 
 
Following adjustment for age, gender, baseline diameter and reactive hyperaemia there were 
no relationships between measures of  endothelial function and anxiety.  Adding 
cardiovascular risk factors to the model individually did not result in any significant 
association between endothelial function and anxiety being found (table 3.28). 
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  FMD% 
 
FMDABS 
  F p 
 
F p 
age & gender* 0.35 0.56 
 
0.13 0.72 
BL dia & RH%$ 0.29 0.59 
 
0.25 0.61 
BL dia, RH%, age & gender 0.11 0.74 
 
0.05 0.82 
Waist (cm) 0.19 0.67 
 
0.11 0.74 
Waist/hip ratio 0.14 0.71 
 
0.07 0.80 
BMI (kg/m2) 0.14 0.71 
 
0.08 0.78 
SBP (mmHg) 0.17 0.68 
 
0.09 0.76 
DBP (mmHg) 0.18 0.67 
 
0.09 0.77 
HR (bpm) 0.20 0.66 
 
0.10 0.75 
Glucose (mmol/L) 0.07 0.79 
 
0.03 0.85 
TC (mmol/L) 0.14 0.71 
 
0.06 0.80 
HDL (mmol/L) 0.08 0.77 
 
0.04 0.85 
Trigs (mmol/L) 0.13 0.72 
 
0.06 0.80 
LDL (mmol/L) 0.16 0.69 
 
0.08 0.78 
NonHDL (mmol/L) 0.15 0.70 
 
0.07 0.79 
CRP (mg/L) 0.14 0.71 
 
0.09 0.76 
IL-6 (pg/ml) 0.22 0.64 
 
0.17 0.68 
Table 3.28:  Association between FMD% and FMDABS and anxiety adjusted for baseline brachial artery 
diameter, reactive hyperaemia, age, gender and each individual risk factor. *= adjusted for age and gender $= 
adjusted for baseline diameter and reactive hyperaemia 
 
Anxiety was not associated with either FMD% or FMDABS following adjustment for 
Framingham risk factor variables.  Adding markers for obesity, inflammation and SES did 
not change the lack of  association between anxiety and endothelial function (table 3.29). 
 
  FMD% 
 
FMDABS 
  F p 
 
F p 
Model 1 0.11 0.74 
 
0.08 0.78 
Model 2 0.25 0.62 
 
0.23 0.63 
Model 3 0.44 0.51 
 
0.44 0.51 
Model 4 0.33 0.56 
 
0.35 0.55 
Table 3.29: Relationship between anxiety and FMD% and FMDABS with adjustments for cardiovascular risk 
factors.  
Model 1 = Age, gender, SBP, TC, HDL & Glucose;  
Model 2 =Age, gender , baseline diameter, reactive hyperaemia, SBP, TC, HDL, Trigs, Glucose, waist/hip 
ratio & waist; Model 3 = Age, gender, baseline diameter, reactive hyperaemia, SBP, TC, HDL, Trigs, Glucose,  
waist/hip ratio, waist, CRP & IL-6;  
Model 4 = Age, gender, baseline diameter, reactive hyperaemia, SBP, TC, HDL, Trigs, Glucose, waist/hip 
ratio, waist, CRP, IL-6 & SES. 
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3.4.2.3 Depression and anxiety  
In this section it was shown that there was no association between measures of  chronic 
stress and endothelial function. 
 
Participants who had depression and/ or anxiety were grouped as described for the IMT 
cohort to create 4 groups.  Table 3.30 shows the number in each group and the mean 
FMD% and FMDABS for each group.  There were no significant differences in endothelial 
function measures between the groups.  Adjustment for age, gender baseline diameter and 
reactive hyperaemia did not show any relationship between these measures of  chronic 
stress and endothelial function (table 3.31). 
 
 
n FMD% FMDABS 
D+A+ 42 4.80 ± 2.49 0.17 ± 0.09 
D+A- 24 5.54 ± 3.24 0.20 ± 0.10 
D-A+ 46 6.02 ± 2.80 0.20 ± 0.09 
D-A- 176 5.49 ± 3.37 0.19 ± 0.10 
Table 3.30: Combined depression and analysis categorisation with mean ± SD for FMD% and FMDABS. 
D+A+ = depression and anxiety, D+A- = depression only; D-A+ = anxiety only; D-A- neither depression 
nor anxiety. 
  FMD% 
 
FMDABS 
  F p 
 
F p 
Anova unadj 1.11 0.35 
 
0.92 0.43 
Age & gender 1.26 0.29 
 
0.91 0.43 
BL dia & RH% 0.71 0.55 
 
0.59 0.63 
BL dia, RH%, age & gender 0.86 0.46 
 
0.69 0.56 
Table 3.31: Association between groupings of depression and anxiety with FMD% and FMDABS, with 
adjustments. 
3.4.2.4 Dyslipidaemia 
In this section it has been shown that there remained no relationship between chronic 
stress and endothelial dysfunction in the presence of  dyslipidaemia.   
 
Participants were divided into those with and without dyslipidaemia if  they met at least one 
of  the criteria as set out in table 3.32. Of  the 288 participants, 141were categorised as 
having dyslipidaemia with most participants having high total cholesterol and meeting at 
least two of  the qualifying criteria. 
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Dyslipidaemia categories 
 
No of categories met 
  TC ≥6 Trigs ≥1.7 HDL <1 LDL ≥4 
 
1 2 3 4 Dyslipidaemia 
Yes 119 45 6 97 
 
42 75 17 3 141 
No 169 243 282 189 
 
          
Table 3.32: Number of participants who met each lipid category and the number of categories they met. 
Units are mmol/l. 
Participants with and without dyslipidaemia were then grouped as to whether they had 
depression and/or anxiety or not, creating four groups. Table 3.33 shows the risk factor 
profiles for each group. Those with dyslipidaemia and depression and/ or anxiety had 
higher heart rates and the males had greater waist circumference and waist hip ratio than 
those with dyslipidaemia but without depression and/ or anxiety. Within the normal lipid 
groups there were a greater proportion of  females to males in the depressed and/ or 
anxious group than in the non-depressed/anxious group.  Additionally, those with 
depression and/or anxiety had lower Trigs than those without chronic stress (table 3.33).  
  Dyslipidaemia Normal 
 
Dep/Anx 
n=59 
No dep/anx 
n=82 p 
Dep/Anx 
n=53 
No dep/anx 
n=94 p 
Age (yrs) 59 ± 5 58 ± 5 0.20 57 ± 5 58 ± 5 0.23 
Women (%) 27 (46) 33 (40) 0.51 28 (53) 32 (34) 0.026 
Waist (cm) 
     
Men 98.29 ± 10.96 93.06 ± 10.3 0.032 88.20 ± 8.91 91.74 ± 11.26 0.17 
Women 91.60 ± 10.56 88.67 ± 14.31 0.38 78.65 ± 11.09 80.53 ± 11.61 0.52 
Waist/hip ratio 
     
Men 0.98 ± 0.06 0.94 ± 0.05 0.004 0.91 ± 0.05 0.93 ± 0.06 0.09 
Women 0.89 ± 0.07 0.86 ± 0.09 0.26 0.81 ± 0.08 0.83 ± 0.07 0.33 
BMI (kg/m2) 27.30 ± 4.51 26.26 ± 3.92 0.15 24.23 ± 3.85 25.10 ± 3.98 0.20 
SBP (mmHg) 126 ± 16 121 ± 16 0.10 117 ± 14 119 ± 13 0.25 
DBP (mmHg) 73 ± 10 71 ± 10 0.19 68 ± 10 70 ± 10 0.23 
HR (bpm) 69 ± 9 65 ± 9 0.005 64 ± 9 66 ± 10 0.19 
Glucose (mmol/L) 5.17 ± 0.45 5.27 ± 0.47 0.20 5.16 ± 0.48 5.16 ± 0.46 0.98 
TC (mmol/L) 6.45 ± 0.93 6.54 ± 0.73 0.55 5.08 ± 0.61 5.08 ± 0.59 0.99 
HDL (mmol/L) 1.67 ± 0.51 1.62 ± 0.51 0.52 1.80 ± 0.44 1.70 ± 0.41 0.16 
Trigs (mmol/L) 1.51 ± 1.08 1.43 ± 0.94 0.66 0.74 ± 0.27 0.84 ± 0.30 0.039 
LDL (mmol/L) 4.08 ± 0.8 4.27 ± 0.71 0.14 2.93 ± 0.59 2.99 ± 0.57 0.52 
NonHDL (mmol/L) 4.78 ± 0.9 4.92 ± 0.8 0.33 3.28 ± 0.64 3.38 ± 0.65 0.34 
CRP (mg/L) 2.07 ± 2.29 1.73 ± 2.22 0.23 1.34 ± 2.16 1.51 ± 2.51 0.58 
IL-6 (pg/ml) 2.03 ± 1.33 1.72 ± 1.28 0.07 1.74 ± 1.46 1.82 ± 1.92 0.84 
BL dia (mm) 3.76 ± 0.74 3.66 ± 0.62 0.37 3.51 ± 0.61 3.61 ± 0.64 0.34 
FMD% (%) 5.52 ± 2.93 5.24 ± 3.14 0.59 5.39 ± 2.72 5.71 ± 3.56 0.57 
FMDABS (mm) 0.20 ± 0.09 0.19 ± 0.1 0.52 0.18 ± 0.09 0.2 ± 0.11 0.40 
RH % (%) 587 ± 269 594 ± 221 0.87 742 ± 260 681 ± 269 0.19 
Table 3.33: Risk factor for participants with and without depression or anxiety by presence or absence of 
dyslipidaemia. 
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Comparisons were then made to see whether there were differences in FMD between the 
groups adjusting for age and gender and brachial artery baseline diameter and RH%.  
There were no relationships between endothelial function and dyslipidaemia and chronic 
stress. Further adjustments for each individual risk factor in addition to age, gender, 
baseline diameter and RH% did not demonstrate any significant relationships (table3.34).   
 
  FMD% 
 
FMDABS 
  F 
 
p F 
 
p 
age & gender 0.62 
 
0.60 
 
0.52 
 
0.67 
bldia & RH% 0.55 
 
0.65 
 
0.38 
 
0.77 
bldia, RH%, age & gender 0.83 
 
0.48 
 
0.67 
 
0.57 
Waist (cm) 0.58 
 
0.63 
 
0.38 
 
0.77 
Waist Hip 0.62 
 
0.60 
 
0.46 
 
0.71 
BMI (kg/m2) 0.69 
 
0.56 
 
0.48 
 
0.69 
SBP (mmHg) 0.74 
 
0.53 
 
0.56 
 
0.64 
DBP (mmHg) 0.62 
 
0.60 
 
0.48 
 
0.70 
HR (bpm) 0.47 
 
0.71 
 
0.36 
 
0.78 
Glucose (mmol/L) 0.87 
 
0.46 
 
0.70 
 
0.55 
CRP (mg/L) 0.66 
 
0.57 
 
0.48 
 
0.69 
IL-6 (pg/ml) 0.67 
 
0.57 
 
0.50 
 
0.68 
Table 3.34: Association between depression and or anxiety and FMD% and depression and or anxiety and FMDABS with 
and without dyslipidaemia, adjusted for baseline brachial artery diameter, reactive hyperaemia, age, gender and each 
individual risk factor.  
3.5 Discussion 
The novel finding of  this chapter was that dyslipidaemia influenced the association 
between chronic stress and IMT in women. Those women with dyslipidaemia and 
depression or anxiety had the greatest IMT even after adjustment for other potential 
confounding risk factors.  It was also found that women who had both depression and 
anxiety had greater IMT than those with neither depression nor anxiety.  
 
In addition, DC was found to be greater in women with regard to both individual measures 
of  chronic stress and those with both depression and anxiety but the relationship was not 
unchanged by dyslipidaemia.  
 
Men with anxiety had lower DC than those men without anxiety, however once heart rate 
was included in the adjustments this relationship was no longer significant.  Those men 
with dyslipidaemia had greater IMT than those with normal lipids but this was irrespective 
of  their chronic stress status.  
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Interestingly, there were no significant differences in endothelial function in those with 
depression and or anxiety, regardless of  the presence or absence of  dyslipidaemia. 
 
3.5.1 Gender differences in the associations of  depression and anxiety with 
IMT and DC    
The initial finding within the whole cohort, whereby no difference was found in IMT 
between those with and without depression, agrees with previous work; however, other 
studies have found increased IMT in those with depression262, 263, 274, 275.  On dividing the 
cohort by gender, the finding of  increased IMT in women with depression does fit with 
some previous studies. Lee et al found in a middle aged Korean cohort that females with 
depressive symptoms had greater IMT than those without symptoms but there was no 
difference between males with and without symptoms of  depression271. In contrast, 
Chirinos et al only found an association between IMT and depression in South American 
Hispanic males but not females270.  The reasons for these different findings are not fully 
understood.  It may be due to women losing the protective effect of  oestrogen as they 
become postmenopausal. Methodological differences between studies may also be partially 
responsible as there is substantial heterogeneity within the literature which can make 
comparisons difficult. For example, Lee et al and Chirinos et al used different 
questionnaires to assess depression symptoms and Lee et al included both the common 
carotid and the bifurcation in their cIMT measurements, whilst Chirinos et al used just the 
common carotid and did not avoid plaque if  it was in the area of  measurement270, 271. 
 
 The finding of  greater arterial stiffness in the control women in comparison to those with 
anxiety or depression was surprising.  For the men, the finding of  decreased DC in those 
with anxiety was more expected, although this relationship was no longer apparent when 
dividing the groups to look at co morbidity and the individual traits.  There is limited work 
looking at the relationship between arterial stiffness and depression or anxiety.  Tiemeier et 
al found that participants with lower carotid DC and greater carotid to femoral pulse wave 
velocity were more likely to have depressive symptoms286.   Seldenrijk et al found an 
association between increased heart rate normalised central augmentation index and 
current depressive and /or anxiety disorder, but did not find any relationship with carotid 
DC287.  These findings both differ from my study, although neither looked at differences 
within genders and Seldenrijk et al’s participants were part of  a cohort specifically selected 
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for having depressive or anxiety disorders rather than a cohort of  the general population as 
in my study287.    
 
3.5.2 Dyslipidaemia 
The novel finding that those women with dyslipidaemia and depression or anxiety had 
greater IMT was interesting. It has previously been shown that people with depression 
and/or anxiety have increased lipid levels and have increased risk of  cardiovascular disease 
and events, in both the healthy population and those with pre-existing coronary disease204, 
211, 252, 253.  The finding in this study, of  increased IMT in older women (largely post-
menopausal) with high lipid levels and depression or anxiety symptoms, highlights a group 
that are potentially at greater risk of  future cardiovascular events. This finding may have an 
impact on cardiovascular risk stratification of  these women. In addition it may help inform 
whether or not lipid lowering therapy should be initiated which can reduce the progression 
of  atherosclerotic disease or whether they should be given greater encouragement to make 
lifestyle changes which are beneficial to cardiovascular health.  The finding that DC was 
greatest in those with depression and or anxiety irrespective of  their lipid profile is 
interesting but does potentially reflect the lesser effect of  lipid levels on DC rather than 
IMT.  
 
There is little previous work looking at the impact of  specific cardiovascular risk factors on 
the relationship between depression and anxiety and measures of  subclinical vascular 
disease. In a study of  police officers, Violanti et al found a positive association between 
depressive symptoms and IMT but only in those officers without hypertension following 
adjustment for other cardiovascular risk factors268. Wagner et al found that the presence of  
type 2 diabetes had no impact on the association between lifetime history of  depression 
and impaired endothelial function359.  The finding by Wagner et al does fit with the lack of  
association between dyslipidaemia and endothelial function within this analysis, but neither 
were any relationships between depression or anxiety symptoms found in my study. 
However, Wagner’s study only included those who had a life time history of  major 
depression disorder and excluded subjects with a depressive disorder within the previous 6 
months of  the study, whereas the participants in my study mostly had current symptoms 
of  depression or anxiety; this may account in part, for the difference in findings.   
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3.5.3 Endothelial function 
It was surprising that the previous finding from the Whitehall II study of  a difference in 
FMD in those with depressive symptoms and endothelial function was not replicated in 
this analysis, although the lack of  difference in endothelial function between those with and 
without anxiety did agree with the previous study284.   This difference in the study findings, 
may, in part be due to the different approaches to categorisation of  presence of  
depression.  Hemingway et al took the top quartile of  the general GHQ, whereas I took 
those with either a result of  4 or more on the GHQ, 16 plus on the CES-D questionnaire, 
those on antidepressant medication or had previously been diagnosed with depression.   
The participants in this analysis were now older and those on blood pressure and 
cholesterol lowering medications (which can improve endothelial function) were excluded. 
This may have excluded some participants with higher depression scores who may have 
accounted, at least in part, for differences in the previous study. A number of  other studies 
have identified an association between depression/anxiety and endothelial function293, 294, 296-
298, 300. Many of  these studies have been in patients who already have cardiovascular disease 
and depression/depressive symptoms or in people with major depression293, 294, 297, 300 .  
Some studies have shown no association between endothelial function and depression 
and/or anxiety302-304, 360. Schott et al, in a study population not dissimilar in age and gender 
to the Whitehall II cohort, found that FMD was lower in males with higher hostility and 
females with greater anger suppression, both traits that can be viewed as negative affect, 
but there was no association between FMD and depression or anxiety symptoms in their 
cohort303.  
 
3.5.4 Potential mechanisms 
A number of  potential mechanisms have been suggested for the relationship between the 
increased risk of  cardiovascular disease and depression/anxiety.  These include increased 
hypothalamic-pituitary-adrenal axis activity (HPA), autonomic nervous system dysfunction, 
inflammatory processes and altered platelet function. 
 
HPA axis dysregulation has been associated with depression and anxiety and can lead to 
elevated levels of  cortisol and impaired regulatory feedback.  Increased cortisol, through 
short-term oral supplementation, impairs endothelial function; inhibition of  adrenal 11-
hydroxylase, and consequently cortisol synthesis, by metyrapone improves flow-mediated 
89 
 
dilatation in patients with treated depression, suggesting a role in the development of  
cardiovascular disease361, 362.  
  
Inflammatory processes play a major role in all stages of  cardiovascular disease from 
initiation through to the destabilisation of  plaques triggering an event. Endothelial 
dysfunction, increased IMT and arterial stiffness are all associated with inflammation as are 
depression and anxiety 363-367. This could therefore provide one potential pathway for the 
increased IMT in women with depression shown in this study.  However, the effects of  
CRP and IL-6 were adjusted for in this analysis so other mechanisms are likely to be more 
prominent. 
 
Lifestyle behaviours may provide an additional factor in the relationship between increased 
IMT and depression. Cigarette smoking, lower physical activity and poor diet with 
increased fat intake are all associated with depression, anxiety and increased cardiovascular 
risk 260, 351.  These circumstances may help create a favourable environment for the 
development/exacerbation of  atherosclerosis. 
 
Dyslipidaemia is associated with worse cardiovascular outcome, increased IMT and 
endothelial dysfunction89, 90, 352. It has been shown that patients with depression or anxiety 
do have increased lipid levels and increased risk of  cardiovascular disease204, 211, 253.  Van 
Reedt Dortland et al demonstrated that patients with more severe symptoms of  depression 
and anxiety were more prone to dyslipidaemia alongside obesity252.  It is worth noting that 
in my analysis those men and women with dyslipidaemia and depression and/or anxiety 
had the greatest waist/hip ratios, but the relationship between dyslipidaemia and IMT 
remained after adjustment for obesity measures.  The combination of  depression and 
dyslipidaemia resulting in the greatest IMT in this cohort may be due to a mixture of  
lifestyle factors, and biological mechanisms such as inflammation.    
 
3.5.5 Limitations   
All the measures of  subclinical vascular disease have their limitations.  A lack of  
standardization of  methodology for both FMD and IMT in particular, can make 
comparisons between studies difficult.  In the WHII study IMT was assessed using 
callipers, however, edge detection software has now become the preferred method of  for 
measuring IMT as it is less operator dependent.  Although those participants on blood 
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pressure and lipid lowering medications were excluded from the analysis other drugs may 
influence the measurements as can environmental factors, exercise, food and stress.  
Although actions were taken to limit and adjust for these influences where possible, 
alongside the intrinsic biological variability they may have an influence on the findings. DC 
only provides a measure of  local arterial stiffness and not large artery stiffness for which 
carotid to femoral pulse wave velocity is considered the gold standard method. 
Unfortunately, these data were not available at this phase of  the WHII study.  However, the 
two measures are related and carotid artery DC can still give valuable information about 
subclinical vascular disease and its relationship with chronic stress.  
  
The depression group is a composite of  participants who have been classified as having 
clinically significant depressive symptoms by meeting the cut off  point on either one of  
two validated questionnaires investigating depressive symptoms, have previously been 
diagnosed as depressed or taking anti-depressant medication.  Therefore, there is likely to 
be a wide range of  severity of  symptoms from mild depression to severe clinical 
depression which may have altered some of  the findings with the vascular measures.  
Additionally, some of  the participants may not have been currently undergoing a depressive 
episode.  This study also did not look at whether participants have had recurrent or just 
single episodes of  depression. These divisions may have identified more relationships 
within the data.  
 
This composite group may also explain why the number of  participants identified with 
depressive symptoms was relatively high in comparison to other studies such as Lee et al 
who used just the CES-D who identified 18.7% of  Korean women and 7.8% of  Korean 
men as having depressive symptoms271.  However, in another study in the Whitehall II 
population, 27% of  participants were identified as having a common mental disorder 
identified using the GHQ, which is similar to the 25% of  participants having been 
identified with depressive symptoms in my analysis368.  Additionally the prevalence of  
depression in the FMD subgroup was the same as an analysis from an earlier phase of  the 
Whitehall II study284. 
 
Similarly using the top quartile of  the GHQ for identifying anxiety means that those 
identified as having anxiety symptoms would not have them as severely as if  the cut off  of  
8 plus had been used. This would have reduced the number of  participants which may have 
had implications for the power of  the analyses. Prevalence of  anxiety in FMD study is 
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greater than Whitehall II previously but participants who were taking anxiolytic medication 
were included in the anxiety group in this analysis284.  
 
Similarly due to issues surrounding power of  the analysis particularly in the FMD cohort, 
anxiety disorder was taken as those within the top quartile rather than achieving 8 or more 
on the GHQ anxiety scale.  This may mean that those classified with anxiety within the 
cohort were not as severely anxious as if  the normal cut off  point had been used.  
 
As this was a relatively healthy population the dyslipidaemia definition was quite broad, 
therefore participants meeting the criteria did not necessarily have severe dyslipidaemia 
which may have impacted on the findings. However, despite this, dyslipidaemia did still 
influence the association between chronic stress and IMT in women.    Replication of  this 
analysis in a population with more severe dyslipidaemia would be useful to help confirm 
whether this finding is true or due to chance and may also identify differences with the 
other measures of  subclinical vascular disease.  Also the classification did not distinguish 
between whether participants had raised LDL or high triglycerides with low HDL. It was 
therefore not possible to investigate whether these different pathologies/classifications 
exerted different influences on the relationships between the sub clinical vascular measures 
and depression and/or anxiety. 
 
Due to a lack of  numbers it was not possible to look at dyslipidaemia and the different 
influences of  depression and anxiety separately within both cohorts. Nor was it possible to 
investigate the influence of  gender within the FMD cohort. The smaller numbers with 
FMD data may have reduced the power of  the analysis which therefore may mean that it 
was not possible to see differences that would be present in a larger population. 
 
Finally, the statistically significant differences in IMT that were seen between the groups in 
women are small and therefore may have limited clinical significance although they 
potentially indicate an acceleration of  the atherosclerotic process within the artery wall.  
Follow up of  these women would be useful to see if  they are more likely to develop CVD 
than women without dyslipidaemia and chronic stress.  Furthermore this was a cross-
sectional analysis to investigate the biological relationships intervention studies and 
prospective studies looking at prognostic outcomes would be required.  
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3.5.6 Conclusion 
In conclusion, it has been shown that women with depression and anxiety have increased 
IMT, which was driven by the presence of  dyslipidaemia. Neither depression nor anxiety 
had a significant effect on subclinical vascular measures in men.  
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Chapter 4. Acute mental stress, lipids 
and endothelial function in an 
epidemiological cohort  
 
4.1 Introduction 
In the previous chapter I have looked at the impact of chronic stress on endothelial 
function and found that there were no differences between those with and without 
depression and /or anxiety and indices of FMD.  In this chapter I wish to explore the 
effects of acute mental stress on future vascular function to see whether these may have a 
greater impact than chronic stress. 
 
As previously discussed, stress has been shown to be an important major risk factor for 
cardiovascular disease26. In addition to chronic stress, acute stressors, such as earthquakes, 
major sporting events or high pressure deadlines have been shown to trigger cardiovascular 
events, although there has been some inconsistency in the results of these studies216-218, 220-222, 
225. Laboratory studies have demonstrated increases in haemodynamic and inflammatory 
markers in response to acute mental stress challenges369-371.   Inflammatory processes play a  
key role in the development of atherosclerotic lesions in the vessel wall for which 
decreased endothelial function is an early signal25. In keeping with this potential link, acute 
inflammation induced by injection of the typhoid vaccination and acute mental stress both 
cause transient endothelial dysfunction325, 364. Therefore, the nature and magnitude of the 
inflammatory response to acute mental stress could be a potential determinant of future 
endothelial dysfunction and cardiovascular events.   
 
Dyslipidaemia is associated with a worse cardiovascular outcome, impaired endothelial 
function and an increased inflammatory profile67, 89, 372.  The relationship between lipids and 
stress responses both within the context of changes in response to a mental stress stimuli 
and the influence of an unfavourable lipid profile are not yet fully understood.  It is not yet 
clear whether the stress response contributes to dyslipidaemia or if an unfavourable lipid 
profile increases the inflammatory and vascular responses to stress.  Lipid levels have been 
demonstrated to increase in response to a stress challenge373.  Additionally, Steptoe et al 
have also shown that 56% of participants whose total cholesterol during stress was in the 
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top tertile had a clinically elevated total cholesterol of greater than or equal to 6.2 mmol/L 
three years later compared with just 16% from the lowest tertile373.   
 
There are a limited number of small studies looking at the immediate response to an acute 
mental stress challenge on endothelial function in cardiovascular risk factor groups and the 
results have been mixed.  Ghiadoni et al found no change in FMD following a stress task in 
type 2 diabetics, whilst Cardillo et al saw no change in NO-dependent dilatation as assessed 
by forearm plethysmography in subjects with hypercholesterolaemia but did see a reduction 
in participants with hypertension325, 374.    However, the longer term effects of the 
inflammatory responses to mental stress both alone and in combination with a 
cardiovascular risk factor on endothelial function are unknown.    
 
In the Whitehall II psychobiology substudy, inflammatory responses to acute mental stress 
have been associated with both increased local arterial stiffness (a measure of structural 
arteriosclerotic/atherosclerotic changes) and larger increases in ambulatory systolic blood 
pressure when these were assessed three years later324, 369.  Thus raising the question of 
whether there are relationships between inflammatory responses to stress and endothelial 
function, as assessed by flow-mediated dilatation, a more dynamic measure of arterial 
pathophysiology than arterial stiffness. This would therefore add additional valuable 
information to the current knowledge about the relationship between acute mental stress 
and sub clinical vascular disease. Although the participants in this cohort were purposefully 
selected from among those without overt major cardiovascular risk factors, it provides the 
opportunity to investigate the influences of high normal lipids, which have been shown to 
infer increased lifetime risk of cardiovascular disease, on the inflammatory responses to 
stress and future endothelial function375. 
4.2 Aims 
Aim:  To investigate the effects of  the inflammatory response to acute mental stress on 
endothelial function and the influence of  cardiovascular risk factors 
Primary Hypothesis: Those participants with a greater inflammatory response to an acute 
mental stress challenge have lower FMD when assessed 3 years later 
Secondary hypothesis 1: Having a cardiovascular risk factor influences the inflammatory 
response to acute mental stress. 
Secondary hypothesis 2: The size of  the inflammatory response to an acute mental stress in 
the context of  dyslipidaemia is associated with a lower FMD 3 years later 
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4.3 Methods 
4.3.1 Participants 
Participants were from the Whitehall II epidemiological cohort who took part in a 
psychobiology substudy in 1999-2000 as described in Chapter 2. Participants were aged 45-
59 years, of  white European origin, lived in the London area, were in full time employment 
and did not have coronary heart disease or hypertension.  Grade of  employment was used 
to identify socio-economic status (SES) and participants were selected on the basis of  this 
to ensure wide variation in status within the cohort. Three years after the acute mental 
stress testing 158 participants underwent an assessment of  endothelial function at Phase 7 
of  the Whitehall study.   
4.3.2 Acute mental stress testing 
 
Figure 4.1: Protocol for acute mental stress testing 
 
Studies took place in either the morning or afternoon in a light and temperature controlled 
laboratory. Participants were requested to have not drunk alcohol or exercised on the 
evening before or on the day of  testing and to have not consumed caffeine or smoked for 
the 2 hours prior to the study.  Anthropometric measurements were made as described in 
Chapter 2. Blood pressure and heart rate were continuously monitored using a Portapress-2 
(Finapress Medical Systems, Amsterdam, NL).  After the insertion of  a venous cannula for 
blood sample collection, participants rested for 30 minutes.  Baseline blood pressure and 
heart rate were recorded for the last 5 minutes of  this rest period and a baseline blood 
sample was drawn.  Following this two stress tasks (computerized colour-word interference 
task and mirror tracing) were administered in random order with a 5 minute inter-task 
interval.  The tasks each lasted for 5 minutes during which blood pressure and heart rate 
were continuously monitored.  A second blood sample was taken immediately after the 
second task.  Participants then rested quietly reading or watching wildlife videos.  Two 5 
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minute post-stress blood pressure and heart rate recordings were made at 15-20 minutes 
and 40-45 minutes.  A third blood sample was taken after 45 minutes (figure 4.1). 
 
Blood samples were processed as described in Chapter 2.  Lipids, glucose and C-reactive 
protein (CRP) were assessed at baseline.  Fibrinogen (Fbg) was measured at all three time 
points whilst IL-6 and TNFα were assessed at baseline and 45 minutes post-stress.  
 
4.3.3 Flow-mediated dilatation 
Having rested supine for 10 mins, participants’ right brachial artery was imaged using 
ultrasound; a Doppler cursor was positioned in the centre of  the artery to assess blood 
flow. Baseline diameter and blood flow measures were recorded for 1 minute.  Following 
this a blood pressure cuff  that had previously been positioned around the forearm was 
inflated to 300 mmHg for 5 minutes to occlude the artery and induce reactive hyperaemia 
on release of  the cuff.  Recording carried on for a further 5 minutes. Images were saved to 
a computer for later offline analysis as described in Chapter 2.  
4.3.4 Phase 7 measurements 
A fasting blood sample was taken at the clinic visit for phase 7.  From this sample glucose, 
total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL) and 
triglycerides (Trigs) were measured. Samples were assessed as described in Chapter 2.  
Height, weight, hip and waist measurements were also taken at this visit as described in 
Chapter 2. 
4.3.5 Statistical analysis 
The two task systolic blood pressure (SBP) recordings were averaged to give one stress 
response. Diastolic blood pressure (DBP) and heart rate (HR) task recordings were treated 
in the same way. Stress reactivity was calculated as the change between baseline level and 
stress sample.  Data was checked for normality and non-normally distributed variables were 
transformed using ln transformation.   
4.3.5.1 Acute mental stress and endothelial function 
Analysis was carried out on the whole cohort and then separated by gender.   Five 
participants were excluded from the analyses as they had started taking lipid or blood 
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pressure medications since participating in the stress testing study.  Differences in baseline 
characteristics between the two genders were analysed using either an independent samples 
t-test or the independent samples Mann Whitney U test. Chi square was used to assess for 
differences in smoking and SES status between the two groups.  Associations between 
endothelial function and baseline haemodynamic, inflammatory and lipid variables were 
investigated using Pearson correlations, partial correlations with adjustment for age, gender, 
reactive hyperaemia (RH%) and baseline brachial artery diameter, were used to account for 
differences between males and females.   
 
 Responses to stress testing were assessed using repeated measures analysis of  variance 
with trial as the within-subject factor and Greenhouse-Geisser adjustments employed 
where appropriate.  Post hoc comparisons were made with Tukey’s least significant 
differences (LSD) test.  To see whether there was a difference in stress responses by 
gender, repeated measures analysis of  variance was used with the addition of  gender as a 
between-subject factor. Results are presented as F (degrees of  freedom of  the effect of  the 
model, degrees of  freedom for the residuals of  the model). Correlations between 
responses to stress and endothelial function were assessed using Pearson correlations.  
 
To compare endothelial function between those with a high response to stress versus those 
with a low or no response to stress for haemodynamic and inflammatory variables, the 
cohort were divided into the top and bottom 40% responders for each variable as per 
Kunz-Ebrecht et al376.  This division meant those participants who bordered the two 
categories were not included allowing for a comparison of  those with a more distinct 
difference in their respective responses between the two groups. Differences in FMD% and 
FMDABS between the high and low stress responders for each variable were assessed using 
one-way analysis of  variance (ANOVA) and analysis of  co-variance (ANCOVA) with 
adjustments for baseline stress variable, baseline brachial artery diameter and RH%.  
 
Presence of  associations between endothelial function and inflammatory responses were 
tested for using multiple linear regression, regressing FMD% or FMDABS on stress-induced 
changes in Fbg, IL-6 and TNFα.  Additional models incorporating other relevant co-
variables were run.  These included baseline level of  the inflammatory marker, baseline 
brachial artery diameter, RH%, age, gender, BMI, waist/hip ratio, systolic and diastolic 
blood pressure, HDL and LDL cholesterol, glucose, CRP  socio-economic status 
(employment grade) and smoking. Two sets of  models were run using these co-variables 
measured firstly at the time of  mental stress testing and secondly at phase 7 of  the 
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Whitehall II study.  Results are presented as unstandardised regression coefficients (β) with 
standard error of  the mean (SEM). 
4.3.5.2 Dyslipidaemia and responses to acute mental stress: 
Participants were classified as having dyslipidaemia if  they met any of  the following lipid 
parameters: total cholesterol≥6; triglycerides ≥1.7; HDL <1; LDL≥ 4 (mmol/L). 
 
Analyses were carried out as for the whole cohort.  To look at the influence of  
dyslipidaemia on the responses to mental stress testing, the variable presence of  
dyslipidaemia replaced gender as the between subject factor in the repeated measures 
ANOVA.   
 
To further investigate whether the inflammatory response to stress might influence 
endothelial function for participants with and without dyslipidaemia the stress change for 
each inflammatory variable was divided into high and low inflammatory responses to stress 
by the median.   These two groups were each further divided by the presence or absence of  
dyslipidaemia creating four groups; dyslipidaemia & high inflammatory response; 
dyslipidaemia & low inflammatory response; normal lipids & high inflammatory response 
and normal lipids & low inflammatory response.  These groups were created for each 
inflammatory variable. ANOVA and ANCOVA were used with adjustments for baseline 
diameter, RH% and baseline inflammatory variable to test whether there were differences 
within the groups with Bonferroni post hoc analyses.  
4.3.5.3 Reactive hyperaemia and responses to acute mental stress 
Associations between RH% and cardiovascular risk factors and the haemodynamic and 
inflammatory responses to stress were investigated using Pearson correlations.  
Comparisons with RH% were made between low and high stress responders using ANOVA 
and ANCOVA as described above.  Adjustments were made for baseline velocity time 
integral (VTI) and baseline stress variable.  Finally the influence of  dyslipidaemia and 
inflammatory response on RH% was investigated having used the same four groupings as 
described in 4.3.5.2 using ANCOVA with the same adjustments as for the low and high 
stress response analysis. 
 
 
99 
 
4.4 Results 
4.4.1 Acute mental stress and endothelial function  
The key finding in this section was that a larger fibrinogen response 45 minutes post stress 
was associated with poorer endothelial function assessed 3 years later.  There was no 
association between IL-6 and TNFα responses to stress and endothelial function. 
 
Table 4.1 shows the participant characteristics of  the acute mental stress cohort with 
endothelial function data as a whole and divided by gender.  It can be seen that males were 
older with higher blood pressure and lipid profile except for HDL which was lower than 
females.  FMD% was significantly lower in males but they had a larger baseline brachial 
artery diameter.  FMDABS was higher in women but not significantly. 
 
Characteristic All (n=153) Male (n=84) Female (n=69) p 
Age (yrs) 52 ± 3 53 ± 3 52 ± 3 0.021 
Smoker (Y) 9 (5.9%) 6 (7.1%) 3 (4.2%) 0.47 
SES 
    
Higher 60 (39.2%) 34 (40.5%) 26 (37.7%) 0.84 
Intermediate 50 (32.7%) 28 (33.3%) 22 (31.9%) 
 
Lower 43 (28.1%) 22 (26.2%) 21 (30.4%) 
 
BMI (kg/m2) 25.23 ± 3.52 25.36 ± 3.25 25.08 ± 3.85 0.63 
Waist/hip ratio 0.84 ± 0.09 0.90 ± 0.07 0.78 ±0.06 <0.001 
SBP(mmHg) 114 ± 12 118 ± 11 109 ± 12 <0.001 
DBP(mmHg) 69 ± 9 71 ± 9 67 ± 9 0.005 
HR(bpm) 64  ± 8 64 ± 9 66 ± 8 0.14 
TC(mmol/L) 5.38 ± 0.87 5.42 ± 0.84 5.32 ± 0.91 0.47 
Trigs (mmol/L)  1.34 ± 0.71 1.45 ± 0.65 1.21 ± 0.76 0.003 
HDL (mmol/L) 1.57 ± 0.39 1.43 ± 0.30 1.74 ± 0.41 <0.001 
LDL (mmol/L)  3.20 ± 0.81 3.34 ± 0.79 3.02 ± 0.82 0.018 
Total/HDL 3.65 ± 1.13 3.96 ± 1.01 3.24 ± 1.13 <0.001 
Glucose (mmol/L) 5.30 ± 0.79 5.34 ± 0.72 5.25 ± 0.88 0.54 
C-reactive protein (mg/L) 1.02 ± 1.29 0.92 ± 0.97 1.13 ± 1.59 0.8 
BL dia (mm) 3.60 ± 0.71  4.02 ± 0.61 3.08 ± 0.41 <0.001 
FMDABS (mm) 0.19 ± 0.10 0.19 ± 0.10 0.20 ± 0.10 0.81 
FMD% (%) 5.70 ± 3.39 5.03 ± 2.96 6.51 ± 3.69 0.012 
RH% (%) 658 ± 260 648 ± 249 665 ± 270 0.61 
Table 4.1: Participant characteristics for the whole acute mental stress and endothelial function cohort and 
by gender. P value is for differences between genders. Mean ± SD or n (%) Data is untransformed 
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Pearson Correlation 
 
Partial# 
  All  
 
Male 
 
Female 
 
All 
Risk factor r p 
 
r p 
 
r p 
 
r p 
Age (yrs) -0.17 0.032 
 
-0.10 0.36 
 
-0.19 0.12 
 
  
BMI (kg/m2) -0.05 0.55 
 
0.04 0.72 
 
-0.12 0.33 
 
0.06 0.46 
Waist/hip ratio -0.14 0.09 
 
0.05 0.66 
 
-0.09 0.48 
 
0.06 0.49 
SBP (mmHg) 0.04 0.61 
 
0.17 0.12 
 
0.07 0.56 
 
0.12 0.15 
DBP (mmHg) 0.12 0.14 
 
0.19 0.08 
 
0.15 0.22 
 
0.22 0.011 
HR (bpm) 0.22 0.006 
 
0.29 0.007 
 
0.09 0.47 
 
0.24 0.006 
TC (mmol/L) -0.06 0.47 
 
0.03 0.78 
 
-0.13 0.28 
 
0.06 0.48 
Trigs (mmol/L) -0.04 0.59 
 
-0.01 0.90 
 
0.00 0.97 
 
-0.01 0.90 
HDL (mmol/L) 0.08 0.34 
 
0.09 0.44 
 
-0.07 0.57 
 
0.04 0.66 
LDL (mmol/L) -0.09 0.28 
 
0.00 1.00 
 
-0.11 0.36 
 
0.05 0.53 
Total/HDL -0.10 0.21 
 
-0.05 0.67 
 
-0.03 0.78 
 
0.01 0.91 
Glucose (mmol/L) -0.05 0.57 
 
-0.05 0.68 
 
-0.02 0.88 
 
0.01 0.93 
CRP (mg/L) -0.04 0.61 
 
0.17 0.13 
 
-0.24 0.05 
 
-0.04 0.64 
BL dia (mm) -0.45 <0.001 
 
-0.50 <0.001 
 
-0.36 0.002 
 
  
FMDABS (mm) 0.95 <0.001 
 
0.96 <0.001 
 
0.94 <0.001 
 
0.94 <0.001 
RH % (%) 0.05 0.55 
 
-0.05 0.64 
 
0.14 0.27 
 
  Table 4.2: Pearson correlations between FMD% and participant characteristics/risk factors in the whole 
cohort and separately by gender plus partial correlations in the whole cohort adjusted for age, gender, reactive 
hyperaemia and brachial artery baseline diameter. 
 
FMD% was positively associated with heart rate and negatively associated with age and 
brachial artery baseline diameter in the whole cohort (table 4.2).  When the population was 
split by gender there was no association with age and the relationship with heart rate was 
only present in males. The same associations were present with FMDABS (table 4.3), there 
was a borderline negative association with waist hip ratio but this was not present when the 
cohort was divided by gender. 
 
Partial correlations between FMD variables and cardiovascular risk factors with adjustment 
for age, gender, reactive hyperaemia and brachial artery diameter showed there to be 
significant positive associations with diastolic blood pressure and heart rate for both FMD% 
and FMSABS (tables 4.2 & 4.3). 
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Pearson Correlation 
 
Partial# 
  All  
 
Male 
 
Female 
 
All 
Risk factor r p 
 
r p 
 
r p 
 
r p 
Age (yrs) -0.18 0.029 
 
-0.04 0.69 
 
-0.24 0.05 
 
  
BMI (kg/m2) -0.06 0.48 
 
0.00 1.00 
 
-0.09 0.45 
 
0.04 0.64 
Waist/hip ratio -0.16 0.05 
 
0.02 0.84 
 
-0.05 0.66 
 
0.05 0.60 
SBP (mmHg) 0.02 0.77 
 
0.14 0.20 
 
0.08 0.50 
 
0.11 0.19 
DBP (mmHg) 0.08 0.35 
 
0.15 0.17 
 
0.12 0.34 
 
0.18 0.037 
HR (bpm) 0.23 0.006 
 
0.27 0.012 
 
0.13 0.28 
 
0.23 0.007 
TC (mmol/L) -0.07 0.41 
 
0.03 0.76 
 
-0.14 0.26 
 
0.05 0.56 
Trigs (mmol/L) -0.07 0.37 
 
-0.05 0.64 
 
-0.01 0.93 
 
-0.04 0.65 
HDL (mmol/L) 0.07 0.38 
 
0.10 0.36 
 
-0.10 0.40 
 
0.01 0.91 
LDL (mmol/L) -0.08 0.32 
 
0.01 0.90 
 
-0.10 0.43 
 
0.07 0.45 
Total/HDL -0.10 0.20 
 
-0.06 0.60 
 
-0.01 0.92 
 
0.02 0.79 
Glucose (mmol/L) -0.08 0.33 
 
-0.09 0.41 
 
-0.04 0.73 
 
-0.03 0.73 
CRP (mg/L) -0.05 0.59 
 
0.15 0.17 
 
-0.21 0.10 
 
-0.05 0.59 
BL dia (mm) -0.45 <0.001 
 
-0.49 <0.001 
 
-0.35 0.003 
 
  
FMD% (%) 0.95 <0.001 
 
0.96 <0.001 
 
0.94 <0.001 
 
0.94 <0.001 
RH % (%) 0.02 0.81 
 
-0.08 0.48 
 
0.09 0.48 
 
  Table 4.3: Pearson correlations between FMDABS and participant characteristics/ risk factors in the whole 
cohort and separately by gender, plus partial correlations in the whole cohort adjusted for age, gender, 
reactive hyperaemia and brachial artery baseline diameter. 
 
Cardiovascular and inflammatory responses to acute mental stress challenges are shown in 
table 4.4.  There were significant responses to the stress challenge for all variables except 
TNFα.   Post hoc tests showed there to be significant increases in blood pressure, heart rate 
and Fbg with the stress tasks.  
 
  Baseline Task  PS1 PS2 F p 
SBP (mmHg) 114 138* 119*≠ 119*≠ 250.3 <0.001 
DBP (mmHg) 69 83* 73*≠ 74*≠ 268.3 <0.001 
HR (bpm) 65 72* 62*≠ 63*≠° 234.7 <0.001 
Fbg (g/L) 2.81 2.87* 
 
2.85* 13.4 <0.001 
IL-6 (pg/ml) 1.12 
  
1.20* 9.2 0.003 
TNFα (pg/ml) 2.12 
  
2.18 2.9 0.09 
Table 4.4: Cardiovascular and biochemical responses to an acute mental stress challenge. Geometric means 
are shown for IL-6 and TNFα and arithmetic means for all other measures. PS =post stress; * = sig diff from 
baseline (p<0.05); ≠ = sig diff from task mean (p<0.05); ° = sig diff from post stress 1(p<0.05).  
 
Table 4.5 shows the responses to acute mental stress by gender.  Fbg was the only 
inflammatory marker with a significant difference between baseline levels for males and 
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females (p=0.006). There were significant responses in all variables except for TNFα. 
However, there was a significantly different response to the stress challenge between the 
two genders for TNFα (F(1,140) =4.0 p=0.047) with a borderline effect for heart rate 
(F(2,296) =3.0 p=0.05).  TNFα increased in response to the stress challenge in males and 
decreased in females. 
  
    
  Trial 
 
Gender interaction 
    Baseline Task  PS1 PS2 F p 
 
F p 
SBP (mmHg) M 118 142 122 122 
247.4 <0.001 
 
2.1 0.10 
F 109 132 116 116  
    
  
  
     
DBP (mmHg) M 71 84 75 75 
267.6 <0.001 
 
0.9 0.41 
F 67 82 72 72  
     
  
 
     
HR (bpm) M  63 70 61 61 
240.3 <0.001 
 
3.0 0.05 
F 66 74 63 64  
     
     
 
  
Fbg (g/l) M  2.69 2.75  2.72 
13.7 <0.001 
 
1.1 0.33 
F 2.95 3.02  3.01  
    
  
 
   
 
  
IL-6 (pg/ml) 
M  1.08 
  
1.14 
9.6 0.002 
 
0.6 0.44 
F 1.17 
  
1.28 
 
    
  
 
   
 
  
TNFα (pg/ml) 
M  2.19 
  
2.31 
2.4 0.12 
 
4.0 0.047 
F 2.04 
  
2.02 
 
Table 4.5: Cardiovascular and biochemical responses to an acute mental stress challenge by gender. 
Geometric means are shown for IL-6 and TNFα with arithmetic means for all other measures. PS= post 
stress 
 
Table 4.6 shows the correlations between FMD% and FMDABS and stress variables for the 
whole cohort and when divided by gender. Both FMD% and FMDABS were positively 
correlated with baseline heart rate (r= 0.22 p=0.006 & r= 0.23 p=0.006 respectively) and 
task heart rate (r= 0.21 p=0.009 & r=0.22 p=0.006 respectively).  However, once the 
population were divided by gender only the correlation between baseline heart rate 
remained for both FMD% and FMDABS in males.  In addition, there was a positive 
correlation between FMDABS and IL-6 response (r=0.24 p=0.035) in males.   
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FMD% 
 
FMDABS 
  All Male Female 
 
All Male Female 
  r p r p r p 
 
r p r p r p 
SBP bl (mmHg) 0.04 0.61 0.17 0.12 0.07 0.56 
 
0.02 0.77 0.14 0.20 0.08 0.50 
SBP tk (mmHg) 0.03 0.74 0.07 0.55 0.09 0.45 
 
0.00 0.98 0.07 0.54 0.05 0.67 
SBP ch (mmHg) -0.01 0.94 -0.05 0.64 0.07 0.59 
 
-0.02 0.77 -0.03 0.81 0.00 1.00 
  
 
  
 
  
 
   
 
  
 
  
  
DBP bl (mmHg) 0.12 0.14 0.19 0.08 0.15 0.22 
 
0.08 0.35 0.15 0.17 0.12 0.34 
DBP tk (mmHg) 0.12 0.13 0.19 0.09 0.10 0.41 
 
0.08 0.34 0.16 0.14 0.05 0.69 
DBP ch (mmHg) 0.03 0.71 0.04 0.69 -0.03 0.83 
 
0.01 0.86 0.06 0.60 -0.07 0.58 
  
 
  
 
  
 
   
 
  
 
  
  
HR bl (bpm) 0.22 0.006 0.29 0.007 0.09 0.47 
 
0.23 0.006 0.27 0.012 0.13 0.28 
HR tk (bpm) 0.21 0.009 0.20 0.08 0.16 0.18 
 
0.22 0.006 0.21 0.06 0.17 0.16 
HR ch (bpm) 0.04 0.67 -0.13 0.25 0.16 0.21 
 
0.05 0.53 -0.08 0.47 0.12 0.35 
  
 
  
 
  
 
   
 
  
 
  
  
Fbg bl (g/L) -0.01 0.93 0.09 0.39 -0.17 0.17 
 
0.02 0.83 0.13 0.26 -0.14 0.25 
Fbg tk (g/L) 0.00 0.95 0.10 0.39 -0.17 0.16 
 
0.00 0.97 0.13 0.23 -0.18 0.15 
Fbg 45 (g/L) -0.01 0.89 0.09 0.44 -0.18 0.14 
 
0.00 0.99 0.11 0.31 -0.17 0.17 
Fbg ch (g/L) -0.02 0.84 0.00 0.99 -0.05 0.71 
 
-0.08 0.35 0.03 0.81 -0.17 0.18 
Fbg 45 ch (g/L) -0.01 0.86 0.02 0.85 -0.10 0.44 
 
-0.06 0.46 0.01 0.91 -0.17 0.16 
  
 
  
 
  
 
   
 
  
 
  
  
IL-6 bl (pg/ml) -0.07 0.41 -0.05 0.65 -0.12 0.35 
 
-0.07 0.39 -0.10 0.37 -0.09 0.50 
IL-6 45 (pg/ml) -0.03 0.77 0.07 0.56 -0.14 0.28 
 
-0.01 0.94 0.06 0.60 -0.10 0.45 
IL-6 ch (pg/ml) 0.08 0.32 0.17 0.14 -0.08 0.54 
 
0.13 0.13 0.24 0.035 -0.05 0.71 
  
 
  
 
  
 
   
 
  
 
  
  
TNFα bl (pg/ml) 0.10 0.22 0.09 0.42 0.16 0.20 
 
0.10 0.26 0.12 0.29 0.12 0.35 
TNFα 45 (pg/ml) 0.10 0.24 0.08 0.49 0.21 0.10 
 
0.10 0.26 0.11 0.34 0.17 0.17 
TNFα ch (pg/ml) 0.00 0.99 -0.02 0.84 0.08 0.51 
 
0.01 0.90 -0.02 0.90 0.10 0.43 
Table 4.6: Pearson correlations for FMD% and FMDABS with the cardiovascular and biochemical responses 
to stress. bl = measurement taken at  baseline; tk = measurement taken during or immediately after  task; 45 
= measurement taken 45 minutes post task & ch = difference between either task or 45 measurement and 
baseline measurement  
 
When haemodynamic and inflammatory responses to acute mental stress were divided into 
high and low responders by taking the top and bottom 40% there were no differences 
between the two groups in FMD% and FMDABS (table 4.7). Following adjustment for 
baseline Fbg, baseline brachial artery diameter and RH%, FMDABS was significantly lower in 
those with a high Fbg response at 45 minutes in relation to those with a low response 
(figure 4.2).  There were no differences between high or low responders for the other 
variables following adjustments. 
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Stress change variable Model 
FMD% 
 
FMDABS 
F p F p 
SBP change 
Unadjusted 0.37 0.54  0.14 0.71 
BL SBP 0.28 0.60  0.12 0.73 
BL dia & RH% 0.37 0.54  0.69 0.41 
BL dia, RH% & BL SBP 1.28 0.26  1.66 0.20 
    
 
  DBP change 
Unadjusted 0.49 0.48  0.24 0.62 
BL DBP 0.29 0.59  0.12 0.73 
BL dia & RH% 0.01 0.93  0.04 0.85 
BL dia, RH% & BL DBP 0.13 0.72  0.21 0.65 
    
 
  HR change 
Unadjusted 0.01 0.91  0.02 0.89 
BL HR 0.02 0.88  0.17 0.68 
BL dia & RH% 0.44 0.51  0.22 0.64 
BL dia, RH% & BL HR 0.22 0.64  0.07 0.80 
    
 
  Fbg change 
Unadjusted 1.60 0.21  1.12 0.29 
BL Fbg 1.55 0.22  1.11 0.29 
BL dia & RH% 0.32 0.57  0.08 0.78 
BL dia, RH% & BL Fbg 0.29 0.59  0.07 0.79 
    
 
  Fbg 45 change 
Unadjusted 0.81 0.37  2.92 0.09 
BL Fbg 0.83 0.36  2.91 0.09 
BL dia & RH% 3.35 0.07  7.69 0.007 
BL dia, RH% & BL Fbg 3.53 0.06  7.85 0.006 
    
 
  IL-6 change 
Unadjusted 0.02 0.89  0.03 0.86 
BL IL-6 0.00 0.98  0.00 0.98 
BL dia & RH% 0.01 0.91  0.00 0.95 
BL dia, RH% & BL IL-6 0.02 0.89  0.09 0.76 
    
 
  
    
 
  TNFα change 
Unadjusted 0.04 0.85  0.02 0.90 
 
BL TNFα 0.08 0.78  0.00 0.95 
 
BL dia & RH% 0.04 0.85  0.04 0.85 
  
BL dia, RH% & BL TNFα 0.08 0.78  0.01 0.91 
 Table 4.7: Associations between endothelial function (FMD% & FMDABS) and haemodynamic and 
inflammatory responses to acute mental stress grouped into the highest and lowest 40% of responders.   
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Figure 4.2: FMDABS calculated from ln transformed baseline and peak brachial artery diameters with SEM 
bars, by high and low Fbg response to a mental stress challenge at 45 minutes, adjusted for baseline arterial 
diameter, reactive hyperaemia and baseline Fbg. Data presented as mean±SEM. 
 
Following multiple linear regression, where change in Fbg at 45 minutes was a continuous 
variable, those participants whose Fbg response remained elevated 45 minutes after the 
stress task had a lower FMDABS after controlling for age, gender, baseline diameter, RH% 
and baseline Fbg level (table 4.8).  This relationship remained following additional 
adjustment for waist hip ratio, SBP, DBP, HDL, LDL, glucose, BMI, SES and smoking 
status (table 4.10). There were no relationships between FMD% and the inflammatory 
responses to the stress challenge, even after adjustment for risk factors assessed 
contemporaneously to the mental stress testing (tables 4.8 & 4.9).   
 
When the analyses were repeated using risk factors measured at phase 7 of  the Whitehall II 
study there were no associations with IL-6 or TNFα (data not shown) or Fbg and FMD% 
(table 4.11).  The association between the Fbg response 45 minutes after stress and 
FMDABS was retained having controlled for risk factors assessed at phase 7 (table 4.11). 
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Fbg stress change 
 
Fbg 45 change 
Adjustment β (SE) p β (SE) p 
FMD% 
  
 
  
Unadjusted -0.07 (0.36)  0.84 
 
-0.07 (0.39)  0.86 
BL sv  -0.07 (0.37) 0.84 
 
-0.07 (0.39) 0.86 
BL dia & RH% -0.15 (0.33)  0.65 
 
-0.52 (0.37)  0.16 
BL dia,  RH% & BL sv -0.16 (0.33)  0.64 
 
-0.52 (0.37)  0.16 
BL dia,  RH%,  BL sv,  age & gender -0.15 (0.32) 0.64 
 
-0.48 (0.36) 0.19 
   
 
  
FMDABS 
  
 
  
Unadjusted -0.017 (0.018)  0.35 
 
-0.015 (0.02)  0.46 
BL sv  -0.017 (0.018) 0.35 
 
-0.015 (0.02) 0.45 
BL dia & RH% -0.022 (0.017)  0.19 
 
-0.038 (0.018)  0.041 
BL dia,  RH% & BL sv -0.022 (0.017)  0.19 
 
-0.038 (0.019)  0.042 
BL dia,  RH%,  BL sv,  age & gender -0.022 (0.016) 0.18 
 
-0.037 (0.018) 0.048 
   
 
  
 
IL-6 change 
 
TNFα change 
FMD% 
    
Unadjusted 0.34 (0.34)  0.32 
 
-0.003 (0.4)  0.99 
BL sv  0.28 (0.36) 0.43 
 
0.07 (0.4) 0.87 
BL dia & RH% 0.18 (0.31)  0.56 
 
0.082 (0.35)  0.82 
BL dia,  RH% & BL sv 0.07 (0.32)  0.83 
 
0.14 (0.36)  0.70 
BL dia,  RH%,  BL sv,  age & gender -0.06 (0.32) 0.85 
 
0.01 (0.35) 0.97 
   
 
  
FMDABS 
  
 
  
Unadjusted 0.025 (0.017)  0.13 
 
0.003 (0.02)  0.90 
BL sv  0.023 (0.018) 0.19 
 
0.006 (0.02) 0.78 
BL dia & RH% 0.017 (0.015)  0.27 
 
0.007 (0.018)  0.71 
BL dia,  RH% & BL sv 0.012 (0.016)  0.47 
 
0.009 (0.018)  0.61 
BL dia,  RH%,  BL sv,  age & gender 0.005 (0.016) 0.75 
 
0.006 (0.018) 0.75 
Table 4.8: Regression analyses examining relationships between endothelial function (FMD% and FMDABS) 
and the inflammatory responses to mental stress.  Analyses are adjusted for key predictors of the 
inflammatory response to mental stress and endothelial function. BL sv = baseline stress variable 
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Fbg change 
 
Fbg 45 change 
 
IL-6 change 
  
TNFα change 
 Adjustment β (SE) p 
 
β (SE) p 
 
β (SE) p 
  
β (SE) p 
SBP (mmHg) -0.22 (0.33)  0.51 
 
-0.5 (0.37)  0.18 
 
-0.08 (0.33)  0.81 
  
0.013 (0.36)  0.97 
DBP (mmHg) -0.27 (0.33)  0.40 
 
-0.58 (0.36)  0.11 
 
-0.11 (0.32)  0.74 
  
-0.024 (0.36)  0.95 
HR (bpm) -0.3 (0.33)  0.36 
 
-0.41 (0.36)  0.25 
 
-0.19 (0.32)  0.55 
  
-0.023 (0.36)  0.95 
TC (mmol/L) -0.14 (0.33)  0.66 
 
-0.46 (0.37)  0.21 
 
-0.09 (0.33)  0.78 
  
0.007 (0.35)  0.98 
TG (mmol/L) -0.14 (0.33)  0.66 
 
-0.48 (0.36)  0.19 
 
-0.07 (0.33)  0.83 
  
0.011 (0.36)  0.97 
HDL (mmol/L) -0.14 (0.33)  0.66 
 
-0.47 (0.36)  0.20 
 
-0.05 (0.33)  0.88 
  
0.019 (0.36)  0.96 
LDL (mmol/L) -0.14 (0.33)  0.66 
 
-0.47 (0.37)  0.21 
 
-0.08 (0.33)  0.81 
  
0.004 (0.36)  0.99 
TC/HDL -0.15 (0.33)  0.65 
 
-0.48 (0.36)  0.19 
 
-0.07 (0.33)  0.84 
  
0.012 (0.36)  0.97 
Glucose (mmol/L) -0.22 (0.32)  0.51 
 
-0.59 (0.36)  0.11 
 
0.03 (0.33)  0.93 
  
0.014 (0.36)  0.97 
CRP (mg/L) -0.12 (0.33)  0.73 
 
-0.5 (0.37)  0.17 
 
-0.05 (0.33)  0.88 
  
0.081 (0.38)  0.83 
BMI (kg/m2) -0.19 (0.33)  0.57 
 
-0.47 (0.36)  0.19 
 
-0.12 (0.33)  0.71 
  
-0.002 (0.36)  0.99 
Waist/hip ratio -0.17 (0.33)  0.60 
 
-0.47 (0.36)  0.20 
 
-0.1 (0.33)  0.76 
  
0.013 (0.36)  0.97 
   
 
  
 
  
  
  
Model 1 -0.34 (0.33)  0.30 
 
-0.69 (0.37)  0.07 
 
-0.03 (0.33)  0.94 
  
-0.068 (0.37)  0.85 
Model 2 -0.19 (0.34)  0.57 
 
-0.59 (0.38)  0.12 
 
-0.07 (0.33)  0.83 
  
-0.038 (0.36)  0.92 
Model 3 -0.26 (0.34)  0.45 
 
-0.68 (0.38)  0.07 
 
0 .00 (0.34)  0.99 
  
-0.08 (0.37)  0.83 
Table 4.9: Stress responses vs FMD%: Multiple linear regression analyses examining the relationship between 
changes in inflammatory variables after mental stress with FMD% adjusted by each risk factor measured 
contemporaneously to stress testing. In addition to each risk factor each analysis was additionally adjusted for 
baseline diameter, RH%, baseline inflammatory variable, age & gender. Three models were then created 
including the following variables; model 1 = baseline inflammatory variable, baseline diameter, RH%, age, 
gender, waist/hip ratio, SBP, DBP, Glucose, HDL & LDL; model 2= as for model 1 excluding glucose and 
with the addition of socio-economic status, smoking and BMI; model 3 = as for model 2 including glucose. 
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Fbg change 
 
Fbg 45 change 
 
IL-6 change 
 
TNFα change 
  β (SE) p 
 
β (SE) p 
 
β (SE) p 
 
β (SE) p 
SBP (mmHg) -0.026 (0.017)  0.12 
 
-0.038 (0.019)  0.044 
 
0.004 (0.016)  0.79 
 
0.005 (0.019)  0.79 
DBP (mmHg) -0.028 (0.017)  0.09 
 
-0.042 (0.018)  0.026 
 
0.004 (0.016)  0.82 
 
0.004 (0.019)  0.85 
HR (bpm) -0.031 (0.017)  0.06 
 
-0.034 (0.018)  0.07 
 
-0.001 (0.016)  0.95 
 
0.003 (0.018)  0.88 
TC (mmol/L) -0.022 (0.016)  0.19 
 
-0.036 (0.019)  0.052 
 
0.004 (0.016)  0.80 
 
0.006 (0.018)  0.76 
TG (mmol/L) -0.021 (0.017)  0.20 
 
-0.036 (0.018)  0.052 
 
0.006 (0.016)  0.73 
 
0.006 (0.018)  0.74 
HDL (mmol/L) -0.022 (0.016)  0.18 
 
-0.036 (0.018)  0.050 
 
0.005 (0.016)  0.74 
 
0.006 (0.018)  0.75 
LDL (mmol/L) -0.022 (0.017)  0.19 
 
-0.036 (0.019)  0.054 
 
0.004 (0.016)  0.80 
 
0.005 (0.018)  0.77 
TC/HDL -0.022 (0.016)  0.18 
 
-0.037 (0.018)  0.048 
 
0.005 (0.016)  0.76 
 
0.006 (0.018)  0.75 
Glucose (mmol/L) -0.024 (0.017)  0.15 
 
-0.04 (0.018)  0.030 
 
0.009 (0.017)  0.60 
 
0.008 (0.019)  0.67 
CRP (mg/L) -0.02 (0.017)  0.23 
 
-0.037 (0.019)  0.046 
 
0.007 (0.016)  0.69 
 
0.005 (0.02)  0.79 
BMI (kg/m2) -0.024 (0.017)  0.16 
 
-0.036 (0.018)  0.050 
 
0.003 (0.017)  0.84 
 
0.005 (0.018)  0.77 
Waist/hip ratio -0.023 (0.017)  0.17 
 
-0.036 (0.018)  0.050 
 
0.004 (0.017)  0.82 
 
0.006 (0.018)  0.75 
   
 
  
 
  
 
  
Model 1 -0.03 (0.017)  0.08 
 
-0.046 (0.019)  0.017 
 
0.006 (0.017)  0.71 
 
0.004 (0.019)  0.84 
Model 2 -0.023 (0.018)  0.20 
 
-0.044 (0.019)  0.024 
 
0.006 (0.017)  0.72 
 
0.002 (0.019)  0.90 
Model 3 -0.025 (0.018)  0.16 
 
-0.047 (0.019)  0.016 
 
0.008 (0.017)  0.64 
 
0.002 (0.019)  0.90 
Table 4.10: Stress responses vs FMDABS: Multiple linear regression analyses examining the relationship 
between changes in inflammatory variables after mental stress with FMDABS adjusted by each risk factor 
measured contemporaneously to stress testing. In addition to each risk factor, each analysis was additionally 
adjusted for baseline diameter, RH%, baseline inflammatory variable, age & gender. Three models were then 
created including the following variables; model 1 = baseline inflammatory variable, baseline diameter, RH%, 
age, gender, waist/hip ratio, SBP, DBP, Glucose, HDL & LDL; model 2= as for model 1 excluding glucose 
and with the addition of socio-economic status, smoking and BMI; model 3 = as for model 2 including 
glucose. 
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FMD% FMDABS 
 
Fbg change Fbg 45 change Fbg change Fbg 45 change 
  β (SE) p β (SE) p β (SE) p β (SE) p 
SBP (mmHg) -0.22 (0.33)  0.50 -0.47 (0.36)  0.19 -0.025 (0.017)  0.14 -0.036 (0.018)  0.053 
DBP (mmHg) -0.18 (0.32)  0.57 -0.5 (0.36)  0.17 -0.024 (0.016)  0.15 -0.038 (0.018)  0.040 
HR (bpm) -0.21 (0.32)  0.52 -0.6 (0.36)  0.10 -0.026 (0.016)  0.12 -0.043 (0.018)  0.018 
TC (mmol/L) -0.09 (0.33)  0.78 -0.45 (0.37)  0.22 -0.018 (0.017)  0.28 -0.034 (0.018)  0.06 
Trigs (mmol/L) -0.06 (0.34)  0.86 -0.4 (0.38)  0.29 -0.016 (0.017)  0.34 -0.03 (0.019)  0.11 
HDL (mmol/L) -0.14 (0.33)  0.68 -0.48 (0.37)  0.20 -0.022 (0.017)  0.20 -0.036 (0.019)  0.053 
LDL (mmol/L) -0.1 (0.33)  0.75 -0.46 (0.37)  0.22 -0.019 (0.017)  0.26 -0.035 (0.018)  0.06 
Glucose (mmol/L) -0.1 (0.33)  0.76 -0.5 (0.36)  0.17 -0.02 (0.017)  0.23 -0.037 (0.018)  0.046 
BMI (kg/m2) -0.2 (0.33)  0.54 -0.51 (0.36)  0.17 -0.024 (0.017)  0.16 -0.037 (0.018)  0.048 
Waist/hip ratio -0.15 (0.33)  0.65 -0.45 (0.37)  0.22 -0.022 (0.017)  0.19 -0.035 (0.019)  0.06 
         
Model 1 -0.08 (0.33) 0.80 -0.54 (0.37) 0.14 -0.016 (0.017) 0.33 -0.04 (0.018) 0.029 
Model 2 -0.09 (0.34) 0.79 -0.54 (0.37) 0.15 -0.015 (0.017) 0.37 -0.041 (0.018) 0.028 
Model 3 -0.05 (0.34) 0.87 -0.56 (0.37) 0.13 -0.014 (0.017) 0.42 -0.042 (0.018) 0.023 
Table 4.11: Stress responses vs FMD% & FMDABS: Multiple linear regression analyses examining the 
relationship between changes in inflammatory variables after mental stress challenge with FMD% adjusted by 
each risk factor measured at Phase 7 of the WHII study. In addition to each risk factor each analysis was 
additionally adjusted for baseline diameter, RH%, baseline inflammatory variable, age & gender. Three models 
were then created including the following variables; model 1 = baseline inflammatory variable, baseline 
diameter, RH%, age, gender, waist/hip ratio, SBP, DBP, Glucose, HDL & LDL; model 2= as for model 1 
excluding glucose and with the addition of socio-economic status, smoking and BMI; model 3 = as for model 
2 including glucose. 
 
4.4.2 Acute mental stress, endothelial function and the influence of  
dyslipidaemia 
The key findings in this section were that the presence of  dyslipidaemia did not influence 
the inflammatory responses to a stress challenge and did not further affect the relationships 
between inflammatory responses and FMD. 
 
A total of  62 participants were categorised as having dyslipidaemia.   Table 4.12 shows the 
number of  participants who met each individual category for dyslipidaemia. 
  Dyslipidaemia categories No of categories met 
  TC≥6 Trigs ≥1.7 HDL <1 LDL ≥4  1 2 3 
Yes 40 36 2 33 27 21 14 
No 112 116 150 119 
   Table 4.12: Number of participants who met each category for dyslipidaemia and the number of participants 
who met one or more of the categories (units= mmol/L) 
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Participant characteristics for the two groups are shown in table 4.13. Those participants 
with dyslipidaemia had a significantly greater BMI, heart rate, lipid profile and CRP level.  
Reactive hyperaemia was significantly lower in the participants with dyslipidaemia but there 
was no difference in FMD between the two groups. 
 
Characteristic Dyslipidaemia (n=62) Normal (n=90) p 
Age (yrs) 52 ± 3 52 ± 3 0.72 
Gender (F) 21 (33.9%) 47 (52.2%) 0.025 
Smoker (Y) 4 (6.5%) 4 (4.4%) 0.59 
SES 
  
0.83 
Higher 23 (37.1%) 37 (41.1%) 
 
Intermediate 22 (35.5%) 28 (31.1%) 
 
Lower 17 (27.4%) 25 (27.8%) 
 
BMI (kg/m2) 26.74 ± 3.02 24.26 ± 3.46 <0.001 
Waist/hip ratio 
   
M 0.93 ± 0.07 0.88 ± 0.06 0.001 
F 0.82 ± 0.06 0.76 ± 0.06 0.001 
SBP (mmHg) 116 ± 12 113 ± 12 0.12 
DBP (mmHg) 71 ± 9 68 ± 9 0.08 
HR (bpm) 67 ± 8 63 ± 8 0.005 
TC (mmol/L) 6.11 ± 0.62 4.87 ± 0.62 <0.001 
Trigs (mmol/L)  1.89 ± 0.77 0.97 ± 0.32 <0.001 
HDL (mmol/L) 1.41 ± 0.31 1.68 ± 0.39 <0.001 
LDL (mmol/L)  3.84 ± 0.61 2.75 ± 0.6 <0.001 
Total/HDL 4.52 ± 0.98 3.04 ± 0.79 <0.001 
Glucose (mmol/L) 5.40 ± 0.90 5.24 ± 0.70 0.38 
CRP (mg/L?) 1.40 ± 1.34 0.73 ± 1.18 <0.001 
BL dia (mm) 3.71 ± 0.68 3.53 ± 0.71 0.09 
FMDABS (mm) 0.20 ± 0.11 0.19 ± 0.1 0.75 
FMD% (%) 5.79 ± 3.49 5.59 ± 3.34 0.31 
RH% (%) 596 ± 241 700 ± 266 0.016 
Table 4.13: Participant characteristics for those with and without dyslipidaemia. Mean±SD or n (%). Data is 
untransformed. 
 
Associations between FMD and baseline risk factors were the same as shown previously 
within the whole cohort (data not shown). As within the whole cohort there were 
significant changes in the cardiovascular and biochemical variables following acute mental 
stress (table 4.14).  The dyslipidaemia group had higher baseline levels for all inflammatory 
markers except IL-6.  However, there were no significant differences in the response to the 
mental stress challenge between those with and without dyslipidaemia. 
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Trial 
 
Lipid interaction 
    Baseline Task PS1 PS2 F p 
 
F p 
SBP (mmHg) Normal 112 135 118 117 
246.09 <0.001 
 
0.62 0.53 
Dyslipid 116 141 121 122  
     
  
 
  DBP (mmHg) Normal 68 81 72 72 
266.35 <0.001 
 
1.58 0.20 
Dyslipid 71 86 76 77  
     
  
 
  HR (bpm) Normal 63 70 61 61 
226.40 <0.001 
 
0.05 0.96 
Dyslipid 67 74 65 65  
     
  
 
  Fbg (g/L) Normal 2.73 2.79  2.79 
12.90 <0.001 
 
1.85 0.16 
Dyslipid 2.92 2.98  2.94  
     
  
 
  IL-6 (pg/ml) Normal 1.18   1.22 
10.69 0.001 
 
2.87 0.09 
Dyslipid 1.04   1.18  
     
  
 
  TNFα (pg/ml) Normal 2.03   2.09 
2.12 0.15 
 
0.00 0.95 
Dyslipid 2.24   2.30  
Table 4.14: Acute mental stress responses by dyslipidaemia. Geometric means presented for IL-6 and TNFα 
with arithmetic means for all other measures. Dyslipid = dyslipidaemia; PS= post-stress  
 
 
Both baseline and task heart rate were positively correlated with FMD% and FMDABS in the 
normal lipid group (table 4.15).  The change in Fbg 20 minutes after stress was positively 
correlated with FMDABS in the normal lipid group (r=0.23 p=0.027) the correlation with 
FMD% was borderline (r=0.21 p=0.05).  However, in the dyslipidaemia group the 
correlation between the change in Fbg immediately post task and FMDABS was negative 
(r=-0.36 p=0.004). There were no correlations between endothelial function and the other 
inflammatory variables. 
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FMD% 
 
 
FMDABS 
 
Dyslipidaemia 
 
Normal 
 
Dyslipidaemia 
 
Normal 
 
r p 
 
r p 
 
r p 
 
r p 
SBP bl (mmHg) 0.01 0.97 
 
0.06 0.57 
 
-0.03 0.80 
 
0.06 0.59 
SBP tk (mmHg) 0.03 0.81 
 
0.01 0.91 
 
0.00 0.98 
 
0.00 0.97 
SBP ch (mmHg) 0.04 0.74 
 
-0.05 0.67 
 
0.03 0.83 
 
-0.07 0.53 
   
 
  
 
  
 
  
DBP bl (mmHg) 0.17 0.20 
 
0.08 0.48 
 
0.10 0.47 
 
0.05 0.64 
DBP tk (mmHg) 0.14 0.29 
 
0.10 0.35 
 
0.07 0.61 
 
0.07 0.50 
DBP ch (mmHg) 0.01 0.94 
 
0.03 0.76 
 
-0.02 0.89 
 
0.02 0.82 
   
 
  
 
  
 
  
HR bl (bpm) 0.15 0.24 
 
0.28 0.009 
 
0.08 0.52 
 
0.33 0.001 
HR tk (bpm) 0.09 0.51 
 
0.29 0.006 
 
0.04 0.77 
 
0.35 0.001 
HR ch (bpm) -0.07 0.59 
 
0.09 0.42 
 
-0.06 0.68 
 
0.11 0.31 
   
 
  
 
  
 
  
Fbg bl (g/L) 0.02 0.90 
 
-0.03 0.76 
 
-0.01 0.91 
 
0.03 0.76 
Fbg tk (g/L) -0.06 0.66 
 
0.02 0.84 
 
-0.12 0.34 
 
0.09 0.40 
Fbg 45 (g/L) -0.01 0.94 
 
-0.02 0.86 
 
-0.05 0.71 
 
0.03 0.76 
Fbg ch (g/L) -0.24 0.07 
 
0.21 0.05 
 
-0.36 0.004 
 
0.23 0.027 
Fbg 45 ch (g/L) -0.11 0.39 
 
0.06 0.59 
 
-0.16 0.23 
 
0.01 0.92 
   
 
  
 
  
 
  
IL-6 bl (pg/ml) -0.05 0.69 
 
-0.08 0.50 
 
-0.12 0.34 
 
-0.04 0.72 
IL-6 45 (pg/ml) -0.02 0.90 
 
-0.03 0.80 
 
-0.04 0.79 
 
0.01 0.94 
IL-6 ch (pg/ml) 0.06 0.67 
 
0.12 0.29 
 
0.13 0.31 
 
0.13 0.26 
   
 
  
 
  
 
  
TNFα bl (pg/ml) 0.11 0.42 
 
0.09 0.39 
 
0.12 0.38 
 
0.08 0.48 
TNFα 45 (pg/ml) 0.13 0.32 
 
0.08 0.50 
 
0.14 0.30 
 
0.07 0.55 
TNFα ch (pg/ml) 0.07 0.60 
 
-0.04 0.73 
 
0.06 0.65 
 
-0.02 0.86 
Table 4.15: Pearson correlations for FMD% and FMDABS with the cardiovascular and biochemical responses 
to stress by presence or absence of dyslipidaemia bl = measurement taken at baseline; tk = measurement 
taken during or immediately after task; 45 = measurement take 45 minutes post task & ch = difference 
between either task or 45 measurement and baseline measurement 
 
To investigate whether the inflammatory response to the acute mental stress alongside the 
presence or absence of  dyslipidaemia influenced future endothelial function, the cohort 
were divided into four groups based on their inflammatory responses to stress and lipid 
profile.  Table 4.16 shows that there were initially no differences in endothelial function 
between the four groups.  Following adjustment for baseline arterial diameter, RH% and 
baseline Fbg level there was a significant difference in FMDABS between the groups for Fbg 
response at 45 minutes post stress.  Post hoc analyses identified that those without 
dyslipidaemia but with a high Fbg response had a lower FMDABS than those with 
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dyslipidaemia and low Fbg response and (p=0.022) (figure 4.3).  There was also a 
borderline difference in FMDABS between those without dyslipidaemia with a high Fbg 
response and those without dyslipidaemia with a low Fbg response (p=0.056). 
 
Inflammatory marker*  Model 
FMD% 
 
FMDABS 
F p 
 
F p 
Fbg change 
Unadjusted 0.48 0.70 
 
0.99 0.40 
BL Fbg 0.48 0.70 
 
0.97 0.41 
BL dia & RH% 0.62 0.61 
 
0.73 0.54 
BL dia, RH% & BL Fbg 0.72 0.54 
 
0.77 0.51 
 
   
 
  Fbg 45 change 
Unadjusted 0.34 0.80 
 
1.10 0.35 
BL Fbg 0.33 0.80 
 
1.09 0.35 
BL dia & RH% 1.98 0.12 
 
3.66 0.014 
BL dia, RH% & BL Fbg 2.10 0.10 
 
3.71 0.013 
    
 
  IL-6 change 
Unadjusted 0.15 0.93 
 
0.25 0.86 
BL IL-6 0.26 0.85 
 
0.37 0.78 
BL dia & RH% 0.71 0.54 
 
0.65 0.58 
BL dia, RH% & BL IL-6 0.76 0.52 
 
0.76 0.52 
    
 
  TNFα change 
Unadjusted 0.19 0.90 
 
0.26 0.86 
BL TNFα 0.13 0.94 
 
0.21 0.21 
BL dia & RH% 1.15 0.33 
 
1.20 0.31 
BL dia, RH% & BL TNFα 1.00 0.39 
 
1.09 0.36 
Table 4.16: The effect of dyslipidaemia and inflammatory responses to mental stress on endothelial function.  
*Participants were divided into presence or absence of dyslipidaemia and (for each inflammatory marker) into 
those with low or high inflammatory response.  Thus, for analysis of each inflammatory variable, participants 
were allocated into four groups; i, dyslipidaemia plus high inflammatory response; ii, dyslipidaemia and low 
inflammatory response; iii, normal lipids plus high inflammatory response and iv, normal lipids with a low 
inflammatory response. F and p are for the ANOVA and ANCOVA with Bonferroni post hoc analyses to 
examine for differences in FMD% and FMDABS between the groups. ANCOVAs were adjusted individually 
for baseline inflammatory variable, baseline diameter and RH% were put in together and then all 3 variables 
were put in the model together. 
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Figure 4.3: Mean FMDABS calculated from ln transformed baseline and peak brachial artery diameters with 
SEM bars, adjusted for baseline arterial diameter, RH% and baseline Fbg by grouping of presence or absence 
of dyslipidaemia and low or high Fbg response to acute mental stress at 45 minutes.  D+ F + = dyslipidaemia 
and high Fbg at 45min response; D+F- = dyslipidaemia and low Fbg at 45min response; D- F+= normal 
lipids and high Fbg at 45min  response; D-F- = normal lipids and low Fbg/ at 45min response * = 
significantly different by Bonferroni p=0.022.   
 
4.4.3 Acute mental stress and reactive hyperaemia 
The key findings in this section were that there was no association between inflammatory 
responses to stress and RH%. Although the presence of  dyslipidaemia did affect RH% , this 
was independent of  the inflammatory responses to stress. 
 
Table 4.17: Pearson correlations between baseline VTI, RH% and cardiovascular risk factors 
0 
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 l
n
 
p=0.013 
* 
* 
 
BL VTI 
 
RH% 
Risk factor r p 
 
r p 
Age (yrs) 0.01 0.89  0.01 0.91 
BMI (kg/m2) -0.09 0.25  -0.09 0.29 
Waist/hip ratio -0.05 0.56  -0.09 0.25 
SBP (mmHg) -0.08 0.33  0.00 0.98 
DBP (mmHg) -0.07 0.38  0.01 0.91 
HR (bpm) -0.04 0.59  -0.22 0.008 
TC (mmol/L) -0.05 0.52  -0.13 0.13 
Trigs (mmol/L) -0.01 0.94  -0.19 0.021 
HDL (mmol/L) -0.03 0.67  0.12 0.14 
LDL (mmol/L) -0.04 0.62  -0.12 0.15 
Total/HDL 0.01 0.89  -0.17 0.038 
Glucose (mmol/L) 0.06 0.50  -0.10 0.24 
CRP (mg/L) 0.06 0.49  -0.10 0.24 
BL VTI (cm) 
  
 -0.53 <0.001 
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As can be seen in table 4.17 there were no associations between baseline velocity time 
integral (VTI) and any cardiovascular risk factors.  RH% was negatively associated with 
heart rate, triglycerides and total/HDL cholesterol.  When baseline VTI and RH% were 
correlated with the haemodynamic and inflammatory stress variables baseline VTI was 
negatively associated with task SBP and change in SBP from baseline (r=-0.19 p=0.023 & 
r=-0.20 p= 0.017 respectively).  It was also positively associated with change in IL-6.  RH% 
was negatively associated with baseline HR and task HR (r= -0.22 p= 0.008 & r= -0.20 p= 
0.017) and positively associated with change in Fbg at 45 minutes post stress (r= 0.16 
p=0.048).  There were no further associations with the other stress variables. 
Stress change variable Model 
RH% 
F p 
SBP change 
Unadjusted 0.97 0.33 
BL SBP 0.93 0.34 
BL VTI 0.10 0.75 
BL VTI & BL SBP 0.14 0.71 
    DBP change 
Unadjusted 0.07 0.79 
BL DBP 0.05 0.82 
BL VTI 0.28 0.60 
BL VTI & BL DBP 0.32 0.57 
    HR change 
Unadjusted 0.12 0.72 
BL HR 0.03 0.86 
BL VTI 0.55 0.46 
BL VTI & BL HR 1.09 0.30 
    Fbg change 
Unadjusted 1.76 0.19 
BL Fbg 1.79 0.18 
BL VTI 0.67 0.41 
BL VTI & BL Fbg 0.71 0.40 
    Fbg 45 change 
Unadjusted 4.22 0.042 
BL Fbg 4.13 0.044 
BL VTI 2.97 0.09 
BL VTI & BL Fbg 2.86 0.09 
    IL-6 change 
Unadjusted 1.85 0.18 
BL IL-6 1.95 0.17 
BL VTI 0.43 0.52 
BL VTI & BL IL-6 0.33 0.57 
    
    TNFα change 
Unadjusted 0.24 0.63 
 
BL TNFα 0.23 0.63 
 
BL VTI 1.26 0.26 
  
BL VTI & BL TNFα 1.27 0.26 
Table 4.18: Associations between reactive hyperaemia and haemodynamic and inflammatory responses to 
acute mental stress grouped into the highest and lowest 40% of responders  
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Having grouped the cohort by dividing the stress change variables into the highest and 
lowest 40% responders, comparisons were made between RH% for the two groups. RH% 
was significantly different between high and low change in Fbg at 45 minutes unadjusted 
and when adjusting for baseline Fbg.  However, when baseline VTI was added to the model 
this relationship was lost (table 4.18). 
 
Inflammatory marker*  Model 
RH% 
F p 
Fbg change 
Unadjusted 3.90 0.010 
BL Fbg 3.82 0.011 
BL VTI 4.00 0.009 
BL VTI & BL Fbg 3.66 0.014 
 
   Fbg 45 change 
Unadjusted 4.26 0.006 
BL Fbg 4.14 0.008 
BL VTI 4.47 0.005 
BL VTI & BL Fbg 4.21 0.007 
    IL-6 change 
Unadjusted 2.68 0.050 
BL IL-6 2.75 0.045 
BL VTI 2.19 0.09 
BL VTI & BL IL-6 2.35 0.08 
    
    TNFα change 
Unadjusted 1.69 0.17 
BL TNFα 1.65 0.18 
BL VTI 2.22 0.09 
BL VTI & BL TNFα 2.20 0.09 
Table 4.19: The effect of dyslipidaemia and inflammatory responses to mental stress on RH%.  Participants 
were divided into presence or absence of dyslipidaemia and (for each inflammatory marker) into those with 
high or low inflammatory response.  Thus, for analysis of each inflammatory variable, participants were 
allocated into four groups: 1, dyslipidaemia plus high inflammatory response; ii, dyslipidaemia and low 
inflammatory response; iii, normal lipids plus high inflammatory response and iv, normal lipids with a low 
inflammatory response. F and p are for the ANOVA and ANCOVA with Bonferroni post hoc analyses to 
examine for differences in RH% between the groups. ANCOVAs were adjusted individually for baseline 
inflammatory variable and baseline VTI, both variables were then added to the model together.  
 
As RH% was found to be significantly lower in the participants with dyslipidaemia (table 
4.13) the effect of  presence of  dyslipidaemia and inflammatory responses to stress on RH% 
was investigated.  There were significant differences in RH% within the groups for Fbg 
stress change, Fbg 45 change and change in IL-6.  Once adjustments were made for 
baseline VTI (which was not different between those with and without dyslipidaemia [5.57 
± 2.43 & 5.62 ± 3.77cm p=0.91]) and inflammatory variable the differences within the IL-
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6 groups were lost (table 4.19).  The differences in RH% remained for both Fbg change and 
Fbg 45 change.  Figures 4.4 A and B illustrate that for both Fbg variables the differences 
were between those with and without dyslipidaemia rather than high and low inflammatory 
responders.   
   
 
Figure 4.4: Mean RH% with SEM bars, adjusted for baseline VTI and baseline Fbg by grouping of presence 
or absence of dyslipidaemia and low or high Fbg response to acute mental stress A: immediately and B 45 
minutes post stress.  D+ F + = dyslipidaemia and high Fbg response; D+F- = dyslipidaemia and low Fbg 
response; D- F+= normal lipids and high Fbg response; D-F- = normal lipids and low Fbg response * and # 
= significantly different by Bonferroni: A * p=0.017 # p=0.032; B * p=0.027 # p=0.028 
 
4.5 Discussion 
The major finding of  this chapter is that participants with an elevated Fbg response to 
stress, 45 minutes post task had lower FMD, reflecting a relative impairment in endothelial 
function, when assessed 3 years later.  This association remained regardless of  the presence 
of  mild to moderate dyslipidaemia. It was also shown that microvascular function, 
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expressed as RH%, is lower in those with mild dyslipidaemia irrespective of  their Fbg 
response to stress. For both FMD and RH% there were no associations with either IL-6 or 
TNFα. Finally, the presence of  a cardiovascular risk factor (dyslipidaemia) did not affect 
the inflammatory responses to an acute mental stress challenge.  
 
The main finding of  a significantly lower FMDABS in those with a high Fbg response at 45 
minutes post stress challenge, was seen, when the data was compared both as categorical 
and continuous data and following adjustment for factors that may affect endothelial 
function.  This finding complements previous analyses from this cohort, which found 
increased carotid artery stiffness and ambulatory blood pressure in those participants who 
had increased inflammatory responses (including Fbg) to a stress challenge324, 369.  
Therefore, the finding from this analysis adds to the evidence of  a potential role for 
inflammation in the relationship between psychological stress and adverse cardiovascular 
outcome.  
 
Endothelial dysfunction is an early indicator of  atherogenesis and can be assessed by   
FMD which is associated with cardiovascular risk377.   Acute mental stress causes 
endothelial dysfunction both during a stress challenge and immediately afterwards, but the 
mechanisms for this are not yet fully understod325, 378.  Inhibition of  cortisol and the 
endothelin-A receptor, have both prevented the impairment of  FMD induced by mental 
stress suggesting potential roles for both of  these factors326, 327.  
 
Inflammation plays a key role in the initiation, development and progression of  
atherosclerosis and is associated with endothelial dysfunction25.   Induced acute systemic 
inflammation and acute mental stress have both been shown to cause immediate 
endothelial dysfunction325, 364, 379. However, there is limited other work investigating whether 
and to what extent the acute inflammatory response to mental stress is implicated in the 
associated endothelial dysfunction.  Ghiadoni et al measured the inflammatory markers IL-
6, IL-1 & TNFα at baseline and 60 mins post stress, but did not find a significant change in 
the cytokine levels or any association between cytokine levels and FMD or change in 
FMD325.  Therefore the finding of  an association between Fbg response at 45 minutes and 
FMD in this chapter is potentially the first to show an association between the 
inflammatory response to acute mental stress and future development of  endothelial 
dysfunction.  
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Fbg, an acute phase protein induced by IL-6 in the inflammatory pathway and a major 
component of  the coagulation cascade, is associated with increased risk of  coronary heart 
disease and stroke235. It is implicated in the development of  atherosclerosis and vascular 
reactivity, through its effects on plaque composition, blood viscosity, endothelial and 
smooth muscle cell activation, platelet aggregation and activation, and immune cell 
recruitment380, 381.  
 
Elevated Fbg may affect endothelial function both by mechanical and biochemical 
processes. Raised Fbg levels increase blood viscosity, which, in turn, augments shear stress 
within the artery, activating endothelial cells238, 380, 382.  This stimulates increased expression 
and activation of  adhesion markers and integrins, resulting in attraction and adherence of  
monocytes to endothelial cells and the greater production of  vasoconstricting agents which 
may further affect endothelial function and vascular tone237, 383, 384.     
 
Vascular injury triggers the coagulation cascade which results in the conversion of  Fbg to 
fibrin which then forms a thin monolayer covering the damaged area.  This layer attracts 
platelets which are also activated by Fbg causing platelet aggregation, inflammatory 
responses and endothelial dysfunction385, 386.  As the injury heals the platelets can also 
become part of  the developing lesion/plaque. Therefore sustained elevation of  Fbg levels 
through reactions to acute stressors could further exacerbate this process. The lack of  an 
association between IL-6 and future FMD may indicate that it is these 
haemostatic/prothrombotic properties of  Fbg that could be more important in this setting 
than its inflammatory properties.   
 
These findings suggest not only might the elevated fibrinogen response triggered by acute 
stress contribute to the development of  ED and clinical CVD, it might also have a role in 
identification of  those at greatest future vascular risk and selection of  appropriate 
preventive therapy in due course. Further work would be required to address these 
questions more specifically. 
4.5.1 Reactive hyperaemia 
Although there was a significant difference in RH% between participants with low and high 
Fbg responses at 45 minutes post stress, the relationship was lost following adjustment for 
baseline VTI.  However, when the impact of  the inflammatory responses in the presence 
or absence of  dyslipidaemia on RH% was investigated, further differences were found with 
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change in both Fbg immediately and 45 minutes post task following adjustment for 
baseline Fbg and VTI.  Post hoc analyses indicated that for both the change in Fbg 
immediately and 45 minutes post stress, the differences appeared to be driven more by 
presence of  dyslipidaemia than the size of  the inflammatory response.   
 
RH% is an indicator of  microvascular function reflecting vasodilatation of  the resistance 
vessels in response to ischaemia-induced vasoactive stimuli387, 388.  Microvascular function is 
associated with cardiovascular risk factors and predictive of  cardiovascular events388-390.  
The finding of  impaired RH% alongside an unchanged FMD in those with dyslipidaemia 
has been shown previously in a study which demonstrated decreased RH% following cuff  
occlusion in untreated hypercholesterolaemia patients compared with treated 
hypercholesterolaemia patients and control subjects391.  As with my study there was no 
difference in the FMD between the untreated hypercholesterolaemia patients and control 
subjects.  The diminished RH% alongside maintained FMD in those with dyslipidaemia may 
in part be due to differences in the vasodilators responsible for driving the change in tone 
which results in RH% and FMD.  Whilst nitric oxide is the main mediator of  FMD, it has a 
less significant role at peak flow and during the flow debt repayment149, 392.   In addition, 
other vasodilators such as adenosine have a greater role in resistance vessel vasodilatation 
during ischaemia than NO393-395.  
 
4.5.2 Inflammatory responses to stress 
Fibrinogen and IL-6 both significantly increased in response to the mental stress challenge 
and although TNFα increased, the change was not significant.  However, when the effect 
of  gender was taken into account in the analysis, there was a significant difference in the 
responses to stress for TNFα.   Women showed a decrease in TNFα, whereas there was an 
increase in men.  This finding does complement a previous analysis by Steptoe et al in the 
Whitehall II psychobiology sub study where they found that women had larger IL-6 
responses and smaller TNFα responses to stress than men396. This may partly account for 
the lack of  a significant increase in TNFα within the whole cohort. In addition, a meta-
analysis of  the effects of  mental stress challenges on inflammatory markers by Steptoe et 
al, found that some markers (e.g. IL-6) may be more sensitive than others (e.g. TNFα) to 
stress350.   
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4.5.3 Dyslipidaemia 
The presence of  mild dyslipidaemia did not appear to have any influence on the 
haemodynamic or inflammatory responses to an acute mental stress challenge.  Neither did 
the presence of  mild dyslipidaemia have an impact on the relationship between Fbg 
responses to stress and future endothelial function. Indeed, somewhat surprisingly, those 
with mild dyslipidaemia had a tendency towards better FMDABS than those without.  The 
finding of  a lack of  influence of  dyslipidaemia, together with that of  Steptoe and Brydon, 
that a greater increase in total cholesterol in response to stress is predictive of  having 
higher total cholesterol 3 years later, could suggest that the stress response may influence 
future incidence of  dyslipidaemia rather than current dyslipidaemia affecting the stress 
response373. However, it is also worth noting that the participants in this study typically only 
had mild dyslipidaemia which may account for why differences were not found between 
groups.  Another study in males with cholesterol >4.1 mmol/L and triglycerides >2.8 
mmol/L (greater than the ≥1.7mmol/L I used) had similar haemodynamic and lipid 
responses to stress to those with normal lipid levels, further indicating that dyslipidaemia 
may well not influence these stress responses397.  
 
4.5.4 Limitations 
There are several limitations to this study. Endothelial function was not assessed at the time 
of  stress testing so it is unknown whether those participants with poorer FMD 3 years later 
already had endothelial dysfunction at the time of  psychophysiological stress testing.  In 
addition endothelial function is influenced by medications, environmental factors, exercise, 
infection and food and although these factors were controlled for as much as is possible in 
a cohort study during FMD assessment and the analysis they may have influenced the 
measurements.   The population was selected for being free of  cardiovascular disease, so 
the dyslipidaemia group consists of  those participants with lipids at the adverse end of  the 
normal range or who have mild dyslipidaemia rather than including those with more severe 
dyslipidaemia. Therefore, the findings may differ in those with more severe dyslipidaemia.  
Additionally, blood samples for this study were not taken in a fasted state.  This may mean 
that some participants were classified as having dyslipidaemia due to elevated non-fasting 
triglycerides, but may have been categorised as normal from a fasted measurement. 
Although this may influence the findings, an important association between non-fasting 
triglycerides and cardiovascular outcomes is well recognised and suggests it is not 
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inappropriate to select participants on the basis of  non-fasting triglycerides398. These results 
are from just one day and do not take into account changes within individual’s 
circumstances in the 3 years between the stress challenge and endothelial function 
assessment which may influence their stress response or cardiovascular health.  Finally, this 
is a post-hoc analysis of  the WHII psychobiology study and although the results are 
consistent with previously published analyses from this study showing a relationship 
between fibrinogen stress responses and large artery stiffness, replication in another cohort 
would be beneficial to confirm whether the findings are due to chance or not.  Further 
prospective studies would also be beneficial to gain greater understanding of  the clinical 
significance of  these results. 
 
4.5.5 Conclusion 
In conclusion, in this chapter I have shown that those participants with an elevated 
fibrinogen response at 45 minutes post stress have reduced endothelial function three years 
later.  The presence of  high levels of  lipids did not influence the relationship between 
fibrinogen and endothelial function. 
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Chapter 5. Summary of  section 1: 
associations between chronic and acute 
stress and subclinical vascular 
measures  
 
5.1 Summary and review of  findings  
In recent years awareness of  the impact of  the psychosocial environment on health has 
been increasing.   Numerous studies have shown the impact of  psychosocial factors on 
cardiovascular mortality and risk in both those who already have cardiovascular (CVD) and 
the general population204, 206. My aim in the first two chapters was to further investigate the 
influences of  long term/ chronic stress and acute stress on subclinical vascular disease.   
 
In Chapter 3 I investigated whether there were any cross-sectional associations between 
depression and anxiety as chronic stressors and subclinical vascular disease, in a large 
prospective cohort.  In addition I also looked at whether the presence of  a known 
cardiovascular risk factor influenced any relationships between depression and anxiety 
symptoms and subclinical vascular disease. I found that women with symptoms of  
depression had greater intima-media thickness (IMT) than those without significant 
depression symptoms, which was also seen in women with both depression and anxiety 
symptoms.  This would suggest that these women were potentially at greater risk of  
developing cardiovascular disease than women without depression or anxiety symptoms 
further adding to the body of  literature in this area262, 263, 271. The presence of  dyslipidaemia 
further increased the potential risk of  cardiovascular disease, as women with depression 
and or anxiety symptoms and dyslipidaemia were found to have the greatest IMT. 
However, it was not possible in this analysis to decipher the causal pathway of  whether in 
these women the depression and or anxiety came first or the dyslipidaemia, which in this 
cohort is only mild dyslipidaemia. It is worth noting that an increase in IMT in men was 
influenced by the presence of  dyslipidaemia rather than depression and or anxiety.    
 
It was surprising to see that the association between anxiety symptoms and distensibility 
coefficient (DC) in women went in the opposite direction than expected; those with anxiety 
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symptoms having more compliant arteries. Further work could investigate the relationships 
with other measures of  arterial stiffness such as aortic pulse wave velocity and central 
blood pressure.   
 
 The association between chronic stress and FMD was not significant, this may have been 
due to the relatively small sample size, and if  there may have been a very small influence on 
FMD, this study may have had insufficient power to detect such a difference.  Additionally, 
although the participants included in the depression group had scores greater than the 
questionnaire threshold for significant symptoms, they may have been clustered at the 
threshold and therefore did not have severe enough psychological “distress” to influence 
vascular pathophysiology more than those with lower scores.  Equally, as those participants 
taking lipid lowering medications had been excluded, participants with dyslipidaemia in this 
analysis only had mildly raised lipids.  Including participants with a more severe lipid 
abnormality may have shown different results. 
 
In Chapter 4 the main purpose was to investigate the effect of  the inflammatory response 
to a mental stress challenge on future endothelial function to try and further understand 
the associations between stress and increased cardiovascular risk. Additionally, I also looked 
at whether the presence of  a cardiovascular risk factor (dyslipidaemia) had any bearing on 
the inflammatory response to a stress challenge and future endothelial function. It was 
found that those participants with an elevated fibrinogen response at 45 minutes had 
poorer endothelial function when assessed 3 years later. When the influence of  
dyslipidaemia was investigated it was shown to have no impact on the haemodynamic or 
inflammatory responses to the mental stress challenge. However, those who had 
dyslipidaemia and greater fibrinogen responses to the stress challenge had poorer conduit 
and micro-vascular function, thereby potentially putting these individuals at greater 
cardiovascular risk.  
 
Fibrinogen has various potential influences on atherogenesis; for example through its 
effects activating endothelial and smooth muscle cells, inflammatory responses, blood 
viscosity, platelet activation and aggregation and through the coagulation cascade 
contributing to the development of  potentially occlusive thrombi380, 381.  Therefore, 
prolonged elevation of  fibrinogen levels in response to acute emotional triggers may help 
to create a sustained proatherogenic environment, encouraging development of  potentially 
vulnerable atherosclerotic plaques.  If  through the haemodynamic responses to acute stress 
the plaque ruptures, increased levels of  fibrinogen, which activates platelets, can lead to 
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larger thrombi which are more prone to occluding arteries and causing a cardiovascular 
event385.  The addition of  a cardiovascular risk factor such as an adverse lipid profile 
increases the propensity for arterial wall lipoprotein uptake, retention and oxidation, further 
exacerbating inflammatory response and atherogenic disease processes. 
 
5.2 Future directions for research and overcoming technical 
challenges 
5.2.1 Chronic stress 
To gain further insights into the associations between depression and anxiety symptoms 
and subclinical vascular disease it would be interesting to take advantage of the longitudinal 
data available from the Whitehall II cohort.  The GHQ was administered at phases 3 and 5 
of the study.  It would therefore be possible to investigate whether those with long-term 
depressive or anxiety symptoms were more likely to develop subclinical vascular disease or 
other cardiovascular risk factors. Equally it would be interesting to investigate whether 
those participants with raised (higher end of normal) lipid levels at phase 3 were more likely 
to develop depression/anxiety symptoms to try and further understand the finding of 
increased IMT in those women with dyslipidaemia and depression and/or anxiety 
symptoms.  
 
In addition it would be interesting to follow-up those participants identified with 
depressive/anxiety symptoms at phase 7.  Further data on depression and anxiety 
symptoms and cardiovascular risk factors have been collected at phase 9, and although 
subclinical vascular measures from phase 7 were not repeated, central pulse wave velocity 
data was collected.  This would enable further investigation of the relationship between 
anxiety and arterial stiffness. In addition, this data would allow investigation into whether 
those participants with depression and/or anxiety developed cardiovascular risk factors or 
disease or had experienced a cardiovascular event. It would also be possible to investigate 
whether there were differences between those who continued to have depressive/anxiety 
symptoms and those who had recovered.  Finally, to further understand the associations 
between dyslipidaemia, depression/anxiety and IMT it would be helpful to investigate this 
in a group with severe dyslipidaemia such as familial hypercholesterolaemia. This would 
potentially add to the evidence of chronic stressors, such as depression and anxiety, 
increasing the risk and exacerbating the development of cardiovascular disease. 
126 
 
5.2.2 Acute stress 
Although there were no associations with IL-6 and TNFα within this analysis it would be 
interesting to look at changes in these variables over a longer time frame post stress, such 
as 2 hours. Greater changes in inflammatory cytokines have been seen over a longer time 
course of measurement and it may be that relationships may be seen with flow-mediated 
dilatation (FMD) measured both concurrently and in the future350, 399. Other work could 
further investigate the association between fibrinogen response, dyslipidaemia and FMD.  
It would be beneficial to look at this in a group of participants with a more distinct lipid 
profile such as familial hypercholesterolaemia who have very high LDL levels and also 
patients with metabolic syndrome that have high triglycerides with low HDL.  Using two 
groups, who have more severe dyslipidaemia than in my analysis but also qualitatively 
different atherogenic lipid profiles, would potentially give further insights into possible 
relationships and help identify those at increased risk of cardiovascular disease from acute 
emotional triggers. 
 
Future work could also look at the data collected on these participants from later phases of 
the Whitehall II study.  This would enable us to investigate whether those participants who 
had elevated fibrinogen at 45 minutes post stress challenge and poorer endothelial 
function, were more likely to develop progressive arterial disease or suffer a cardiovascular 
event than those participants with a lower response.  
 
5.2.3 Endothelial function assessment 
Within both chapters analyses were limited to some extent by numbers of participants who 
had undergone endothelial function testing especially when compared with those who had 
IMT & DC assessment.  Ultrasound assessment of IMT is easier and quicker to carry out 
than FMD.  Although FMD has been measured in large studies such as ALSPAC and 
Framingham, it is not a simple technique to carry out and can be time consuming to set up 
in a time limited protocol151, 389. A technique for assessing endothelial function that is quick 
to set up, easy to use and largely operator independent would be beneficial not only to large 
population studies such as the Whitehall II study but also for studies in specialist vascular 
laboratories.  The dataset for mental stress and endothelial function is one of the largest to 
date.   A lot of the studies looking at acute mental stress testing and concurrently assessed 
FMD are on relatively small numbers of participants. Therefore, a relatively simple 
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technique for assessing endothelial function that could fit easily within large vascular 
epidemiology protocols would be very useful for assessing changes occurring acutely and 
over longer-term follow up. 
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Chapter 6. Development of  protocol 
and reproducibility of  flow-mediated 
slowing 
 
6.1 Introduction 
Endothelial dysfunction is one of  the earliest clinically measurable indicators of  
atherogenesis within an artery.  Assessment of  endothelial function is a useful tool for 
understanding the disease process and has been demonstrated to be related to increased 
cardiovascular risk174, 176.  The current gold standard technique for the non-invasive 
assessment of  endothelial function is flow-mediated dilatation (FMD), which is highly 
reproducible in a controlled specialist vascular laboratory, but requires a high level of  
operator skill and relatively expensive equipment.  It can be used in large population studies 
but this can be logistically challenging and expensive151.  As previously discussed in Chapter 
1, there are alternative methods available but their reproducibility and clinical relationships 
to endothelial function are less well defined and validated150.   
 
Pulse wave velocity (PWV) is a measure of  arterial stiffness. Increased central PWV is 
associated with the presence of  cardiovascular risk factors, coronary artery disease and 
higher cardiovascular event rates33, 93, 400, 401.   This technique has recently been harnessed as 
a potential method for assessing endothelial function.  First described by Naka et al, it 
utilises a two cuff  oscillometric method of  measuring PWV in the brachio-radial tract and 
uses a hyperaemic stimulus to cause smooth muscle relaxation in the artery leading to a 
decrease in the speed of  the pressure waveform164. Its use as a method for measuring 
endothelial function is based on the Moens–Korteweg equation (equation 6.1) which 
demonstrates that PWV is directly proportional to arterial wall width and Young’s modulus 
(a measurement of  elastin and collagen concentration or arterial stiffness) and inversely 
proportional to vessel diameter and blood viscosity.  Therefore, increased arterial wall 
width and stiffness leads to higher PWV and smooth muscle tone, whilst a larger lumen 
diameter and greater blood viscosity decreases PWV402.  Additionally, the release of  NO 
and vascular tone also influence PWV403, 404. This would suggest that the reactive 
hyperaemic stimulus increases the shear stress, releasing NO from the endothelium, leading 
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to smooth muscle relaxation and vasodilatation of  the blood vessel, thereby decreasing 
PWV. 
Equation 6.1:402 
             
 
PWV =Pulse wave velocity; E= Young’s modulus; h =wall thickness; R= radius;ρ = blood density 
 
Since this method was first published other groups have applied this theory and tested it 
using other techniques for assessing PWV (such as applanation tonometry), most 
commonly in the carotid – radial tract165.  Different occlusion cuff  positions have also been 
used with some favouring an upper arm occlusion and whilst others place it just below the 
medial epicondyle165, 166.  The equipment first used in the original study by Naka et al, has 
since been transformed and is now a small portable device run by a laptop which is very 
simple to use.  This development means that this technique has the potential to be a 
simpler, more affordable alternative method for the assessment of  endothelial function 
which may be ideally placed for use in non-specialist vascular laboratories and large 
population studies.  
 
Naka et al have already demonstrated that PWV slows in response to a hyperaemic stimulus 
in healthy subjects and that this response is reduced in patients with chronic heart failure164. 
However, the reproducibility of  this change in PWV has not been demonstrated and 
neither has a direct comparison with FMD (as the gold standard method) been carried out.  
Therefore, it is important to carry out studies to validate this potential method of  non-
invasive endothelial function assessment in order to justify its wider use. 
 
6.2 Study Aims 
Aims: 
to investigate whether a change (slowing) in PWV could be seen in response to an 
increase in flow following a standard hyperaemic stimulus (flow-mediated slowing 
[FMS]) and to validate and/or refine the protocol as developed by Naka et al164.  
 
to investigate the technical and logistical issues and determine the reproducibility of  
FMS.  
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Hypothesis: FMS is a reproducible method of  assessing changes in conduit vessel 
stiffness in response to reactive hyperaemia and can therefore serve as a measure of  
endothelium dependent vasomotor function.  
6.3 Method 
6.3.1 Flow-mediated dilatation 
All measurements were carried out in a temperature controlled room. Blood pressure was 
assessed before and after endothelial function testing using an automatic 
sphygmomanometer (Omron 750) on the left arm. Skin temperature was measured and if  
less than 29OC the hand was warmed with a heated wheat bag. 
 
Using a high-resolution ultrasound probe (7.5MHz, ALOKA Prosound 5500) held in a 
stereotactic clamp (ALOKA), the right brachial artery was imaged, 5 to 10 cm above the 
antecubital fossa. A Doppler cursor was positioned in the centre of  the vessel for 
continuous assessment of  blood flow using pulsed-wave Doppler. Baseline measures of  
diameter and flow were recorded for 1 minute. An automatic air regulator (Logan 
Research;Rochester, Kent, United Kingdom) was used to inflate a pneumatic cuff  
(Hokanson SC5) positioned around the forearm as specified in each protocol to 250 
mmHg for 5 minutes to induce brachial artery FMD.  Following rapid deflation of  the cuff  
brachial artery diameter and blood flow was recorded for a further 5 minutes.  Images 
triggered to the R-wave of  the ECG were captured every 3 seconds directly to a computer 
for later offline analysis and recorded onto video for backup.   
 
Brachial artery diameter was measured with edge detection software (Brachial Tools, Iowa 
City, Iowa) (see figure 6.1).  Baseline diameter was an average of  the first 20 frames; peak 
diameter was an average of  3 consecutive frames. Absolute change in diameter was 
calculated as in equation 6.2a and FMD percentage change was calculated as in equation 
6.2b. 
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Figure 6.1: Demonstration of an ultrasound image with region of interest for analysis of change in diameter 
following a 5 minute occlusion of the forearm. On the right of the figure is the change of diameter over the 
course of the study.  
 
Equation 6.2a 
                                           
 6.2b 
 
     
                               
                
      
 
Blood flow was analysed using the flow analyser within the Brachial Tools software. 
Velocity time integral (VTI) was used to represent blood flow. Baseline VTI was an average 
of  the first 20 frames.  Peak VTI was the maximum VTI within the first 15 seconds 
following deflation of  the occlusion cuff.  Absolute change in VTI was the difference 
between peak VTI and baseline VTI.  Reactive hyperaemia (RH%)was calculated as in 
equation 6.3.   
 
Equation 6.3 
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6.4 Protocol Development of  flow-mediated slowing method 
6.4.1 Flow-mediated slowing, general method 
FMS of  the brachial artery was measured using the Vicorder (Skidmore Medical, UK) on 
the right arm unless otherwise specified. Two narrow Hokanson SC5 blood pressure cuffs 
were positioned (one on the upper arm just below the armpit; the second on the lower 
arm) in order to assess PWV.  A blood pressure cuff  attached to a rapid cuff  inflator was 
placed on the lower arm for occlusion of  the forearm (figure 6.2).    The positioning and 
order of  the cuffs on the lower arm varied according to study. 
 
Figure 6.2: Example of cuff positions for assessing FMS.        = occlusion cuff      = PWV cuff. 
 
 Baseline PWV recordings were made for 5-10 minutes.  The occlusion cuff  was then 
inflated to 250mmHg for 5 minutes.  Changes in PWV following deflation of  the occlusion 
cuff  were recorded for a further 10 minutes.  Positioning of  the lower PWV cuff  and 
occlusion cuff  varied according to protocol. Baseline PWV was the average of  all readings 
recorded over the 5 or 10 minute period prior to forearm occlusion. Using the lowest PWV 
value following occlusion cuff  release unless otherwise specified, FMS% was calculated 
using equation 6.4. 
 
Equation 6.4.  
     
                
      
      
 
FMS = Flow-mediated slowing; PWV = Pulse wave velocity; Min = Minimum PWV post occlusion cuff 
release; BL = Baseline 
6.4.2 Statistical analysis 
Although none of  the preliminary studies were powered for statistical analysis, data was 
tested for normality using Shapiro-Wilk. Paired sample t-test or Wilcoxon signed rank test 
was used to test for differences between methods when comparing two groups.  For larger 
comparisons, one-way ANOVA with Bonferroni was used to explore differences between 
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groups or for non-parametric data, Friedmans two-way analysis of  variance by rank was 
used. A p-value of  <0.05 was considered as statistically significant. Statistical analysis was 
carried out using SPSS version 18. 
 
6.4.3 Preliminary scoping studies 
6.4.3.1 Aim 
The aim of  the preliminary study was to repeat the published technique by Naka et al and 
evaluate concurrent measurement of  FMS and FMD164.   
6.4.3.2 Methods 
FMS, FMD and blood flow were evaluated as described above.  The cuffs were positioned 
with the upper cuff  just below the armpit; the occlusion cuff  was proximal to the wrist 
with the second PWV cuff  proximal to the occluding cuff  (figure 6.3).  PWV data was 
captured every minute for 10 minutes before and after cuff  inflation.  Assessments of  FMS 
and FMD were made both individually and simultaneously on the right arm see figure 6.4. 
Changes in brachial artery diameter, blood flow and PWV were assessed in one subject.  
 
 
Figure 6.3: Set up for simultaneous assessment of FMS and FMD. Cuff positions remained the same for 
separate assessment of both FMS and FMD.        = occlusion cuff      = PWV cuff     = ultrasound 
probe.  
 
 
Figure 6.4: Protocol for the initial testing of the FMS method for comparison with FMD 
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6.4.3.3 Results and implications  
When FMS was assessed on its own and simultaneously with FMD, PWV did not decrease 
following release of  the occlusion cuff  (see figure 6.5).  When taking change in PWV at 1 
minute post cuff  release as undertaken by Naka et al, PWV had increased by 4.50% when 
assessed individually and by 2.14% when assessed concurrently with FMD164. Brachial 
artery diameter increased following release of  the occlusion cuff  on both occasions 
indicating that there was vasodilatation (FMD alone 3.8% and FMD with concurrent FMS 
assessment 4.84%).   
 
Figure 6.5: Results for the initial FMS study in one subject. Pulse wave velocity (PWV) was recorded at one 
minute intervals for 10 minutes as baseline and 10 minutes post occlusion cuff release. PWV was not 
recorded during the occlusion period. 
 A measurable change in blood flow was also seen (reactive hyperaemia FMD alone 351% 
and with simultaneous FMS assessment 254%).  This was low when compared to that of  
published data with the standard forearm cuff  position (RH% 642±350)405. 
  
These observations raised two important questions: 
 How does cuff position affect the magnitude of the hyperaemic stimulus and the 
quality of the FMD image; 
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 What is the optimal protocol for acquisition of the PWV measurement to capture 
flow-mediated changes? 
6.4.4 Study 1 Assessment of  forearm cuff  positions 
6.4.4.1 Aim 
To assess the impact of  varying the hyperaemic stimulus on FMS and FMD responses.  
6.4.4.2 Method 
The flow stimulus was increased by positioning the occlusion cuff  in the middle of  the 
forearm to increase the amount of  arm being occluded (figure 6.6B).  This was compared 
with the original cuff  position just proximal to the wrist (figure 6.6A) in 5 subjects. FMS 
and FMD measurements were obtained simultaneously for both positions. Tests were 
carried out 30 minutes apart with the order alternated (figure 6.7).   FMS and FMD were 
assessed as previously described but PWV was captured approximately every 20 seconds.  
 
 
Figure 6.6: The different cuff positions for the occluding cuff and lower PWV cuff. A. Wrist occlusion cuff. 
B. Mid forearm occlusion cuff.      = occlusion cuff      = PWV cuff = ultrasound probe. 
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Figure 6.7: Protocol for assessment of FMS and FMD with different occlusion cuff positions.  Subjects 
underwent either low cuff or mid cuff assessment first.  Following a 30 minute break they then underwent 
repeat FMS and FMD assessment with the alternative occlusion cuff position. 
6.4.4.3 Results 
 
n=5 Subjects 
Age (years) 27 ± 7 
Gender (M:F) 4:1 
SBP (mmHg) 126 ± 19 
DBP (mmHg) 72 ± 16 
Table 6.1: Subject characteristics 
 
  Mid cuff placement Low cuff placement 
Subject BL PWV 
(m/s) 
Min PWV 
(m/s) 
FMSABS 
(m/s) 
FMS% 
(%) 
BL PWV 
(m/s) 
Min PWV 
(m/s) 
FMSABS 
(m/s) 
FMS% 
(%) 
1 6.15 6.07 -0.08 -1.23 7.98 7.49 -0.49 -6.18 
2 5.37 5.45 0.08 1.48 *    
3 5.15 4.79 -0.36 -7.06 5.88 5.56 -0.32 -5.43 
4 7.62 6.81 -0.81 -10.61 9.44 9.18 -0.26 -2.78 
5 5.34 5.10 -0.24 -4.53 7.23 7.01 -0.22 -3.04 
Table 6.2: PWV data for both occlusion cuff positions. * = data missing for technical reasons.  BL PWV = 
baseline pulse wave velocity; Min PWV = minimum pulse wave velocity; FMSABS = absolute change in pulse 
wave velocity; FMS% = flow-mediated slowing as a percentage. 
 
Five subjects were studied who were all non-smokers, age and blood pressure can be seen 
in table 6.1. There was variable amount of  slowing of  PWV in response to reactive 
hyperaemia with both the mid and wrist occluding cuff  positions (table 6.2). Mean FMS% 
was similar for both cuff  positions (mid -4.39± 4.75 % and low -4.36±1.7 %, p= 0.61).  
Table 6.3 shows the individual results for FMD.  The mean FMD% was lower when the 
occlusion cuff  was positioned low on the arm (mid cuff  FMD% 3.05 ± 1.18 %  vs low cuff  
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FMD% 2.30 ± 1.74 %), however, this was not a significant reduction (p=0.52), although 
this study was not powered for statistical comparison between groups.    
 
  Mid cuff placement Low cuff placement 
Subject BL dia 
(mm) 
PK dia 
(mm) 
 FMDABS 
(mm) 
FMD% 
(%) 
BL dia 
(mm) 
PK dia 
(mm) 
 FMDABS 
(mm) 
FMD% 
(%) 
1 3.24 3.40 0.16 4.95 3.49 3.51 0.02 0.68 
2 4.21 4.31 0.11 2.50 * 
  
  
3 3.79 3.89 0.09 2.50 3.77 3.89 0.12 3.14 
4 4.06 4.20 0.14 3.38 4.18 4.37 0.18 4.41 
5 2.85 2.90 0.05 1.92 2.88 2.91 0.03 0.98 
Table 6.3 FMD data for both occlusion cuff positions. *Data missing due to technical problem. BL dia= 
baseline diameter; PK dia = peak diameter; FMDABS = absolute change in diameter; FMD%= flow-mediated 
dilatation expressed as a percentage 
 
  Mid cuff placement Low cuff placement 
Subject BL  VTI 
(m) 
Pk VTI 
(m) 
Abs VTI 
(m) 
RH 
(%) 
BL  VTI 
(m) 
Pk VTI 
(m) 
Abs VTI 
(m) 
RH% 
(%) 
1 0.039 0.268 0.229 689 0.049 0.193 0.144 394 
2 0.088 0.354 0.267 404 * 
  
  
3 0.052 0.188 0.136 363 0.063 0.137 0.074 219 
4 0.039 0.183 0.144 464 0.039 0.136 0.097 347 
5 0.055 0.185 0.130 338 0.034 0.112 0.078 329 
Table 6.4: Flow data for both occluding cuff positions.*Data missing due to technical problem. BL VTI = 
baseline velocity time integral; PK VTI = peak velocity time integral; ABS VTI = absolute change in velocity 
change integral; RH% = Reactive hyperaemia as a percentage  
 
In the majority of  subjects RH% was measurably greater with the mid arm occlusion cuff  
than the wrist cuff  (table 6.4). The mean RH% for the mid cuff  position was 452 ± 141 % 
and for the low cuff  position it was 322 ± 74 % but the difference between the two was 
not significant (p=0.10).  However, absolute VTI was significantly reduced with the lower 
occlusion cuff  position (mid cuff  0.160 ± 0.047 m & low cuff  0.098 ± 0.032 m, p = 
0.005). 
6.4.4.4 Implications 
Changing the position of  the occluding cuff  to the mid-forearm did not increase the 
change in PWV following a 5 minute period of  ischaemia.  There was a slight increase in 
the size of  the reactive hyperaemic stimulus but not enough to achieve similar results as 
Naka et al who found a reduction in PWV of  14% (absolute 0.7 m/s) when the occlusion 
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cuff  was positioned at the wrist164. These results suggest that a more proximal position for 
the occlusion cuff  is likely to be required in order to generate consistently sufficient 
reactive hyperaemia to be able to test the potential of  this method.  
6.4.5 Study 2A Intermittent or continuous PWV recording 
6.4.5.1 Aim 
Two methods are available on the Vicorder to record PWV.  The method used in the 
previous studies was to inflate the cuffs to 65mmHg, take a measurement and then deflate 
the cuffs, a process that takes approximately 15-20 seconds. Alternatively the cuffs are 
inflated and left whilst a reading is saved automatically every 3.5 seconds (continuous).    A 
continuous method might technically seem preferable as the cuffs are inflated to sub-
diastolic pressure and left for the duration of  the baseline and reinflated for post release of  
the occlusion cuff.  However, there is potential that a continuous venous occlusion may 
have an effect on arterial stiffness which may have an impact on the FMS and blood flow 
responses following reactive hyperaemia. Therefore, the aim of  the study was to assess the 
effect of  continuous versus intermittent PWV recording on the hyperaemic stimulus.   
6.4.5.2 Methods 
 
Figure 6.8: Set up of the cuffs and ultrasound probe for FMS and FMD assessment.      = occlusion cuff      
= PWV cuff = ultrasound probe. 
 
Three subjects were studied who had previously had FMS and FMD assessed with the 
intermittent PWV recording method. FMS and FMD were set up as previously described 
with the occluding cuff  positioned in the mid-forearm (figure 6.8).   Changes in flow were 
measured using pulse-waved Doppler during vascular studies in the three healthy 
volunteers under the following conditions (figure 6.9).  
 During intermittent assessments of PWV at 20 second intervals with simultaneous 
FMD acquisition 
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 During continuous acquisition of PWV (measurement recorded every 3 seconds) 
with simultaneous FMD assessment 
 During FMD without PWV assessment 
 
 
Figure 6.9: Protocol for assessment of FMS and FMD to compare recording of the PWV signal either 
continuously or intermittently.  
6.4.5.3 Results  
Despite the PWV trace being displayed on the screen during the study the data failed to 
register in the system due to a malfunction within the software (repaired after consultation 
with the manufacturers).  Therefore there was no PWV data available for all 3 subjects for 
the continuous PWV recording method. However, the intermittent recording PWV data 
capture was successful but as previously shown there was limited detectable FMS (mean 
FMS% -1.42 ± 3.01 %) (table 6.5) 
 
Subject BL PWV (m/s) Min PWV (m/s) FMSABS (m/s) FMS% (%) 
1 6.15 6.07 -0.08 -1.23 
2 5.37 5.45 0.08 1.48 
3 5.34 5.10 -0.24 -4.53 
Table 6.5: Data for the intermittent recording of PWV.  BL PWV = baseline pulse wave velocity; Min PWV 
= minimum pulse wave velocity; FMSABS = absolute change in pulse wave velocity; FMS% = flow-mediated 
slowing as a percentage. 
 
Flow data showed that the reactive hyperaemic response was lower for continuous PWV 
recording than intermittent PWV recording and FMD by itself  (mean responses for RH% 
were 357 ± 88 %, 471 ± 183 % and 467 ± 138 % respectively p=0.26).  This difference 
was not statistically significant, but the study was not powered for statistical analysis.  The 
hyperaemic responses for intermittent PWV recording and FMD were similar (table 6.6).  
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 Continuous   Intermittent   FMD only   
Subject BL 
VTI 
(m) 
PK 
VTI 
(m) 
ABS 
RH 
(m) 
RH 
(%) 
BL 
VTI 
(m) 
PK 
VTI 
(m) 
ABS 
RH 
(m) 
RH 
(%) 
BL 
VTI 
(m) 
PK 
VTI 
(m) 
ABS 
RH 
(m) 
RH 
(%) 
1 0.075 0.232 0.157 311 0.039 0.268 0.229 682 0.052 0.167 0.115 324 
2 0.068 0.310 0.242 458 0.087 0.332 0.245 382 0.070 0.334 0.264 478 
3 0.068 0.204 0.136 301 0.053 0.185 0.132 350 0.038 0.23 0.192 600 
Table 6.6: Flow data from the brachial artery during continuous and intermittent PWV recording and FMD 
only. BL VTI = baseline velocity time integral; PK VTI = peak velocity time integral; ABS RH = Absolute 
change in VTI; RH% = Reactive hyperaemia  
Individual FMD results are presented in table 6.7. The mean results for FMD suggested 
that it was attenuated during continuously recorded PWV in comparison to both 
intermittent recording and FMD only (2.16 ± 2.17 %, 3.12 ± 1.61 % and 3.71± 2.74 % 
respectively).   
 
 
Continuous PWV recording Intermittent PWV recording FMD only 
Sub
ject 
BL 
dia 
(mm) 
PK 
dia 
(mm) 
FMD
ABS 
(mm) 
FMD% 
(%) 
BL 
dia 
(mm) 
PK 
dia 
(mm) 
FMD
ABS 
(mm) 
FMD
% (%) 
BL 
dia 
(mm) 
PK 
dia 
(mm) 
FMD
ABS 
(mm) 
FMD
% (%) 
1 3.33 3.34 0.01 0.33 3.24 3.40 0.16 4.95 3.74 3.86 0.12 3.25 
2 4.21 4.40 0.19 4.55 4.21 4.31 0.11 2.50 4.10 4.37 0.27 6.65 
3 2.91 2.95 0.05 1.59 2.85 2.90 0.05 1.92 2.90 2.94 0.04 1.22 
Table 6.7: Subject data for FMD assessed during continuous and intermittent PWV recording and FMD 
only.  BL dia= baseline diameter; PK dia = peak diameter; FMDABS = absolute change in diameter; FMD%= 
flow-mediated dilatation as a percentage.  
6.4.5.4 Implications 
With the limited data available the continuous recording of  PWV appeared to decrease the 
flow stimulus and FMD response suggesting that this may not be the most appropriate 
method for assessing the two techniques simultaneously.  As the change in PWV following 
a period of  forearm ischaemia was still very low with the mid-forearm cuff  position, 
moving the occlusion cuff  to just below the medial epicondyle may stimulate a greater 
slowing in PWV.  The additional stimulus may also make it easier to investigate the impact 
of  continuous PWV recording on the flow stimulus in comparison to intermittent PWV 
recording. 
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6.4.6 Study 2B: Further investigations of  cuff  position and PWV recording  
6.4.6.1 Aim 
Due to the limited changes in PWV with the occlusion cuff  at the wrist or mid-forearm, it 
was decided to test the effect of  positioning the occlusion cuff  in the traditional position 
for an FMD study, just below the medial epicondyle.  This would increase the area of  arm 
being made ischaemic and which in turn would increase the flow stimulus and therefore 
increase the slowing of  PWV. Therefore, the aim of  this study was to assess the effect on 
hyperaemia and FMS of  changing the occluding cuff  position to just below the medial 
epicondyle. The second aim was to further investigate the most appropriate method for 
recording the PWV data by comparing continuous and intermittent recordings of  PWV in 
a larger number of  subjects. 
6.4.6.2 Methods 
Ten subjects were studied with the PWV cuffs positioned as previously described and the 
occlusion cuff  placed just below the medial epicondyle as in figure 6.10.  The order of  the 
studies varied for each subject (figure 6.11).  Area under the curve (AUC) of  the flow 
response to the 5 minute ischaemic period was assessed in addition to the other measures.    
VTI was calculated from each Doppler waveform using proprietary software on the 
ALOKA for the 2 minute period following release of  the occlusion cuff.  The time of  each 
screen of  waveforms was noted and AUC was then calculated from these data. 
 
 
Figure 6.10: Occluding cuff positioned up to 1cm below the medial epicondyle.      = occlusion cuff      = 
PWV cuff   =ultrasound probe 
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Figure 6.11: Protocol for comparing intermittent and continuous recording of PWV for FMS assessment 
with the occlusion cuff at the forearm. Each subject completed all 3 studies in varying order 
6.4.6.3 Results 
Brief  characteristics of  the ten subjects studied are included in table 6.8. Baseline PWV was 
similar when measured with both the intermittent or continuous PWV recording methods 
(table 6.9).  Absolute change in PWV (FMSABS) and FMS% were numerically higher with the 
intermittent method of  recording PWV than the continuous method but this was not 
statistically significant (figure 6.12).   
 
n=10 Subjects 
Age (years) 28 ± 6 
Gender (M:F) 5:5 
Systolic blood pressure (mmHg) 113 ± 9 
Diastolic blood pressure (mmHg) 69 ± 7 
Table 6.8: Subject characteristics 
n=10 Study A (FMSINT) Study B (FMSCONT) p-value 
BL PWV(m/s) 7.29  ± 0.91 7.23  ± 0.73 0.70 
Min PWV (m/s) 5.95 ± 0.66 6.09 ± 0.75 0.46 
FMSABS (m/s) -1.35 ± 0.41 -1.13 ± 0.40 0.24 
FMS% (%) -19.69  ± 4.15 -15.72  ± 5.40 0.12 
Table 6.9: Comparison of intermittent (study A) and continuous (study B) recording of PWV for FMS 
studies (mean ± SD).  BL PWV = baseline pulse wave velocity; Min PWV = minimum pulse wave velocity; 
FMSABS = absolute change in pulse wave velocity; FMS% = flow-mediated slowing as a percentage.  
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Figure 6.12: Figures showing the individual results for comparison of continuous and intermittent recording 
of PWV for A absolute change in PWV and B percentage change from baseline –FMS%.  CPWV = 
continuous recording of pulse wave velocity; IPWV = intermittent recording of pulse wave velocity.  
 
Flow and FMD responses during intermittent and continuous recording of  PWV 
 
Both RH% and the AUC of  the hyperaemic response were significantly lower with 
continuous PWV recording than intermediate PWV recording (p=0.013 & 0.001 
respectively) suggesting a decreased flow stimulus for FMD and FMS.  Peak diameter 
measured during continuous PWV recording was significantly lower than when assessed 
during intermittent PWV recording (p=0.035). Both absolute and percentage change in 
diameter measured during continuous PWV recording were lower than those recorded 
during intermittent PWV recording but neither quite reached significance (p=0.050 & 
0.054 respectively) (table 6.10).   
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Comparison of  FMD acquired simultaneously with the two methods of  PWV recording and by it self 
 
There was no difference between the 3 groups for baseline brachial artery diameter. 
(p=0.95)  Analysis of  the data including FMD alone with oneway-ANOVA, revealed 
differences between the groups for the flow response (PKVTI, RH and RH AUC), peak 
diameter, absolute change in diameter and FMD%.   Post-hoc analyses (Bonferroni) 
identified that in all cases the differences were between continuous PWV recording and 
FMD only (table 6.10). Reactive hyperaemia was lower during continuous PWV recording 
in comparison to both intermittent recording and FMD only but this did not reach 
significance in post hoc analysis(p=0.06 & 0.09 respectively). 
 
N=10 Study A (FMSINT) Study B (FMSCONT) p-value∫ Study C (FMD) p-value§ 
BL dia (mm) 3.59 ± 0.56 3.57 ± 0.57 0.51 3.51 ± 0.58 0.95 
PK dia (mm) 3.77 ± 0.55 3.67 ± 0.60 0.035 3.77 ± 0.60 0.90 
FMDABS (mm) 0.18 ± 0.09 0.10 ± 0.06* 0.050 0.26 ± 0.11* 0.002 
FMD% (%) 5.19  ± 3.10 2.70 ± 1.36* 0.054 7.62 ± 3.99* 0.005 
BL VTI(m) 0.047 ± 0.111 0.049 ± 0.009 0.36 0.055 ± 0.013 0.30 
PK VTI(m) 0.349 ± 0.135 0.228 ± 0.090* 0.013 0.357 ± 0.089* 0.021 
ABS RH (m) 0.302 ± 0.130 0.179 ± 0.090* 0.011 0.302 ± 0.089* 0.019 
RH% (%) 756 ± 266 471 ± 174 0.013 687 ± 224 0.022 
RH AUC 1461 ± 341 1105 ± 344* 0.001 1675 ± 261* 0.002 
Table 6.10: Comparison of the impact of intermittent (study A) and continuous (study B) recording of PWV 
for FMS studies on FMD and flow data (mean ± SD).  ∫= p-values for paired t-test between the two PWV 
recording methods. §= p-value for ANOVA between FMD and flow data for all groups. * identifies 
significance between the groups with bonferroni post hoc test. BL dia = baseline diameter; PK dia = peak 
diameter; FMDABS = absolute change in diameter; FMD% = Flow-mediated dilatation as a percentage; BL 
VTI = baseline velocity time integral; PK VTI = peak velocity time integral; ABS RH = Absolute reactive 
hyperaemia; RH% = Reactive hyperaemia; RH AUC = reactive hyperaemia area under the curve during 
reactive hyperaemia. 
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Figure 6.13: Comparison of absolute and percentage change FMD assessed during intermittent and 
continuous methods of recording PWV with FMD measured by itself.  p-values are for comparison by 
ANOVA, * = significant difference between the two variables by post hoc Bonferroni. 
6.4.6.4 Implications 
 Positioning of  the occlusion cuff  just below the medial epicondyle provided enough of  a 
stimulus to drive detectable slowing in PWV in addition the FMD response was also 
increased. Comparison of  the two different methods for recording the PWV 
measurements demonstrated that continuous assessment of  PWV had a significant impact 
on reactive hyperaemia and other blood flow measures. Additionally, there was a trend for 
FMS to be lower with this method although this was not significant.  FMD responses were 
also lower with the continuous PWV recording method. These results suggest that placing 
the occlusion cuff  positioned just below the medial epicondyle, with the two PWV cuffs 
positioned on the upper arm and above the wrist appears to be the most technically 
suitable protocol for assessment of  FMS.  PWV should be recorded using the intermittent 
method as this has the least impact on the flow stimulus.  
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6.4.7 Study 3 Assessment of  FMS on the same or contralateral arm to FMD 
6.4.7.1 Aim 
The aim was to assess the impact of  measuring both techniques on the one arm, on the 
FMS and FMD responses when compared with measurements made on separate arms. 
This would also provide the opportunity to consider the practicality of  studying both arms 
simultaneously.  
6.4.7.2 Methods 
 Ten subjects were studied on two occasions.  FMS and FMD were assessed simultaneously 
on the right arm or with FMS on the left arm and FMD on the right (figure 6.14).  FMD 
and FMS were measured as previously described. PWV was captured using the intermittent 
method (figure 6.15). 
 
   
Figure 6.14: Set up of cuffs and ultrasound probe for assessment of FMS and FMD for A simultaneous 
assessment of FMS and FMD on the right arm. B assessment of FMD on the right arm with C assessment of 
FMS on the left arm. .       = occlusion cuff       = PWV cuff   =ultrasound probe 
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Figure 6.15: Protocol for comparison of FMS and FMD assessed simultaneously on the same arm or on with 
FMD measured on the right arm with FMS on the left arm 
6.4.7.3 Results 
As shown in table 6.11 FMD% was greater when assessed on its own but this did not reach 
significance (p=0.11) (figure 6.16). The flow responses were similar between FMD assessed 
on the same arm as FMS or on separate arms.   
 
 N=10 Right arm FMD Right arm both p-value 
BL dia(mm) 3.43 ± 0.61 3.59 ± 0.59 0.16 
PK dia (mm) 3.67 ± 0.62 3.76 ± 0.60 0.24 
FMDABS (mm) 0.24 ± 0.16 0.17 ± 0.07 0.17 
FMD% (%) 7.21 ± 5.07 4.79 ± 2.11 0.11 
BL VTI(m) 0.049 ± 0.019 0.044 ± 0.009 0.51 
PK VTI(m) 0.350 ± 0.104 0.364 ± 0.125 0.61 
ABS RH (m) 0.301 ± 0.103 0.319 ± 0.117 0.49 
RH (%) 785 ± 229 802 ± 163 0.96 
Table 6.11: Comparison of data when assessing both FMS and FMD on the right arm or FMS on the left 
arm and FMD on the right arm (mean ± SD). BL dia= baseline diameter; PK dia = peak diameter; FMDABS 
= absolute change in diameter; FMD% = flow-mediated dilatation as a percentage; BL VTI = baseline 
velocity time integral; PK VTI = peak velocity time integral; ABS RH = absolute change in velocity time 
integral; RH = Reactive hyperaemia. 
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Figure 6.16: Comparison of FMD % when assessed on the same arm as FMS assessment or on the 
contralateral arm to FMS measurement. 
Baseline PWV was significantly higher in the left arm than the right (8.87 ± 0.56 m/s vs 
7.49 ± 0.29 m/s, p=0.012). The difference in FMS between the two arms was numerically 
lower but not statistically significant (left arm -24.42 ± 1.96 % vs right arm -19.90 ± 1.35 
%, p=0.14) (figure 6.17). 
 
 
Figure 6.17: Figure showing individual results for comparison of FMS % when assessed on the same arm as 
FMD assessment and on the contralateral arm to FMD measurement. 
6.4.7.4 Implications 
From the results it can be seen that using one arm for simultaneous comparison of  the two 
techniques did not have a significant effect on the measurements.  Participants had also 
reported that one arm was more comfortable for them, which could have an impact on 
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their results. Additionally using just one arm allows other measures to be assessed during 
the study such as blood pressure.  
6.4.8 Summary and brief  discussion of  protocol development 
The aim of  this section was to ensure that a change in PWV could be seen following a 
standard hyperaemic stimulus and to refine the protocol as required.  The key initial finding 
was that when first testing the method as specified in Naka et al, using a 5 minute occlusion 
just above the wrist, a reduction in PWV was not seen164.However, after adaptation and 
rigorous refinement of  the protocol, a reduction in PWV post-hyperaemia could be 
induced.   
 
The unexpected observation of  a lack of  slowing of  PWV in the first participant evaluated 
raised questions about the most appropriate position for the occlusion cuff  and the best 
method of  recording the PWV waveforms to achieve the most accurate and therefore 
repeatable results. The next study therefore looked at whether moving the occlusion cuff  
position to mid-forearm led to a reduction in PWV following reactive hyperaemia and if  
this change was greater than that achieved with the occlusion cuff  at the wrist. The initial 
studies in 5 participants comparing the cuff  position just above the wrist and the cuff  on 
the mid-forearm showed limited reductions in PWV following reactive hyperaemia. There 
was however, no difference in FMS% between the two cuff  positions. FMD did appear to 
be marginally greater with the mid forearm cuff  position.  
 
We then compared two methods for acquiring the PWV data, intermittent recording and 
continuous recording.  The initial comparison study on three participants was carried out 
with the occlusion cuff  positioned around the mid forearm.  We became concerned that 
the persistent cuff  inflation for the continuous recording of  PWV was having an adverse 
impact on reactive hyperaemia through venule occlusion.  As the change in PWV was also 
still rather low in these studies it was decided to repeat the experiment in a larger number 
of  subjects but with the occlusion cuff  positioned just below the medial epicondyle as 
most commonly used in FMD studies.  This led to an increase in the flow stimulus and 
consequently a larger reduction in PWV, along with a greater change in brachial artery 
diameter.  Although continuous recording of  PWV did not significantly affect the change 
in PWV following reactive hyperaemia, there was a decrease in the flow stimulus.  
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Finally, we looked at whether FMS acquisition had an impact on FMD when assessed 
simultaneously on the same arm. The data appeared to show that there was no significant 
effect on FMD.  However, it was noted that there was a significant difference in baseline 
PWV between the two arms.  This may be due to differences in how the arteries originate 
from the aorta. On the right side the brachocephalic artery branches off  the aorta before 
dividing into the common carotid and the subclavian arteries, whereas on the left the 
subclavian artery comes directly off  the aorta.  
 
It is worth noting that the number of  participants tested in these preliminary studies was 
small and therefore they may be underpowered for statistical analysis, which would 
therefore put the statistical findings at risk of  type I and type II errors. 
 
In conclusion, from these preliminary studies it was found that the most appropriate 
protocol for FMS assessment is for the occlusion cuff  to be positioned just below the 
medial epicondyle, with the PWV cuffs positioned just above the wrist and immediately 
below the arm pit. The PWV waveforms should be acquired following regular inflation and 
deflation of  the cuffs at approximately 20 second intervals.  It is worth noting, that with 
this method, part of  the arterial tract being studied (approximately one third) is being made 
ischaemic. This does have implications regarding whether the changes in PWV following 
reactive hyperaemia will be purely mediated by NO or whether other vasodilators may play 
a role. The next stage in the validation process of  this technique would be to assess the 
reproducibility of  this protocol. 
6.5 Reproducibility study 
6.5.1 Aim 
To demonstrate the reproducibility of  the FMS technique 
6.5.2 Methods 
6.5.2.1 FMS  
Flow-mediated slowing was assessed using the Vicorder. Two Hokanson SC5 cuffs were 
positioned around the upper and lower right arm to assess PWV, a third cuff  was placed 
just below the medial epicondyle to occlude the forearm for 5 minutes (figure 6.18). PWV 
was assessed using intermittent inflation and deflation for 5 minutes prior to the occlusion 
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to assess baseline PWV. Following the release of  the occluding cuff  PWV data were 
acquired for a further 10 minutes.  
  
Figure 6.18: Set up of cuffs and ultrasound probe for assessment of FMS and FMD.       = occlusion cuff           
= PWV cuff   =ultrasound probe 
6.5.2.2 FMD 
FMD was assessed as described in the protocol development section. 
6.5.2.3 Arterial stiffness 
Pulse wave analysis was assessed using the Vicorder. Participants were seated and a 
Hokanson SC10 was positioned around the upper portion of  the right arm. A blood 
pressure measurement was taken using the Vicorder, the cuff  was then reinflated to 
diastolic blood pressure to record brachial artery waveforms which were saved to the 
Vicorder. This was repeated a second time and the results were averaged. Measurements of  
augmentation pressure and central blood pressure were recorded. 
 
Central pulse wave velocity was assessed using the Vicorder. Subjects were rested semi-
supine at an angle of  approximately 30o. A narrow cuff  was positioned around the neck 
with the bladder over the right carotid artery; a Hokanson SC10 was then position around 
the upper thigh of  the right leg. The distance from the suprasternal notch to the centre of  
the thigh cuff  was measured with a tape measure and entered into the Vicorder. Both cuffs 
were then inflated to 65 mmHg and the waveforms were recorded.  Two readings within 
0.5 m/s of  each other were accepted and the results averaged. 
6.5.2.4 Protocol 
25 apparently healthy volunteers aged between 21 and 37 were recruited locally. Subjects 
were asked on visit one to arrive having previously fasted and avoided caffeine and heavy 
exercise for 8 hours. Consent was obtained and a medical history taken to ensure subjects 
met the inclusion criteria. Anthropometric measurements of  height, weight, hip and waist 
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were taken. Seated blood pressure was taken using the Vicorder. Blood samples were taken 
from the finger tip of  the non dominant hand and analysed using the Alere Cholestech 
LDX (Alere LTD, Cheshire, UK) to check fasting lipid and glucose status. Subjects then 
rested supine on a bed for 10 minutes before their vascular function was assessed. 
6.5.2.5 Analysis 
Baseline PWV was calculated as the average of  all PWV measurements recorded in the first 
5 minutes. Minimum PWV was the lowest PWV value recorded within 2 and a half  minutes 
following the release of  the occlusion cuff. As previously described FMS was expressed as 
absolute change in PWV (minimum PWV – baseline PWV) and percentage change 
([absolute change/ baseline PWV]x100)). In addition, FMS at 1 min post cuff  release was 
also calculated as absolute change in PWV and percentage change) for comparison with 
previously published work and to see if  this was more reproducible than maximum change. 
 
Data are presented as mean ± SD. Data were checked for normality using the Shapiro-Wilk 
test. Within method reproducibility was demonstrated using percentage of  the coefficient 
of  variation calculated as ((SD of  the differences/overall mean)/√2)x100. Bland-Altman 
plots were also used to assess agreement between the repeated data. The relationship 
between FMD and FMS was examined using Pearson and Spearman correlations. Paired t-
tests and related-samples Wilcoxon signed rank tests were used to look for differences 
between variables from visit 1 and visit 2. A p-value of  <0.05 was considered statistically 
significant. Statistical analysis was carried out using SPSS version 18. 
6.5.3 Results 
The key finding in this section was that this new FMS protocol produced reproducible 
results. 
n=25 Healthy controls 
Age (years) 27 ± 5 
Gender (M:F) 18:7 
Body mass index (kg/m2) 25.35 ± 2.41 
SBP(mmHg) 122 ± 10 
DBP (mmHg) 72 ± 7 
Central SBP (mmHg) 111 ± 8 
Augmentation pressure (mmHg) 3 ± 3 
Aortic PWV (m/s) 6.42 ± 0.76 
TC (mmol/L) 3.92 ± 0.79 
Glucose (mmol/L) 4.54 ± 0.58 
Table 6.12: Subject characteristics  
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Table 6.12 shows the characteristics of  the 25 participants recruited for the study. Room 
temperature, skin temperature and blood pressure pre and post endothelial function testing 
were not significantly different between visits (table 6.13).  
  Visit 1 Visit 2 p-value 
Room temperature (°C) 22.87 ± 1.27 22.86 ± 1.09 0.98 
Skin temperature (°C) 31.45 ± 2.09 31.57 ± 1.82 0.82 
Pre systolic blood pressure (mmHg) 113 ± 10 114 ± 12 0.65 
Pre diastolic blood pressure (mmHg) 65 ±7 64 ± 6 0.67 
Pre heart rate (bpm) 60 ± 11 59 ±7 0.27 
Post systolic blood pressure (mmHg) 113 ± 10 112 ± 12 0.42 
Post diastolic blood pressure (mmHg) 64 ± 6 64 ± 6 0.89 
Post heart rate (bpm) 60 ± 9 60 ± 8 0.72 
Distance between FMS PWV cuffs (cm) 32.5 ± 3.48 32.4 ± 3.21 0.94 
 Table 6.13: Factors that may influence vascular measurements for visit 1 and 2.  Supine blood pressure 
results pre and post assessment of endothelial function are also shown.   
  Visit 1 Visit 2 p-value CV% 
Baseline PWV (m/s) 7.64 ± 1.05 7.53 ± 0.91 0.37 3.3 
 
  
   Min PWV (m/s) 6.04 ± 0.78* 5.93 ± 0.72* 0.40 4.1 
Max FMSABS (m/s) -1.60 ± 0.58 -1.60 ± 0.42 0.99 8.2 
Max FMS% (%) -20.66 ± 6.02  -21.12 ± 4.32 0.55 7.3 
  
    1 min PWV (m/s) 6.45 ± 0.82* 6.27 ± 0.83* 0.14 4.8 
1 min  FMSABS (m/s) -1.19 ± 0.59 -1.27 ± 0.43 0.47 18.4 
1 min FMS% (%) -15.22 ± 6.33 -16.95 ± 5.35 0.25 17.2 
 
  
   Baseline Diameter (mm) 3.85 ± 0.72 3.84 ± 0.71 0.71 2.2 
Peak Diameter (mm) 4.01 ± 0.71 4.00 ± 0.70 0.86 2.3 
FMDABS (mm) 0.16 ± 0.12 0.17 ± 0.11 0.58 28.1 
FMD% (%) 4.31 ± 3.36 4.55 ± 3.14 0.55 26.6 
 
  
   Baseline VTI (m) 0.045 ± 0.016 0.042 ± 0.016 0.34 15.5 
Peak VTI (m) 0.299 ± 0.071 0.292 ± 0.076 0.57 8.1 
Absolute VTI (m) 0.254 ± 0.063 0.25 ± 0.072 0.73 10.3 
RH% (%) 715 ± 187 752 ± 229 0.42 14.9 
Table 6.14: Results for both FMS and FMD studies for visits 1 and 2. P-values are for comparison between 
visit 1 and visit 2.  Reproducibility is demonstrated by CV% = coefficient of variation expressed as a 
percentage. * = significantly different from baseline pulse wave velocity (PWV), P<0.001.  For FMS studies 
two analyses of results were completed, maximum change post cuff release (max) and change in PWV at 1 
minute post cuff release (1min). Min PWV = minimum PWV post release of occlusion cuff; FMSABS = 
absolute change in PWV; FMS% = percentage change in PWV from baseline; FMDABS = absolute change in 
brachial artery diameter; FMD% = change in brachial artery diameter from baseline diameter expressed as a 
percentage; VTI = velocity time integral.  
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The results for both methods of  vasomotor function assessment are shown in table 6.14. 
There was no significant difference between visits for either technique. Following reactive 
hyperaemia both minimum PWV values for the two methods of  analysing FMS (maximum 
change and PWV at 1 minute) were significantly decreased from baseline PWV.  From table 
6.14 it can be seen that for both absolute and FMS%, a larger response was seen with taking 
the maximum change rather than change at 1 minute. Maximum change also had a lower 
CV% (Max FMS% = 7.3 % vs 1 min FMS% = 17.2 %) demonstrating better reproducibility. 
Overall the technique was very reproducible with a good CV% for the baseline PWV and a 
lower CV% than FMD in this study.  Bland-Altman plots also show good agreement for 
the measures (figure 6.19).  
 
 
Figure 6.19: Bland-Altman plots for a) baseline PWV, b) minimum change PWV, c) absolute change in PWV 
d) FMS as a percentage. = 1.96 standard deviation;  =mean difference between the two 
measures 
Interestingly, there was no correlation between the two methods of  vasomotor function 
assessment except for between max FMSABS and FMDABS for visit 2 (max FMS%/ FMD% 
V1 r = 0.27, p=0.19, max FMS%/FMD% V2 r = -0.39, p=0.05, max FMSABS/FMDABS V1 r 
= 0.14 p=0.52 & max FMSABS/FMDABS V2 r = -0.45, p = 0.022). The only association 
between FMS assessed at 1 minute and FMD was again between 1min FMSABS and FMDABS 
for visit 2 (1 min FMS%/FMD% V1 r = 0.18 p = 0.39, 1 min FMS%/FMD% V2 r =0.28 p 
=0.18, 1 min FMSABS/FMDABS V1 r = 0.08, p= 0.72 & 1 min FMSABS/FMDABS V2 r = -
0.45 p = 0.024) (figure 6.20). 
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Figure 6.20: Relationship between max FMSABS and FMDABS and max FMS% and FMD% for both visit 1 (A 
&B) and visit 2 (C&D). 
6.5.4 Discussion 
The novel finding in this section was that the oscillometric method for assessing FMS was 
very reproducible. Both maximal percentage and absolute changes in PWV were more 
reproducible than readings taken at the one-minute time point post-cuff release. The 
change in PWV at 1 minute was also lower than maximal FMS, suggesting that taking 
readings at 1 minute intervals misses the maximum change in PWV, therefore potentially 
underestimating the result. It would also partially explain why my results using maximal 
FMS are greater than those seen by Naka et al who assessed PWV 1 minute post occlusion 
cuff  release, in addition to any influence from the difference in occlusion cuff  position.   
 
FMS also had superior reproducibility to that of  FMD acquired simultaneously using 
ultrasound on the same arm in this study. Despite a very good CV% for measurement of  
baseline diameter (CV 2.2%), FMD had relatively poor reproducibility when expressed as 
both absolute and percentage change in diameter (CV 28.1% and 26.6% respectively). 
Although in the preliminary studies concurrent assessment of  FMS on the same arm did 
not appear to have a great effect on FMD, the results of  the reproducibility study suggest 
there may have been more of  an impact than expected. The repeated inflation and 
deflation of  the PWV cuffs with the resultant movement of  the artery and surrounding 
muscles may well have limited the accuracy of  measurement of  arterial diameter by 
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ultrasound during reactive hyperaemia. A CV% of  7.1% for FMD has been shown in a 
study by Donald et al which is comparable to that found for FMS in this chapter150. In the 
study by Donald et al, FMD had superior reproducibility to other non-invasive methods of  
assessing endothelial function (changes in pulse contour analysis and pulse wave analysis 
following inhalation of  salbutamol). The CV% for FMS were also smaller than these 
alternative methods (pulse wave analysis CV% 11.5%) and pulse contour analysis CV% 
18.2%), demonstrating its potential for use as a measure of  vasomotor function150. 
 
Other studies have investigated the change in PWV following a reactive hyperaemic 
stimulus as a method for assessing vasomotor function and shown good reproducibility165, 
166. However, these studies have assessed carotid to radial PWV and used different 
techniques such as applanation tonometry and mechanotransducers, to measure PWV. In 
addition, different occlusion cuff  positions have been used. For example, Kamran et al 
placed the occlusion cuff  around the upper arm, whilst Graf  et al. placed the occluding 
cuff  at the forearm, as we have done in our reproducibility study165, 166.  
 
The mixed results for associations between FMD and FMS are surprising. The lack of  
association between FMD and FMS parameters for visit one does agree with previous 
findings by Dhindsa et al.406. Donald et al also found no association between FMD and 
other measures of  endothelial function and therefore this could indicate different 
influences of  mechanical and physiological changes on diameter and stiffness of  the 
vessels walls for the different methods150.  It is unclear why visit 2 should then show an 
association between the FMSABS and FMDABS. Although Kamran et al did find a similar 
relationship between FMD and change in PWV expressed as a percentage167. The numbers 
in this study are relatively small and therefore the findings may be due to chance and would 
therefore comparisons of  these two methods would benefit from being carried out in 
larger populations.    
 
6.5.4.1 Limitations  
One limitation of  this study is due to the repositioning of  the occlusion cuff  to just below 
the medial epicondyle and therefore above the lower PWV measurement cuff. This 
repositioning may impact on the mechanisms which underpin the changes in vascular tone. 
It has been shown in FMD studies that when the cuff  is positioned just below the elbow, 
the resultant dilatation is mediated by NO. However, when an upper arm occlusion cuff  
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position is used, the change in diameter is not purely mediated by NO, and as such other 
factors may also be contributing to the reduction in PWV in response to hyperaemia149. 
This limitation could be overcome if  the software on the Vicorder was developed to allow 
the lower PWV measurement cuff  to also be used as the occlusion cuff. 
6.5.4.2 Conclusion 
In conclusion, it has been shown in this chapter that FMS is a highly reproducible 
technique and has potential to become a useful tool for the assessment of  vasomotor 
function. Further validation studies are needed to explore its ability to detect differences in 
vasomotor function in those with a cardiovascular risk factors and following interventions 
which are known to alter endothelial function. 
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Chapter 7. Flow-mediated slowing and 
familial hypercholesterolaemia 
 
7.1 Introduction 
In the previous chapter I have developed the protocol for FMS and demonstrated that it is 
a reproducible technique.  To further validate this method it now needs to be tested in a 
population of  patients that have previously been shown to have diminished endothelial 
function. 
 
Familial hypercholesterolaemia (FH) is a common autosomal dominant disorder of  
lipoprotein metabolism. There are a number of  causes; most commonly it is due to 
mutations in the LDL receptor gene, which decrease the function or numbers of  the 
receptors.  Genetic abnormalities have also been found in the apolipoprotein B gene, 
reducing interactions between the receptor and LDL, and in the PCSK9 gene, which 
increases the rate of  turnover of  the LDL receptor75. In response to these mutations, the 
liver’s capacity to catabolise LDL in a regulated manner is impaired, prolonging the length 
of  time these atherogenic lipoproteins remain in the plasma, and increasing their 
propensity to undergo oxidation and other chemical modification.  These LDL particles 
pass through the endothelium into the subendothelial space, where they are retained, or are 
taken up by macrophages leading to the formation of  cholesterol-laden foam cells. This 
therefore promotes the rapid development of  atherosclerotic disease.   
 
Patients can either have two defective alleles (homozygous) or just one (heterozygous). 
Homozygous FH is relatively rare, but patients tend to have dramatically elevated high total 
and LDL cholesterol levels, resulting in accelerated atherosclerosis, supra valvular aortic 
stenosis and are at very high risk of  dying prematurely76.  Heterozygous FH is relatively 
milder and far more common affecting 1 in 500 of  the population, although more recent 
analyses have found this to be as high as 1 in 25077. Patients are still at a greater risk of  
rapid development of  atherosclerosis, typically presenting clinically at a much earlier stage 
in life than those without FH76. 
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Previous work has shown the presence of  endothelial dysfunction in conduit arteries 
(including by assessment of  flow-mediated dilatation [FMD]) and the microcirculation in 
both adults and children with FH92, 139, 405, 407, 408.  The effects of  increased LDL are both 
complex and multifactorial, but, may in part, be due to direct effects of  oxidised and 
modified LDL on endothelial nitric oxide synthase and nitric oxide production409, 410.  In 
addition, other changes that occur in the vessel wall, such as lipoprotein-endothelial 
activation and the uptake of  lipoproteins by macrophages, causes the activation of  
inflammatory processes and increased oxidative stress, which also lead to endothelial 
dysfunction9, 411, 412. Therefore, diminished endothelial function as assessed by FMD has 
previously been shown in those with FH, this would be an interesting group to study to 
test whether differences in vasomotor function could be seen in FMS and compared with 
FMD. 
 
7.2 Aims 
Aim: To investigate whether FMS is able to detect vasomotor dysfunction in a group of  
patients with a cardiovascular risk factor known to cause endothelial dysfunction. 
 
Hypothesis: FMS is able to detect vasomotor dysfunction in those with FH when 
compared with a group of  healthy matched control subjects. 
 
7.3 Methods 
7.3.1 Subjects 
FH patients who met the Simon Broome criteria (as described in Chapter 1) were recruited 
through the FH cascade database or when attending lipid clinics at the University Hospital 
of  Wales and University Hospital Llandough78.  Healthy controls were recruited from staff  
and the local area. Those FH patients on vasoactive medication were asked to not take 
them on the morning of  the study. Patients were not requested to stop lipid lowering 
therapy. 
7.3.2 Pulse wave analysis  
Pulse wave analysis was assessed with the Vicorder (software version 5.04) with the 
participants seated.  A Hokanson SC10 cuff  was positioned on the study arm and blood 
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pressure was assessed.  The cuff  was then inflated to diastolic pressure and augmentation 
index and pressure were measured. Two readings were accepted which had differences in 
augmentation pressure (AP) of  ≤5 mmHg and augmentation index (AIx) of  ≤5%, the 
mean of the two readings was then taken as the result. 
 
7.3.3 Pulse wave velocity 
Central PWV was assessed using the Vicorder; with the patients lying semi supine at an 
angle of  approximately 30o to reduce venous interference.   A narrow cuff  was positioned 
around the neck with the bladder placed over the site of  the right carotid artery. A second 
cuff  (Hokanson SC10) was wrapped tightly around the upper right thigh over the femoral 
artery. Path length was measured from the supra sternal notch to the middle of  the thigh 
cuff  using a tape measure, care was taken not to follow the contour of  the body. Having 
entered the path length into the Vicorder both cuffs were then inflated to 65mmHg. Once 
good quality waveforms were acquired the signal was saved and a repeated measurement 
made.  Two readings with a difference of  in PWV ≤0.5m/s were averaged for the final 
result. 
7.3.4 Flow-mediated slowing 
FMS was assessed as previously described in the reproducibility study in Chapter 6.  Three 
cuffs were positioned around the study arm as shown in figure 7.1.  The outer two cuffs 
were to assess PWV whilst the middle cuff  occluded the vessel for 5 minutes to induce 
reactive hyperaemia. The distance between the two outer cuffs was measured using a tape 
measure from mid point to mid point and entered into the Vicorder.  PWV was assessed 
for 5 minutes for a baseline reading prior to occlusion and recorded for a further 10 
minutes following cuff  deflation.  Data was analysed as previously described. 
7.3.5 Flow-mediated dilatation 
The right brachial artery was imaged using an ultrasound probe; a Doppler cursor was 
positioned in the centre of  the artery image to assess changes in flow.  The same cuff  was 
used for the 5 minute occlusion period as for FMS (see figure 7.1). Baseline images were 
recorded 1 minute before inflation of  the occluding cuff  continuously until 5 minutes post 
cuff  release. Images were analysed and changes calculated as described in Chapter 6. 
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Figure 7.1: Diagram of cuff and ultrasound probe placement for assessment of endothelial function by FMS 
and FMD.       = occlusion cuff       = PWV cuffs        =ultrasound probe 
7.3.6 Bloods 
Blood samples were collected for assessment of  total cholesterol, high density lipoprotein 
(HDL), Triglycerides, low density lipoprotien (LDL), total-HDL ratio and fasting glucose. 
All samples were analysed at the Clinical Biochemistry laboratory at University Hospital 
Wales.  
 
Serum was prepared by centrifugation of  blood at 4000 rpm for 8 minutes and stored at -
30°C prior to analysis. Total cholesterol, HDL, and triglycerides were assayed using an 
Aeroset automated analyser (Abbott Diagnostics, Berkshire, UK); LDL was calculated 
using Friedewald’s formula and glucose was measured using the Aeroset chemistry system 
[Abbott Diagnostics, Berkshire, UK].The intra- and inter-assay coefficients of  variation 
were all less than 9%. 
 
7.3.7 Protocol 
Subjects attended the Wales Heart Research Institute having fasted overnight.  Participants 
were consented and completed a medical history form to check they were eligible for the 
study.  A blood sample was taken from the left arm to test lipids and fasting glucose levels.  
Height and weight were measured.   
 
Participants then underwent arterial stiffness assessment. Subjects then rested seated for 5 
minutes before blood pressure was assessed followed by PWA using the Vicorder. This was 
followed by assessment of  aortic PWV.   
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Vasomotor function was then assessed. Participants rested supine for 10 minutes and two 
blood pressure measurements were taken using an automatic sphygmomanometer (Omron 
705IT).  Blood pressure was repeated before and after both vasomotor function 
assessments.  FMD and FMS were simultaneously assessed on the right arm as described 
above.   
 
7.3.8 Analysis 
Power calculations had suggested that with α=0.05 and a required Power of  0.8 (80%) and 
σ=5%, a sample of  at least 20 was required to detect a difference in FMS between the two 
groups. 
 
Variables were checked for normality using the Shapiro-Wilk test.  Relationships between 
healthy controls and patients with FH were tested using either an independent samples t-
test or the independent samples Mann-Whitney U test.  Spearman correlations were used 
to look at associations between FMS and FMD and risk factor variables. SPSS version 20 
was used for the analysis. Data is presented as mean ± SD unless otherwise stated. 
 
7.4 Results 
The key finding in this section was that FMS was lower in those patients with FH 
compared with controls. There were no differences in FMD (obtained concurrently with 
FMS) observed between the two groups. 
 
Characteristics FH Control p 
Age (years) 49 ± 11 48 ± 11 0.75 
Gender (M:F) 10:12 10:12 
 
BMI (kg/m2) 28.11 ± 3.69 25.34 ± 2.76 0.007 
TC (mmol/L) 5.72 ± 1.54 5.01 ± 0.83 0.06 
LDL (mmol/L) 3.83 ± 1.53 3.07 ± 0.77 0.08 
Trigs (mmol/L) 1.36 ± 0.97 0.96 ± 0.44 0.037 
non-HDL (mmol/L) 4.46 ± 1.62 3.52 ± 0.8 0.021 
HDL (mmol/L) 1.26 ± 0.32 1.49 ± 0.50 0.07 
TC/HDL 4.9 ± 2.23 3.78 ± 1.61 0.023 
TG/HDL 1.22 ± 1.08 0.89 ± 1.05 0.016 
FGluc (mmol/L) 4.96 ± 0.53 5.04 ± 0.39 0.37 
Table 7.1: Patient characteristics and lipid profiles for the two groups. TG/HDL = triglycerides – high 
density lipoprotein ratio 
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Table 7.1 shows the patient characteristics for the two groups.  The healthy control group 
had significantly lower BMI, non-HDL, total cholesterol to HDL ratio and triglycerides to 
HDL ratio than FH patients.  HDL was higher in the control group and the remaining lipid 
parameters were lower but these did not reach significance. All but two FH patients were 
on lipid lowering therapy.  Of  the treated patients all were on statin therapy, with 8 also 
taking ezetimibe, 1 on a fibrate and 3 patients taking ezetimibe and a resin.  Three patients 
had evidence of  cardiovascular disease, either from an event or having had bypass surgery. 
 
  FH Control p 
SBP (mmHg) 138 ± 17 123 ± 14 0.007 
DBP (mmHg) 80 ± 10 75 ± 8 0.07 
PP (mmHg) 57 ± 14 48 ± 10 0.009 
HR (bpm) 57 ± 7 57 ± 8 0.99 
Central SBP (mmHg) 132 ± 17 117 ± 13 0.006 
Central PP (mmHg) 52 ± 14 42 ± 10 0.013 
AP (mmHg) 11.86 ± 7.62 7.89 ± 4.73 0.06 
AIx (%) 21.50 ± 7.63 18.00 ± 8.78 0.17 
Aortic PWV (m/s) 7.4 ± 0.77 6.85 ± 0.82 0.06 
Table 7.2: Seated blood pressure and measurements of arterial stiffness. 
 
Three FH patients were on blood pressure medications but had not taken them on the 
morning of  the study.  All blood pressure and measurements of  arterial stiffness were 
lower in the healthy control subjects when compared with the FH patients.  However, only 
peripheral systolic pressure, pulse pressure and central systolic and pulse pressure reached 
significance as can be seen in table 7.2. 
 
 
 
FH HC p 
Room temp (°C) 23.1 ± 1.2 22.4 ± 1.4 0.12 
Skin temp (°C) 31.4 ± 1.8 31.4 ± 1.9 0.98 
SBP (mmHg) 127 ± 17 116 ± 12 0.016 
DBP (mmHg) 74 ± 10 70 ± 9 0.12 
HR (bpm) 59 ± 7 56 ± 9 0.30 
Table 7.3: Room and skin temperature and supine blood pressure assessed prior to vasomotor function 
assessment. 
 
Room and skin temperature did not differ significantly between the two groups (table 7.3). 
Only supine systolic blood pressure was significantly higher in the FH group than the 
control group.  
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  FH Control p 
BL dia (mm) 3.59 ± 0.60 3.56 ± 0.61 0.86 
Pk dia (mm) 3.75 ± 0.63 3.72 ± 0.63 0.89 
FMDABS (mm) 0.16 ± 0.07 0.16 ± 0.11 0.98 
FMD% (%) 4.33 ± 1.64 4.68 ± 3.04 0.90 
BL VTI (m) 0.045 ± 0.010 0.042 ± 0.015 0.54 
Pk VTI (m) 0.349 ± 0.075 0.328 ± 0.101 0.43 
Absolute RH (m) 0.304 ± 0.069 0.286 ± 0.091 0.45 
RH% (%) 796 ± 159 816 ± 234 0.74 
Table 7.4: FMD and blood flow measurements for FH and healthy control participants. FMD =Flow-
mediated dilatation. 
There was no difference in brachial artery baseline diameter between the two groups (FH 
3.59 ± 0.60 vs HC 3.56 ± 0.61 mm p=0.86). Both baseline velocity time integral and 
reactive hyperaemia were similar between FH and control subjects (table 7.4). FMD did not 
differ significantly between FH patients and the age and gender matched controls (see 
figure 7.2). 
 
 
Figure 7.2: FMD results for FH and healthy controls mean ± SEM   
 
  FH Control p 
BL PWV (m/s) 7.74 ± 0.79 8.15 ± 0.93 0.12 
Min PWV (m/s) 6.55 ± 0.54 6.63 ± 0.71 0.66 
FMSABS (m/s) -1.20 ± 0.49 -1.52 ± 0.53 0.023 
FMS% (%) -15.13 ± 5.04 -18.41 ± 5.15 0.023 
Table 7.5: FMS results for FH and healthy controls. 
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Baseline PWV was similar between the two groups (table 7.5). FMSABS was greater in the 
healthy controls compared to the FH patients (-1.52 ± 0.53 vs -1.20 ± 0.49 p=0.023).  
FMS% was also lower in the FH group than the healthy controls as shown in figures 7.3 and 
7.4.  
 
Figure 7.3: Individual results for FMS% for FH patients and matched controls 
 
Figure 7.4: FMS% results for FH patients and matched controls mean ± SEM    
 
There were no correlations between FMD and FMS variables within FH or control groups 
or when both groups were combined.  Within the FH group, FMDABS was positively 
correlated with BMI and TG/HDL ratio (r=0.45 p=0.034 & r=0.46 p=0.033 respectively) 
and negatively correlated with HDL (r=-0.55 p=0.008) as was FMD% (r=-0.49 p=0.048).  
There were no associations with FMS variables in this group. In the healthy control both 
FMSABS and FMS% were negatively correlated with TG/HDL ratio (r=-0.49 p=0.021 & r=-
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0.43 p=0.046 respectively) and positively correlated with fasting glucose (r=0.47 p=0.029 & 
r=0.48 p=0.023 respectively). FMS% was also negatively associated with HR (r=-0.45 
p=0.035).  FMDABS and FMD% were not correlated with any risk factor variable in the 
healthy control group.  
 
7.5 Discussion 
The aim of  this chapter was to investigate whether it is possible to detect a difference in 
vasomotor function using the FMS method in a group of  patients with FH, a condition in 
which endothelial dysfunction is well recognised. The novel finding of  this study was that 
vasomotor function, as determined by FMS, was diminished in patients with FH. Both 
FMSABS and FMS% were significantly lower in the FH group than the control group, in this 
study.  However, there was no difference in FMD between the two groups. The finding of  
poorer vasomotor function in patients with FH does agree with previous findings139, 405, 407. 
This work also adds to that of  Naka et al and Pegge et al who found that the reduction in 
PWV following reactive hyperaemia was diminished in chronic heart failure and diabetes 
patients164, 171. Furthermore, other groups who have used a similar approach, but with 
different assessment techniques, have shown reduced slowing of  PWV following reactive 
hyperaemia, in patients with hypertension and other risk factors 165, 167, 170, 413. The finding of  
diniminshed vasomotor function in this study therefore demonstrates the potential of  this 
method for identifying changes/differences in vasomotor function in people with 
cardiovascular risk factors. Whether or not the differences seen in this study are clinical 
significant requires further studies with hard clinical outcomes.  In addition, clinical cut off  
values of  vasomotor dysfunction, which may help identify those at increased cardiovascular 
risk, have not been determined for this method and would be of  interest to determine in 
future prospective studies.  
 
The lack of  difference in FMD between the two groups may be due to the impact of  
concurrent assessment of  FMS. This does impact on the reproducibility of  FMD, as 
reported in the previous chapter, so could be expected to decrease the sensitivity and 
power of  the measure. It may also be that the two methods assess different vasomotor 
pathways. Additionally, the FH patients in this study are an actively managed group and the 
majority were on statin therapy, which is known to improve endothelial function98. This 
may account for the lack of  difference in FMD between the FH patients and controls. 
However, we were still able to detect a decrease in FMS, indicating that either alternative 
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pathways are involved, or the concurrent assessment of  the two techniques diminished the 
power of  FMD in this study. 
 
Peripheral blood pressure and central pressure were significantly greater in the FH group. 
Although aortic PWV and augmentation pressure and index were all greater in magnitude 
in the FH group, these differences only trended towards statistical significance. Both aortic 
PWV and augmentation index have been shown to be increased in people with 
hypercholesterolaemia but statin therapy does decrease both aortic PWV and augmentation 
index which may account for the borderline significance of  these two variables in my 
study93, 414, 415. In addition, these measures were not the primary outcome of  the study and 
as such the study may have been underpowered to see a significant difference in these 
measures. 
 
A limitation of  this study is the lack of  comparison of  the two techniques with 
endothelium independent vasodilatation through the administration of  the NO donor 
glyceryl trinitrate (GTN). Naka et al had previously demonstrated that the reduction in 
PWV following administration of  GTN was similar in chronic heart failure patients and 
controls (9.0% and 8.8% p=0.95), demonstrating a maintained smooth muscle function in 
these patients164. Also, the main aim of  this study was the comparison of  FMS with FMD 
as a practical measure of  vasomotor function in response to reactive hyperaemia, which is 
more consistently associated with cardiovascular physiology than endothelium independent 
vasodilatation responses.  
 
Both FMS and FMD are likely to be influenced by external environmental factors and 
other factors such as infection and medications, although we tried to control for these as 
far as possible, using a range of  accepted recommendations, there may have been some 
influence from external factors on the study results. 
 
It would also have been interesting to use multiple regression to identify factors 
independently associated with FMS. However, theses analyses were not carried out in this 
study as it is a relatively small cohort, with well treated FH patients, and therefore would 
have had limited power and be less likely to demonstrate clinically meaningful relationships. 
 
It is also worth noting that although the FH group did have higher TC and LDL, they were 
not significantly greater than the control group. This indicates that the participants with FH 
were clinically well managed and this may have had an impact on the results seen in this 
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chapter, although vasomotor dysfunction was still identifiable as indicated by the reduced 
FMS response. 
 
7.5.1 Conclusion 
In conclusion, differences in vasomotor function as assessed by FMS were detectable in a 
stable group of  patients with FH, when compared with age and gender matched controls.  
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Chapter 8. Lipoprotein apheresis and 
flow-mediated slowing in patients with 
familial hypercholesterolaemia 
 
8.1 Introduction 
In the preceding chapter, it was demonstrated that flow-mediated slowing (FMS) was 
reduced in patients with familial hypercholesterolaemia (FH), when compared with healthy 
matched controls. To further test FMS as a method for assessing vasomotor function, I 
wanted to investigate whether this technique was also sensitive enough to detect a change 
in vasomotor function following lipoprotein apheresis (LA); an acute lipid lowering 
intervention, which has previously been shown to improve endothelial function.  
 
Statin therapy has been very effective at reducing and controlling LDL levels in patients 
with FH96.  However, some patients are unable to tolerate the treatment, are resistant to 
multi-modality treatment and maintain persistently high LDL levels or have progressive 
coronary artery disease despite maximal therapy104. LA is an extracorporeal treatment akin 
to renal dialysis, which is used to remove atherogenic lipoprotein particles from the 
circulation, providing an alternative treatment for lowering LDL levels.  There are a 
number methods used for extracting LDL using an extracorporeal circulatory process; 
these include the use of  a dextran sulphate-cellulose column and a non-haemolytic column 
(DALI). 
 
In addition to reducing LDL cholesterol levels, long term use of  lipoprotein aphereis 
treatment has been demonstrated to reduce the progression of  atherosclerosis and to 
improve outcome and survival111.  Koziolek et al carried out a retrospective analysis of  10, 
906 lipoprotein apheresis sessions and found that major cardiovascular events (death, 
cerebrovascular accident, myocardial infarction, limb amputation and end-stage renal 
failure) reduced from 7.02% events per patient per year at the beginning of  treatment to 
1.17% during treatment.  Myocardial revascularisation rates also decreased from 22.8% to 
3.8% per patient per year111. 
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One possible reason for these reductions in cardiovascular events may be the improvement 
and preservation of  endothelial function. Studies in patients with FH or high cholesterol 
have shown diminished endothelial function in both the peripheral and coronary 
circulation, as we have also found and reported on in the previous chapter89-91. This may in 
part, be due to inflammation, increased oxidative stress and inhibition of  nitric oxide 
synthase379, 410, 412. Vasodilatory function can be improved acutely in both the 
microvasculature and the coronary circulation following a single session of  lipoprotein 
apheresis treatment in FH patients113, 114, 116.   However, only one study has looked at the 
effect of  LA treatment on FMD in FH patients117. They found that FMD was similar in 
patients, who had been on LA treatment for 3 to 5 years, and age and gender matched 
controls, however, there was no change in FMD immediately following treatment. It is 
worth noting that the study only consisted of  6 patients and so may have been 
underpowered to detect a difference.  This finding also contrasts with Mellwig et al, who 
found an acute improvement in coronary vasodilatory responses to dipyridamole post- 
HELP apheresis  (as assessed using cardiac positron emission tomography) in both patients 
on long term apheresis and those undergoing their initial treatment115. Acute LA treatment 
could therefore be a useful clinical model to investigate whether FMS is able to detect an 
immediate improvement in vasomotor function. 
8.2 Aim 
Aim: to investigate the effect of lipoprotein apheresis treatment on vasomotor function as 
assessed by flow-mediated slowing.   
 
Hypothesis:  an improvement in vasomotor function will be detectable by flow-mediated 
slowing. 
8.3 Methods 
8.3.1 Subjects 
12 patients who attend the Lipid Apheresis Unit at University Hospital Llandough were 
recruited.  Patients attend the unit once a fortnight for their treatment, so the study was 
fitted around their normal treatment day. Patients were asked to attend having fasted 
overnight, and to refrain from taking any vasoactive medications.  All patients had 
heterozygous FH, 10 had been shown to have genetic mutations. 
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8.3.2 Pulse wave analysis and aortic pulse wave velocity 
These were assessed as described in Chapter 7. 
8.3.3 FMS 
FMS was assessed as previously described.  Three cuffs were positioned around the study 
arm as shown in figure 8.1.  The outer two cuffs were to assess PWV whilst the middle 
cuff  occluded the vessel for 5 minutes to induce reactive hyperaemia. The distance between 
the two outer cuffs was measured using a tape measure from mid point to mid point and 
entered into the Vicorder.  PWV was assessed for 5 minutes for a baseline reading prior to 
occlusion and recorded for a further 10 minutes following cuff  deflation.  Data was 
analysed as previously described. 
 
 
 
Figure 8.1: Diagram of cuff placement for FMS assessment of endothelial function.       = occlusion cuff     
= PWV cuff    
8.3.4 Blood samples 
Blood samples were collected for assessment of  total cholesterol (TC), high density 
lipoprotein (HDL), Triglycerides (Trigs), low density lipoprotein (LDL), TC-HDL ratio and 
high sensitivity C-reactive protein (hsCRP). Lipid parameters were measured by the Clinical 
Biochemistry laboratory at University Hospital Llandough and hsCRP was analysed at the 
Clinical Biochemistry laboratory University Hospital Wales. The lipid samples were 
analysed as described in Chapter 7. hsCRP was assayed by nephelometry (BNTM II system, 
Dade Behring, Milton Keynes, UK). 
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8.3.5 Lipoprotein apheresis treatment  
 Direct adsorption of  lipoproteins (DALI)  
 The DALI system, (Fresenius Medical Care, Germany) adsorbs LDL directly from whole 
blood.  Blood was perfused through an adsorber containing polyacrylate beads which 
consist of  polyanions with negative charges which attract the cationic groups of  
apolioprotein B-rich lipoproteins.  A 15-17 gauge backeye needle was inserted into the 
patient’s vein.  The machine was primed with 20000 units of  heparin for anticoagulation; 
acid citrate dextrose solution was then continuously infused into the blood line as it exited 
the patient’s vein. Two sizes of  adsorber were used for the treatment, 750 and 1000ml.  
Blood flow was in the range of  60 -75ml/min and 5.5-7.5L of  whole blood were treated 
per session. 
 
Liposorber LA-15  
The LA-15 (Kaneka, Japan) separates the plasma from the whole blood. It consists of  two 
columns of  cellulose beads covalently bound with dextran sulphate to selectively adsorb 
ApoB-rich lipoproteins from plasma. The two columns were used alternately, as one was 
operated for apheresis the other was regenerated with a solution of  hypertonic sodium 
chloride. Heparin was used to prime the system (5000 units) and then infused at 1.3ml -
1.5ml/hr for anticoagulation.  Plasma flow rate ranged from 50-75ml/min with 3-4L of  
plasma processed. The blood was returned to the patient through a second needle in either 
the same or other arm. 
 
LiposorberD 
The LiposorberD system (Kaneka, Japan) takes the whole blood from the patient and uses 
heparin (5000 units) for priming and acid citrate solution as an anticoagulant.  Whole blood 
was pumped through the dextran sulphate column where the ApoB-rich lipoproteins are 
removed.  Once the lipids were removed the blood was returned to the patient. Blood flow 
was up to 110ml/min with 12L of  whole blood treated in the session.    
 
8.3.6 Protocol 
Patients were consented on arrival at the unit, and height and weight were measured.  
Patients were asked which arm was normally used for their apheresis treatment and the 
non-treatment arm was used for measurements. Where both arms were used for treatment, 
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the right arm was used unless there were old fistulas present.   Vascular assessment was 
carried out in a temperature controlled room prior to apheresis. Subjects then had two 15 
to 17 gauge backeye needles positioned, as per their usual clinical care.  Blood samples were 
taken immediately from one of  the needles for clinical purposes, including lipid parameters. 
An additional sample was taken for assessment of  hsCRP. Subjects then underwent their 
standard apheresis treatment.  Blood samples were repeated at the end of  treatment. A 
second vascular assessment was undertaken following the treatment after a period of  
acclimatisation (see figure 8.2). 
 
 
Figure 8.2: Protocol for the investigation of the effect of lipoprotein apheresis on vasomotor function 
assessed using flow-mediated slowing. 
8.3.7 Analysis 
A power calculation estimated that a sample size of  12 (two-sample t-test, α=0.05 and a 
required power of  0.8 (80%) would be needed to see a significant change in FMS following 
apheresis treatment. 
 
Data were checked for normality using the Shapiro-Wilk test.  Differences between 
variables before and after LA were tested using either a paired t-test or a related samples 
Wilcoxon-signed rank test depending on whether the data was normally distributed or not. 
Pearson and Spearman correlations were used to look at the associations between lipid and 
inflammatory parameters with FMS responses.  Data are presented as mean ± SD unless 
otherwise stated.  
 
8.4 Results 
The novel finding in this section was that vasomotor function as assessed by FMS in the 
peripheral circulation was improved by a single LA treatment. 
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Table 8.1 shows the patient characteristics.  As can be seen ten patients were on statins and 
three were on nitrate medications. Further clinical information on the participants is in 
appendix 2.  Participants had been asked to fast and if  possible to avoid taking vasoactive 
medications on the morning of  the study. Two patients had a light breakfast at least 4 
hours prior to testing, whilst two participants had taken their blood pressure medications 
on the morning of  the study.  
 
Characteristics n=12 
Age (years) 58 ± 10 
Gender (M:F) 9:3 
BMI (kg/m2) 30 ± 4 
SBP  (mmHg) 140 ± 18 
DBP (mmHg) 82 ± 10 
Statins 
 
             Rosuvastatin 6/12 
             Atorvastatin 4/12 
Nitrates 3/12 
Diabetes 6/12 
Presence of coronary disease .10/12 
Table 8.1: Patient characteristics and medications 
 
The patients were being treated using three different LA systems (DALI n=8, LA-15 n=3 
& LiposorberD n=1). Average treatment time was 2 hrs 37 mins, ranging from 1 hour 55 
mins to 3 hours 40 mins. 
 
  Pre LA Post LA p-value 
TC (mmol/L) 6.05 ± 1.57 2.72 ± 0.84 <0.001 
LDL (mmol/L) 4.08 ± 1.44 1.37 ± 0.65 0.002 
Trigs (mmol/L) 1.77 ± 0.57 0.89 ± 0.34 <0.001 
NonHDL (mmol/L) 4.90 ± 1.40 1.78 ±0.56 0.002 
HDL (mmol/L) 1.15 ± 0.47 0.94 ± 0.46 0.002 
TC/HDL 5.82 ± 2.09 3.38 ± 1.66 0.002 
Trigs/HDL 1.95 ± 1.68 1.47 ± 1.87 0.003 
hsCRP (mg/L) 2.31 ± 4.65 1.76 ± 3.83 0.002 
Table 8.2: Lipid and hsCRP measures before and after LA treatment. Trig/HDL = triglycerides – high 
density lipoprotein ratio. 
 
Table 8.2 shows the changes in the lipid profile of  the participants. All lipid parameters and 
hsCRP decreased significantly following treatment.   
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  Pre LA Post LA p-value 
AIx(%) 23.9 ± 6.0 23.0 ± 8.7 0.82 
AP (mmHg) 13± 5 14 ± 7 0.59 
Central SBP (mmHg) 137 ± 17 143 ± 17 0.06 
Central PP (mmHg) 54 ± 12 60 ± 12 0.09 
Aortic PWV (m/s) 9.2 ± 2.5 8.7 ± 3.0 0.30 
FMS SBP (mmHg) 143 ± 25 143 ± 23 0.93 
FMS DBP (mmHg) 79 ± 9 78 ± 9 0.91 
FMS HR (bpm) 58 ± 10 63 ± 13 0.027 
Table 8.3: Results for measures of arterial stiffness, blood pressure and heart rate pre and post LA treatment  
There was no difference in room and skin temperature before the pre and post apheresis 
FMS studies (room temperature 24.5 ± 0.8 oC vs 24.9 ± 0.6 oC p=0.07 and skin 
temperature 31.3 ± 2.1 oC vs 30.3 ± 1.4 oC p=0.17 )  Augmentation index and pressure 
were unaffected by LA treatment as was aortic PWV (table 8.3). Central blood pressure 
increased slightly post-treatment, but this did not reach significance.  Heart rate rose 
following apheresis treatment (58 ± 10 bpm vs 63 ± 13 bpm, p=0.027).    
 
 
BL PWV (m/s) Min PWV (m/s) FMSABS  (m/s) FMS% (%) 
Pre LA 8.75 ± 1.18 7.06 ± 1.00 -1.69 ± 0.92 -18.81 ± 9.84 
Post LA 9.16 ± 1.18 6.92 ± 0.91 -2.24 ± 0.91 -24.09 ± 7.61 
Difference 0.41 -0.14 -0.55 -5.28 
Percentage change (%) 
  
32.54 28.07 
p-value 0.19 0.53 0.015 0.016 
Table 8.4: FMS results for pre and post LA treatment. P-value is for the difference between the pre and post 
values.  . 
Baseline PWV did not change significantly between the two measurements (pre LA 8.75 ± 
1.18 m/s & post LA 9.16 ± 1.18 m/s, p=0.19).  FMSABS did improve after apheresis 
treatment (table 8.4). As can be seen in figure 8.3, FMS% increased significantly by 28% 
following LA treatment (p=0.016). Two participants did not withhold their vasoactive 
medication on the morning of  the study.  When the analysis was repeated with these two 
participants excluded the improvement in FMS remained significant (FMSABS p=0.028 & 
FMS% p=0.028). 
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Figure 8.3: FMS before and after LA treatment (mean ± SEM) 
In figure 8.4 it can be seen that FMS% increased in the majority of  participants following 
LA treatment. A slight decrease in FMS% response was seen in three participants. 
 
Figure 8.4: Individual FMS responses before and after LA treatment 
 
 
BL  PWV 
 (m/s) 
 Min PWV  
(m/s) 
 FMSABS  
(m/s) 
 FMS%  
(%) 
   
  r p 
 
r p 
 
r p 
 
r p 
TC (mmol/L) -0.15 0.65 
 
0.04 0.91 
 
0.23 0.47 
 
0.25 0.43 
LDL (mmol/L) -0.120 0.54 
 
-0.10 0.76 
 
0.15 0.65 
 
0.15 0.63 
Trigs (mmol/L) -0.39 0.21 
 
-0.22 0.49 
 
0.26 0.42 
 
0.23 0.48 
NonHDL (mmol/L) -0.28 0.38 
 
-0.14 0.67 
 
0.21 0.52 
 
0.20 0.52 
HDL (mmol/L) 0.29 0.35 
 
0.35 0.26 
 
0.15 0.63 
 
0.30 0.34 
TC/HDL -0.36 0.25 
 
-0.42 0.18 
 
0.02 0.96 
 
-0.03 0.92 
Trig/HDL -0.57 0.05 
 
-0.52 0.09 
 
0.23 0.47 
 
0.11 0.73 
hsCRP (mg/L) 0.35 0.27 
 
0.09 0.79 
 
-0.39 0.22 
 
-0.37 0.24 
Table 8.5: Pearson and Spearman correlations between pre apheresis FMS responses and lipids and 
inflammatory parameters. 
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Correlations were used to investigate whether there were any associations between baseline 
lipid and inflammatory parameters and pre apheresis FMS responses and also between the 
change in FMS% and FMSABS and changes in lipid and inflammatory parameters. As can be 
seen in table 8.5, there were no significant correlations between baseline measures. 
 
   Change in FMSABS Change in FMS% 
  r p r p 
TC (mmol/L) -0.08 0.80 -0.06 0.86 
LDL (mmol/L) 0.02 0.95 0.03 0.92 
Trigs (mmol/L) -0.41 0.19 -0.58 0.05 
Non-HDL (mmol/L) -0.06 0.87 -0.10 0.76 
HDL (mmol/L) -0.12 0.72 -0.22 0.50 
TC/HDL 0.03 0.92 -0.06 0.85 
Trig/HDL -0.19 0.56 -0.19 0.56 
hsCRP (mg/L) 0.11 0.75 0.15 0.63 
Change in Total C (mmol/L) 0.04 0.91 0.05 0.89 
Change in LDL (mmol/L) -0.08 0.81 -0.06 0.85 
Change in Trigs (mmol/L) 0.90 <0.001 0.78 0.003 
Change in nonHDL (mmol/L) 0.03 0.93 0.08 0.81 
Change in HDL (mmol/L) 0.16 0.61 0.34 0.27 
Change in TC/HDL -0.18 0.57 -0.09 0.78 
Change in Trigs/HDL 0.38 0.23 0.26 0.41 
Change in hsCRP (mg/L) 0.32 0.31 0.01 0.97 
Table 8.6: Correlations between change in pre and post FMSABS and FMS% and lipid and inflammatory 
parameters 
As can be seen in table 8.6, there was an association between change in FMSABS and change 
in triglycerides (r=0.90 p=<0.001).  This association was also seen between change in 
FMS% and change in triglycerides (r=0.78 p=0.003).  There was a negative correlation 
between baseline triglycerides and change in FMS% but this did not quite reach significance 
(r=-0.58 p=0.05). 
 
  Diabetic n=6 Non-diabetic n=6 p 
BL PWV (m/s) 8.54 ± 1.48 8.96 ± 0.9 0.56 
Min PWV (m/s) 6.9 ± 1.39 7.22 ± 0.46 0.61 
FMSABS (m/s) -1.64 ± 1.05 -1.75 ± 0.88 0.85 
FMS% (%) -18.68 ± 12.12 -18.94 ± 8.11 0.97 
Change FMSABS (m/s) -0.84 ± 0.55 -0.26 ± 0.58 0.22 
Change in FMS% (%) -7.63 ± 7.63 -2.93 ± 4.48 0.11 
Table 8.7: Comparison of baseline FMS responses and change in absolute and percentage change FMS 
following LA in diabetic and non-diabetic patients. 
180 
 
As there were equal numbers of  those with and without diabetes an exploratory analysis 
between the two groups was carried out.  There were no differences in baseline or post 
apheresis FMS between the two groups (table 8.7). 
 
n=7 LA Healthy controls p 
BL PWV (m/s) 8.68 ± 1.11 8.00 ± 0.59 0.10 
Min PWV (m/s) 6.73 ± 0.8 6.64 ± 0.49 0.95 
FMSABS (m/s) -1.95 ± 1.11 -1.36 ± 0.25 0.14 
FMS% (%) -21.59 ± 11.89 -16.96 ± 2.53 0.23 
Table 8.8: Comparison of baseline FMS results between 7 LA patients and 7 age and gender matched 
controls. 
In a further exploratory analysis comparing a small group of  the LA patients to age and 
gender matched healthy controls there were no significant differences between baseline 
PWV or FMS variables (table 8.8).  
 
8.5 Discussion 
The major finding in this chapter was that a single treatment of  LA treatment improved 
vasomotor function as assessed by flow-mediated slowing in the brachio-radio arterial tract 
in patients with FH on chronic apheresis treatment. In agreement with previous studies a 
single session of  LA resulted in significant reductions in LDL and other ApoB containing 
lipoproteins 113, 114. A significant decrease in HDL was also found in this study in contrast to 
some studies113, 416.  
 
The finding of  improved vasomotor function is in contrast with Stadler et al, who found 
that patients on long term LA treatment had similar FMD to age and gender matched 
healthy controls and saw no additional improvement in FMD immediately after LA 
treatment117. However, their study was in a smaller number of  patients compared to ours (6 
versus 12) and therefore may not have had enough power to detect a difference in FMD 
before and after apheresis treatment.  My findings do agree with a greater body of  work 
that has shown an improvement in vasomotor function in the microvasculature and 
coronary circulation113-116. A comparison of  some of  my LA patients with age and gender 
matched controls did show that baseline endothelial function was maintained and in fact 
was higher than the controls, although this did not reach significance. Furthermore, the 
study was not powered to address this comparison. Nevertheless, this does agree with 
Stadler et al, who also found no difference in baseline FMD between apheresis patients and 
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matched controls117. However, it does suggest that long term apheresis treatment may 
improve baseline endothelial function.  In another study of  11 patients with end stage renal 
disease and peripheral arterial disease who underwent 10 sessions of  LA treatment FMD 
was improved 4 weeks after the final treatment118. This could suggest a longer term 
beneficial effect of  apheresis treatment on vasomotor function and may be one pathway 
through which LA treatment leads to a decrease in CVD in FH.  
 
The improvement in vasomotor function following LA treatment may be due to a number 
of  factors. These include the significant reduction of  LDL and oxidised LDL, increased 
expression of  eNOS mRNA in endothelial cells and the reduction of  inflammatory 
cytokines such as CRP and TNFα 116, 417 418-420.   
 
Unlike Igarashi et al who found an association between LDL and change in coronary 
endothelial function here there was no relationship between FMS and LDL but there was 
an association between change in triglycerides and change in FMS 113. Those participants 
who showed the greatest decrease in triglycerides had the most improved vasomotor 
function.  Decreased endothelial function has been shown to be associated with high levels 
of  triglycerides, although the results of  studies are varied421, 422. One study that did 
demonstrate lower FMD in those with mild to moderate hypertriglyceridaemia compared 
to matched controls also found that they had higher levels of  the eNOS inhibitor 
asymmetric dimethylarginine (ADMA)421.  Treatment of  hypertriglyceridaemia with drug 
therapy (fenofibrate) has been shown to improve endothelial function and reduce levels of  
ADMA423. The more specific reduction of  hypertriglyceridaemia by LA could have a 
beneficial effect on vasomotor function.  
 
None of  the measures of  arterial stiffness (aortic PWV, augmentation pressure and 
augmentation index) were significantly changed by LA treatment. This agrees with a 
previous study by Passauer et al who found no change in aortic PWV or augmentation 
index following a single LA treatment in 20 hypercholesterolaemia patients undergoing 
regular treatment for a minimum of  3 months120.  Similarly, Reimann et al, found no change 
in augmentation index and central blood pressure one year after baseline measurement, in 
patients with a history of  cardiovascular disease, who previously had been undergoing 
regular apheresis treatment121. PWV is predominantly a measure of  the mechanical 
properties of  the vessel wall and as such was unlikely to be changed by apheresis treatment.  
Augmentation pressure and index reflect changes in wave reflection and AIx in particular is 
dependent on the duration of  the cardiac cycle, the speed and intensity of  the pulse wave.  
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However, despite a significant increase in heart rate post apheresis treatment, there was no 
change in AIx. It is possible, that the change in heart rate was not great enough to cause 
changes in AIx, or the study had insufficient power to see a difference. 
   
There are a number of  limitations with this study. Due to time and space constraints it was 
not possible to assess flow-mediated dilatation alongside FMS as had been undertaken in 
previous chapters.  Assessment of  endothelium-independent function with glyceryl 
trinitrate would have been useful to test whether LA treatment also had beneficial effects 
on the underlying smooth muscle responsiveness to NO as well as the flow-mediated 
response.  In addition, it was not possible to check whether changes in baseline blood flow 
or reactive hyperaemia were in part responsible for the improvement of  vasomotor 
function. This is one limitation of  the FMS method in comparison with FMD as it is not 
possible to assess the flow stimulus which is driving the change in PWV. 
 
Participants were asked not to take vasodilatory medications on the morning of  the study 
to limit the effect of  these medications on their vascular function. However, two patients 
forgot to withhold this medication, so this may influence the results, although exclusion of  
these two participants did not affect these results. In addition, due to the size of  this study, 
it was also not possible to adjust for the effects of  other medications that the participants 
were taking.  
 
It would have been interesting to investigate whether the system used for LA, influenced 
the change in vasomotor responses. However, to investigate this, a larger, multicentre 
(ideally international) trial would be required, as within the UK, the number of  patients on 
LA treatment at each centre is very small, due to the nature of  the treatment and its 
expense, and is therefore limited to those in most need.   
 
The analyses exploring differences between diabetic and non-diabetic FH patients within 
the cohort, and the comparisons with age and gender matched controls, were unpowered.  
Therefore, they were very likely to be underpowered, increasing the likelihood of  type I 
and type II errors within the analysis.  These analyses are only speculative and any findings 
need to be confirmed in a properly powered study in patients with diabetes and age and 
gender matched controls. In addition, it is worth noting that this is a small study and 
although powered to detect a difference in FMS other findings may be due to chance.  A 
larger study that replicated these findings would add greater confidence that these results 
were not due to chance.  It would also have enabled multiple regression analyses to be 
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carried out allowing for adjustment of  other clinically relevant variables which may have 
influenced vasomotor function.  Finally, additional studies with prognostic outcomes would 
also enable determination of  whether the statistically significant improvement in FMS was 
of  clinical significance.   
8.5.1 Conclusion 
In conclusion, it was found that a single treatment of  LA treatment improves vasomotor 
function, as assessed by FMS, in patients with FH. This finding indicates that the technique 
is sensitive enough to be able to detect acute changes in vasomotor function.  
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Chapter 9. Summary of  section 2: 
development and validation of  flow-
mediated slowing 
 
9.1 Summary of  development and validation of  FMS 
protocol 
The aim of  the second half  of  this thesis was to demonstrate the reproducibility and 
further validate a method, flow-mediated slowing (FMS) for the assessment of  vasomotor 
function.  
 
In Chapter 6 the original protocol, described by Naka et al, was tested and found not to be 
repeatable164. I therefore developed and refined the technique.  Initial studies first looked at 
the most appropriate position for the occlusion cuff  (wrist, mid forearm or just below the 
elbow) for inducing the reactive hyperaemia.  It was found, that positioning the occlusion 
cuff  just below the elbow gave the best stimulus for assessing both FMS and flow-
mediated dilatation (FMD).  Studies looking at the most appropriate method for acquiring 
pulse wave velocity (PWV), whether using continuous cuff  inflation or intermittent cuff  
inflation, were also carried out. Intermittent cuff  inflation, which provided a reading at 
approximately 15 second intervals, was identified as being the most suitable method.  
Finally, I looked at whether concomitant assessment of  FMS and FMD on the same arm 
was possible, and concluded that it had limited impact on the resultant FMD. This initial 
body of  work resulted in identifying the most appropriate protocol for the assessment of  
FMS which included the occlusion cuff  being positioned just below the elbow, PWV 
assessed intermittently and FMD and FMS being concomitantly assessed on the same arm.   
 
Having determined the most appropriate protocol for the method, I then demonstrated the 
reproducibility of  the technique in a group of  healthy volunteers. It was shown that FMS 
was highly reproducible, when expressed either as an absolute, or percentage change 
derived from the maximal change in PWV, following the release of  the occlusion cuff.  
Naka et al, in their original study had assessed PWV at 1 minute intervals; however in our 
study this was found to be less comprehensive and less reproducible than the maximum 
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change in PWV164. The reproducibility shown for this technique was similar to other 
studies using the same principles but different techniques for assessing PWV.  Kamran et 
al, used applanation tonometry to measure carotid to radial PWV and demonstrated a 
coefficient of  variation (CV) of  12%, whilst Graf  et al, who used mechanotransducers for 
carotid to radial PWV assessment, had a CV of  9.7%165, 166. Our method was more 
reproducible than  some other potential methods of  endothelial function assessment such 
as pulse contour analysis150. 
 
In Chapters 7 and 8, the aim was to further validate the technique for assessing FMS by 
investigating whether the method was sensitive enough to detect a)  differences vasomotor 
responses in those with and without a cardiovascular risk factor, and b) changes in 
vasomotor responses following an acute intervention.  For this, two studies were carried 
out in patients with familial hypercholesterolaemia (FH), a population at very high risk of  
developing cardiovascular disease.  The first study was a case-control to investigate whether 
differences in vasomotor function could be detected between patients with FH and age and 
gender matched controls. Patients with FH were indeed found to have lower FMS 
responses than the control group.  In Chapter 8 we then assessed FMS before and 
immediately after a single lipoprotein apheresis treatment, an acute non-pharmacological 
lipid lowering therapy. An improvement in FMS was demonstrated post apheresis 
treatment in these patients. These two chapters show that this technique is sensitive enough 
to detect an impact on vasomotor function, as has been demonstrated with other 
established methods for assessing vascular physiology 91, 113, 116, 139. 
 
There are limitations with this method.  Moving the occluding cuff  to just below the elbow, 
means that approximately a third of  the arterial tract being studied is made ischaemic 
during occlusion.  In FMD studies, it has been shown that when the occlusion cuff  is 
proximal to the imaged artery, the resultant vasodilatation is not entirely NO mediated.  
This is demonstrated by the arterial response not being completely inhibited by the 
administration of  the nitric oxide synthase inhibitor L-NMMA. However, when a distal 
occlusion cuff  is used the FMD response is abolished89, 149.  It is therefore possible that the 
observed slowing in PWV following reactive hyperaemia is not fully mediated by NO. 
Thus, although this specific protocol is likely to reflect endothelium dependent vasomotor 
responses to increased shear stress, the specific mechanisms and whether it is NO-
dependent is unclear at this time.  Future work would ideally look at combining the lower 
PWV cuff  and the occlusion cuff  into one to remove this problem.  In addition, studies 
comparing FMS responses prior to and post administration of  L-NMMA and other 
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endothelial vasodilator pathway inhibitors such as tetraethylammonium would help to 
answer this question. It is also worth noting, that whilst Naka et al demonstrated the effects 
of  acetylcholine and L-NMMA on PWV in the arm, they did not evaluate its effect on 
changes in PWV with reactive hyperaemia164. 
 
Another limitation of  the method is that it does not provide detailed information regarding 
the flow stimulus which can be measured in FMD studies.  Differences in reactive 
hyperaemia between groups with risk factors for cardiovascular disease are not common as 
was shown in those with and without FH Chapter 7, although differences may be seen at 
more advanced stages of  disease. This may potentially limit the methods used for detailed 
mechanistic studies of  vascular function, particularly in groups with advanced diseases. 
However, it is well placed, due to its ease of  use and relatively low cost and consequent 
scalability, to be used as a global indicator of  vasomotor function for use in large 
population studies, early stage disease groups and, potentially, clinical trials.  
 
Together the studies in these three chapters demonstrate that FMS is a highly reproducible 
method for the assessment of  vasomotor function and is sensitive enough to detect 
differences in vascular function in response to disease and following an acute intervention. 
This simple and reliable technique is an accessible method for assessing vascular function 
which can provide clinically relevant and complementary information in addition to other 
non-invasive methods.   
 
Future work would potentially involve incorporating the protocol into the Vicorder system 
software allowing it to be run directly from the computer. An advantage of  this would be 
the ability to use the lower cuff  for both PWV assessment and occlusion of  the arm to 
induce reactive hyperaemia. By decreasing the number of  cuffs, and removing the need for 
an external cuff  inflator, this would streamline the study process reducing the cost and 
complexity of  the technique and importantly, it would mean that part of  the arterial tract 
being studied was not being made ischaemic. Work has begun on this in partnership with 
Skidmore Medical and it is intended to carry out trials of  this software. Further studies also 
need to be carried out in different disease groups, larger populations, and to explore the 
ability to detect changes with other interventions known to affect endothelial function such 
as ischaemia reperfusion, acute mental stress and a high fat meal. To extend the work 
within the FH population it would also be interesting to see whether other lipid lowering 
therapy such as statins and emerging lipid lowering drugs also improve FMS. 
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Chapter 10. General summary and 
conclusions 
 
The aims of this thesis were: Firstly, to investigate the associations between both chronic 
and acute stress and endothelial function, as well as between chronic stress and structural 
vascular disease; Secondly to develop, refine and validate a new technique for the 
assessment of vascular endothelial function that could be more suitable for large scale use 
by researchers (and potentially clinicians) outside of the setting of a specialist vascular 
laboratory. 
 
The first half of this thesis explored the relationships between both chronic and acute 
mental stress and vascular structure and function and the influence of dyslipidaemia on 
these relationships.  In Chapter 3 the key findings were that women with depression 
and/or anxiety had the greatest IMT which was further exacerbated by the presence of 
dyslipidaemia, suggesting an important progression of early vascular disease and potentially 
increased long-term risk.  The implication of this for women is that those with depression 
and/or anxiety aside from improving their mental health should also have their other 
cardiovascular risk factors carefully monitored to further reduce their risk of a 
cardiovascular event.  Equally, chronic stressors such as depression or anxiety should also 
be potentially taken into account when assessing and treating an individual’s cardiovascular 
risk, particularly in women.  
 
In Chapter 4 it was found that those participants who had the greatest increase in the 
inflammatory marker fibrinogen 45 minutes after the acute mental stress challenge were 
subsequently found to have poorer endothelial function, suggesting they may be at 
increased cardiovascular risk in the long term. It also builds on previous work showing that 
participants with high inflammatory responses (IL-6, TNFα & fibrinogen) have greater 
arterial stiffness and blood pressure 3 years later324, 369. Further work is required to 
investigate whether and how this might lead to future development of structural and 
functional changes and cardiovascular events, as well as exploring these responses as a 
potential means of improving long-term risk prediction and treatment selection. 
 
This work also identified the need for a straight forward method of vascular function 
assessment that would be provide reliable data as well as be easy to use in large population 
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studies and outside the specialist vascular laboratory. The second half of this thesis 
therefore focussed on demonstrating the reproducibility and validation of such a potential 
technique.  
 
In Chapter 6 the key finding was that FMS was a highly reproducible method for assessing 
vasomotor function. This demonstrated the potential of this method to become an 
important tool for assessing vasomotor function. This was highlighted in Chapter 7 in 
which I found that vasomotor responses in FH patients, as assessed by FMS, were 
impaired compred with age and gender matched controls, in keeping with studies using 
established techniques.  This showed that this new method could potentially be used to 
address scientific questions requiring evaluation of vasomotor dysfunction, for example the 
influence of novel pathways and treatments on the development vascular pathology in teh 
clinical setting. Finally the sensitivity of the technique was shown in Chapter 8 where the 
key finding was that a single treatment of an acute lipid lowering intervention (lipoprotein 
apheresis) improved vasomotor function which was detectable by FMS.  
 
Together these novel findings shown in Chapters 6 to 8 demonstrate the potential of FMS 
as a valid method for assessing vasomotor (dys)function with potential capability for being 
used in large epidemiological studies and, importantly, by non-vascular specialists. This 
technique could be used in larger studies to look at associations with other cardiovascular 
risk factors as well as the impact of interventions which may alter vasomotor function. For 
example, studies could look at the implications of chronic stress, such as depression and 
anxiety, on the cardiovascular system and also the physiological responses to acute mental 
stressors, to further understand how these responses lead to acute cardiovascular events 
and disease formation and progression. 
 
10.1 Future research 
Due to its ease of  use and operator independence, this cuff  based method of  assessing 
vasomotor function by FMS could be used in a variety studies in many different areas and 
not just by vascular specialists.  Following on from investigating associations between 
vascular function and acute and chronic stress, FMS could be used to investigate the role 
of  vasomotor function in psychopathology, for example I plan to undertake a study with 
colleagues investigating the influence of  vasomotor function on the relationship between 
hydration status and cognitive function of  older adults. Furthering the LA study, FMS 
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could be used to investigate the effects of  new drugs, such as PCSK-9 inhibitors, on 
vasomotor function, to assess how their effect on vascular function compares with that of  
LA in patients with FH.  Also based on the model of  the LA study, renal physicians could 
use FMS to investigate the effects of  renal dialysis on vasomotor function looking at both 
the acute and short term effects of  a single dialysis session as well as the impact of  longer 
term therapy. 
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Appendix 1 
 
 
Whitehall II Phase 7 questionnaire  
https://www.ucl.ac.uk/whitehallII/pdf/s7-questionnaire 
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Appendix 2 
 
Subject Gender Cardiovascular history LA system Lipid lowering medications Cardiac medication 
1 M  Kaneka D100 Rosuvastatin AP 
2 M MI Dali 750 Rosuvastatin, Ezetimibe + 
Omacor 
βB + AP 
3 M MI, stroke Dali 1000 Rosuvastatin, Ezetimibe + 
Eicosapentaenoic acid 
βB , AIIRA, DIUR 
+ AP 
4 M CABG Dali 750 Omacor βB, DIUR, RI + AP 
5 M MI Dali 1000 Atorvastatin AP 
6 F  Kaneka LA-15   
7 M MI, CABG, Stents Dali 1000 Atorvastatin, Ezetimibe + 
Eicosapentaenoic acid 
Docoshexaenoic acid + 
Fenofibrate 
βB ,DIUR ,AP + NI 
8 M MI,  CABG , PCI Dali 750 Rosuvastatin, Ezetimibe, 
Omacor + Fenofibrate 
AP 
9 F CABG, chronic stable 
angina 
Kaneka LA-15 Rosuvastatin + Ezetimibe βB, AIIRA, DIUR, 
CCB, AP +NI 
10 M CABG, MI Dali 1000 Atorvastatin, Ezetimibe + 
Tredaptive 
AP 
11 F MI, stents Dali 750 Rosuvastatin + Ezetimibe βB + AP 
12 M CABG, PCI, MI , PVD 
aortic-bifemoral graft, 
TIA & AF, AV fistula 
Kaneka LA-15 Atorvastatin, Ezetimibe, 
Omacor + Tredaptive 
βB, AIIRA, DIUR, 
AP, NI, AC + CG 
Table 1. Cardiovascular medical history and medications of the patients undergoing lipoprotein apheresis 
treatement.  LA = lipoprotein apheresis; M= male; F=female; MI=myocardial infarction; CABG= coronary 
artery bypass graft; PCI=percutaneous intervention; PVD= peripheral vascular disease; TIA = transient 
ischaemic attack; AF= atrial fibrillation; AV fistula = arteriovenous fistula; AP = Antiplatelet; βB= beta 
blocker; AIIRA = angiotensin II receptor agonist; DIUR = diuretic; RI = renin inhibitor; NI= nitrate; CCB – 
calcium channel blocker; AC = anticoagulant; CG= cardiac glycoside. 
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